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Aim
The main objective of this thesis is to provide a conceptual framework for 
the use of central nervous system (cns) biomarkers in early phase clinical 
drug development. 
Outline
In the introduction the current use of biomarkers in early cns drug 
development is discussed. A conceptual framework for the classifi cation 
of biomarkers is suggested, based on general questions that these 
markers should provide information on. The body of this thesis (chapters 
1-7) exemplifi es the use of these markers within this conceptual 
framework.
Chapter 1 describes a study of the fi rst administration in man of a 
potential drug with a novel mechanism of action (naaladase inhibition) 
and a relative uncertain therapeutic indication (e.g. neuropathic pain). 
Sensitive markers for functional domains were included in the test-
battery to establish a general cns-profi le. In chapter 2, this approach 
was used to compare the effects of two drugs with a similar mechanism 
of action (sumatriptan and rizatriptan) relative to an active comparator 
of a different drug class (temazepam). Chapters 3 and 4 investigate the 
time course of central nervous system effects of centrally active anti-
hypertensive agents (rilmenidine and moxonidine) in patients following 
prolonged treatment as estimated by sensitive markers for sedation.
In the studies presented in chapters 1-4, each biomarker was studied 
separately, as a measure of the effects of a drug on a certain functional 
cns-domain. It is possible that certain combinations of functionale cns-
effects characterize specifi c pharmacological actions. This possibility is 
explored in chapter 5, which investigates whether drug class specifi city 
of sensitive markers can be enhanced using a composite of markers. 
A combination of effect scores on the some of the most commonly and 
reproducible cns-biomarkers (saccadic peak velocity, visual analogue 
scales for alertness and electroencephalography) was determined from 
historical data from the Centre for Human Drug Research (chdr) to 
examine the specifi city of various composites of combined scores, 
for different drug classes.
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This approach may lead to the identifi cation of biomarker combinations 
that provide a “pharmacological footprint” for drugs or even a drug 
class. However, this use of composite biomarkers seems to have little 
face validity. In chapter 6, a potential model for cognitive impairment is 
explored, by exposing healthy volunteers to moderate levels of hypoxia. 
Hypoxia-induced cognitive impairment could be a useful model to show 
benefi cial effects of (certain types of) cognitive enhancing agents, in the 
early phases of drug development.
Chapter 7 exemplifi es the type of work needed for selection and 
validation of biomarkers for specifi c pharmacological (receptor-specifi c) 
activity. In this chapter, an attempt is made to validate a potential 
functional marker (eye-blinks) for in vivo central dopamine receptor 
activity. For this purpose, the effects of both a dopamine agonist and 
antagonist are investigated using eye blink rate and plasma prolactin 
levels as potential biomarkers for specifi c dopaminergic activity.
In the conclusions and discussion a critical evaluation of the presented 
conceptual biomarker framework is given and directions for future 
biomarker research are offered.
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Background
The use of biomarkers in early phase development of central nervous 
system drugs seems challenged by the fact that a vast number of often 
poorly validated tests is being used as ill-defi ned biomarkers. Especially 
in the area of neuropsychological tests, the majority of tests are used 
sporadically or do not show a consistent treatment response, thus 
lacking basic test requirements such as reproducibility and sensitivity.
To date in early cns drug development, the justifi cation of a 
particular selection of tests still seems to lie mainly in its ability 
to show adverse effects. For older drugs with a small therapeutic 
range, this approach is useful since the maximum tolerated dose in 
healthy volunteers is often close to the dose that is both tolerable and 
effective in patients. For such drugs, the main focus of early phase drug 
development lies on evaluating safety and tolerability. 
This situation is changing, or has been changing for a number of 
years. For novel cns active agents the drug concentrations that are 
associated with pharmacological activity, therapeutic effi cacy and 
adverse events are further apart. Due to the increased selectivity of novel 
cns active drugs for receptors, neurotransmitters or even brain regions, 
the therapeutic range is broadened. The maximum tolerated dose in 
healthy volunteers can no longer be used as a reliable indicator for 
pharmacological activity and therapeutic effi cacy. 
This necessitates a new approach to cns biomarkers in the early 
phases of drug development. There is an increasing need to include 
markers for the pharmacological activity of the drug and/or activity of 
the drug on disease related (patho)physiology, and wherever possible 
also markers for potential therapeutic effects. Indeed, it seems likely 
that biomarkers will play an increasingly important role in all phases of 
drug development, including regulatory review. It is unlikely, however, 
for many of these biomarkers to become established well enough to 
be used in regulatory decision making as surrogate endpoints, thereby 
substituting for traditional clinical endpoints. 
It has been suggested that ideally the attributes of a biomarker 
should include the following*: clinical relevance, sensitivity and 
specifi city to treatment effects, reliability, practically and simplicity.
Although based on these recommendations biomarkers can now 
be ordered according to their linkage to the disease or their clinical 
relevance, this does not form a conceptual framework for the selection 
of tests in early drug development. Many biomarkers may be closely 
linked to a particular disease in patients (e.g. memory testing related 
Ref. 1
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to dementia), but their relevance in early drug development in healthy 
volunteers may be entirely unknown (e.g. memory testing for cognitive 
enhancers). This apparent contradiction has contributed to the 
questionable reputation of cns-biomarkers in early drug development 
– which is also fuelled by their vast number. Consequently, there is a need 
for a novel approach to biomarker selection and classifi cation.
Objectives of biomarkers in early drug development
The main objective of cns biomarkers in early drug development is 
that they provide reliable information that is of consequence to the 
development program, at the earliest possible time. In early cns drug 
development, there are basically four general questions on which 
biomarkers can provide information:
1. Proof of cns-penetration and functional cns effects, which can be 
 sub-divided into:
 A. Biomarkers of cns pharmacokinetics
 B. Biomarkers of adverse effects
2. Proof of pharmacodynamic principle (biomarkers of mechanism 
 of action)
3. Proof of pathophysiological principle (biomarkers of effects on  
 relevant pathophysiological process)
4. Proof of therapeutic principle (biomarkers of therapeutic effects)
 
A single biomarker may provide information on more than one area. 
Biomarkers of cns penetration and functional cns-effects
Currently, an overwhelming number of neuropsychological different 
tests (or tests variants) are being used by different research groups, often 
sporadically and with poor sensitivity. The majority of these tests can be 
classified as measures of ‘cns-activity’. They are aimed at showing cns 
penetration, or showing indications of adverse effects. Quite often, their 
interpretation is highly dependent on the experience of the investigator, 
and how the tests have previously been affected by other drugs. This 
poses problems for new drugs with innovative action mechanisms. The 
large number of cns-tests also makes it impossible to identify ‘the best 
method’ with the most favourable test-characteristics, simply because 
suitable methods differ widely for each objective (cns-penetration, 
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adverse event profiling, confirmation of action mechanism). It is better, 
therefore, to define the information that is required, and select the most 
accurate test that can provide this information. Information about ‘cns 
activity’ can be divided into several primarily neurophysiological or 
neuropsychological domains. 
This is illustrated by three recent literature reviews that evaluated 
biomarkers for neuroleptics, ssri antidepressants and benzodiazepine 
anxiolytics.* In these reviews, the use of biomarkers in healthy volunteer 
studies was evaluated: 65 studies with neuroleptics, 56 with ssri’s 
and 56 with benzodiazepines, which reported the use of 101, 63 and 64 
different neuropsychological tests, respectively. Only 15%, 20% and 32% 
of these tests were used fi ve times or more. The percentages of tests that 
never showed any signifi cant treatment effects were 48%, 54% and 29%, 
respectively. Despite the large number of tests, only a small number of 
primary cognitive domains were addressed (table 1). 
The domains which were most frequently affected by these psychotropic 
agents were ‘attention’, memory, visuomotor and motor functions. 
Only a few tests within these domains showed any drug effects. The 
majority did not provide meaningful information about the drug. A 
cns-test-battery to quantitate ‘cns-activity’ should at least cover 
these four domains. Within each domain, the method(s) with the best 
test characteristics should be used. These properties include not only 
basic methodological features like sensitivity and reproducibility, 
but also properties that are needed in early drug development, like 
repeatability (to show relationships to changing plasma concentrations) 
and responsiveness to therapeutic drug levels. These ideal methods have 
not yet been identifi ed, although the reviews provide some indications, 
showing that a rational choice can start with gathering of available 
experience from the literature and among psychopharmacological 
research groups. This should lead to more uniform test batteries, which 
will be of great benefi t to the development of novel psychoactive drugs.
Biomarkers for pharmacological effects
These biomarkers are expected to show a response to a specifi c pharma-
codynamic effect of a cns active drug. In early drug development there 
are only a very small number of validated biomarkers that provide 
information on pharmacodynamic cns effects of drugs. Potentially these 
biomarkers could be valuable at the early stages of drug development, 
especially if its pharmacodynamic mechanisms of action in vivo are 
Ref.2,3,4
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not elucidated. These biomarkers then provide a pharmacological proof 
of principle for novel cns drugs. This aim requires the marker to be as 
specifi c as possible to a certain pharmacodynamic pathway, as well as 
sensitive.
In the area of neuropsychological tests, no test can be mentioned 
that demonstrates a specifi c pharmacological effect. Most tests can be 
affected by a number of drugs with very different mechanisms of action 
(ssri’s, benzodiazepines and neuroleptics all similarly affect attention 
tasks). As mentioned, these tests at best show that a drug affects a 
certain neuropsychological domain, regardless of the pharmacological 
pathway of the drug. This is largely due to the fact that several functional 
neurological (neurotransmitter) systems must be orchestrated in order to 
perform on a neuropsychological test.
There are a few neuro-endocrine biomarkers that are able to indicate, 
with reasonable sensitivity and specifi city, a pharmacodynamic 
mechanism of action. Plasma prolactine for example has been used 
frequently in drug research to demonstrate a d2-receptor antagonist 
effect of drugs. This aided considerably in the development of many 
neuroleptic drugs, for which d2-receptor antagonistic activity was 
an important pharmacodynamic effect and a predictor of therapeutic 
effi cacy. Another example is the plasma cortisol response to serotonergic 
drugs. Although the specifi city of the cortisol response to 5ht-receptor 
subtype agonism is not completely elucidated, it does demonstrate a 
5ht-receptor agonistic drug effect. 
An important limitation of these biomarkers is that the 
physiological activity of some neuro-endocrine systems is so low that 
a pharmacological effect is indiscernible. Furthermore, more subtle 
pharmacodynamic effects like those of modern neuro-modulatory drugs 
will only become apparent in neuro-endocrine systems with an abnormal 
activity. A way of enhancing the sensitivity of neuro-endocrine tests is by 
challenging the involved neurophysiological system, creating an elevated 
activity. These challenges can be pharmacological (mcpp or 5ht as a 
serotonin challenge) or physical (heat stress for cortisol). 
A relatively novel approach is the use of functional mri (fmri).* 
The blood oxygen level-dependent (bold) signal measured by fmri is 
determined by local changes in the ratio of oxygenated to deoxygenated 
haemoglobin, resulting from increased blood fl ow in response to neural 
activity that is not matched proportionately by locally increased oxygen 
consumption. The pharmacological mri (phmri) involves measuring 
drug related changes in the bold signal. In humans, fmri measurements 
are usually made while the subject is performing a cognitive task. 
Ref. 5
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Therefore, the results of phmri potentially provide information about 
the pharmacodynamics of the drug (‘neurocognitive profi ling’) and 
the transmitter mechanisms that normally underpin the coherent and 
adaptive activation of large-scale neurocognitive systems activated by 
task performance. However, this approach has important limitations. 
Drug effects on the bold signal could be mediated by effects on cerebral 
vasoactivity rather than direct effects on neurons. Often, changes in 
the bold response occur in the absence of behavioural changes, which 
raises questions about the signifi cance of these fi ndings. It seems that 
phmri can provide useful pharmacological information, but only when 
combined with neurophysiologic, neuroendocrine or neurocognitive 
tests.
Biomarkers for (patho)physiological principle
Many cns-diseases can be viewed as derangements of normal 
physiological systems. Effects of a new drug on relevant system in 
healthy volunteers may also provide evidence that drug may correct 
pathophysiology in patients. For example, augmentation of serotonergic 
neurotransmission is associated with increased memory consolidation, 
which may be relevant to its therapeutic and cognitive actions in acutely 
depressed patients, which often show memory impairment.* In another 
study,* short-term administration of two different antidepressant types 
had similar effects on emotion-related tasks in healthy volunteers, 
reducing the processing of negative relative to positive emotional 
material. Such effects of antidepressants may ameliorate the negative 
biases in information processing that characterize mood and anxiety 
disorders. They also suggest a mechanism of action potentially 
compatible with cognitive theories of anxiety and depression. 
As for most cns (especially psychiatric) diseases no clear pathophysi-
ological concept is known, the use of this type of biomarker is severely 
hindered. 
Biomarkers for therapeutic principle
To state the obvious, diseases are not present in healthy volunteers. 
However, the use of ‘subsyndromal’ patient populations in early drug 
development may aid in the development of cns drugs. This seems 
particularly relevant for psychiatric diseases, where no clear dichotomy 
Ref. 6 
Ref. 7 
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between healthy and disease states seems present. The clinical defi nition 
of psychiatric diseases such as affective and anxiety disorders are largely 
phenomenological and clear anatomical or functional distinguishing 
characteristics are rarely present. Although the use of ‘subsyndromal’ 
patient populations is not often used in phase one drug development, 
some studies in patients with ‘minor depression’ show a favourable 
treatment response to ssri’s.*
More often, biomarkers for therapeutic activity are evaluated in a 
‘disease model’, in which a disease-like state is induced in healthy 
volunteers. In the development of most cns drugs animal disease 
models are used to obtain an indication of therapeutic activity. The 
predictive quality of these models for therapeutic effi cacy in humans is 
often very limited. Only a few disease models have been used in human 
pharmacology. In the development of cognitive enhancers two models 
have been used frequently: induced cerebral hypoxia* and scopolamine 
induced amnesia.* For modelling affective disorders, tryptophan 
depletion produces clear mood lowering effects.* For many cns diseases 
no model is available in humans. Again, in the use of disease models, an 
important limitation is the lack of understanding of pathophysiological 
pathways in many of the cns diseases.
Conclusions
With the above mentioned limitations, is there any benefi t in using 
biomarkers in early central nervous system drug development? 
Despite these limitations, different biomarker classes can contribute 
to early proof of different development principles. A necessary fi rst step 
is to realise what a specifi c biomarker actually provides information on. 
The presented division into classes of biomarkers should present 
a conceptual framework to achieve this. Within each biomarker class, 
the most useful biomarkers should be identifi ed. This is particularly 
relevant for the biomarkers for functional cns-effects, where an 
overwhelming number of tests are currently used. Here, there is a great 
need for more uniform practical, sensitive and specifi c test batteries. 
Improved understanding of pathogenesis of cns-diseases will 
hopefully lead to more useful biomarkers for pathophysiological and 
therapeutic activity. It will probably also lead to a mutual substitution 
of pharmacological, pathophysiological and therapeutic biomarkers, 
reducing the number of tests and increasing their value in early central 
nervous system drug development.
Ref. 8 
Ref. 9, 10
Ref. 11, 12, 13, 14, 15, 16
Ref. 17
18  biomarkers in early phase development of central nervous system drugs
references
1  Lesko LJ, Atkinson AJ, Jr. Use Of Biomarkers And 
Surrogate Endpoints In Drug Development 
And Regulatory Decision Making: Criteria, Validation, 
Strategies. Annu.rev.Pharmacol.Toxicol. 2001; 41:
347-366.
2 De Visser SJ, Van Der Post JP, De Waal PP, Cornet F, 
Cohen AF, Van Gerven JM. Biomarkers For The Effects 
Of Benzodiazepines In Healthy Volunteers. Br.J.Clin.
Pharmacol. 2003; 55:39-50.
3 De Visser SJ, Van Der PJ, Pieters MS, Cohen AF, 
Van Gerven JM. Biomarkers For The Effects Of 
Antipsychotic Drugs In Healthy Volunteers. Br.J.Clin.
Pharmacol. 2001; 51:119-132.
4 Rijnbeek B, De Visser SJ, Franson KL, Cohen AF, Van 
Gerven JM. rem  Sleep Effects As A Biomarker For 
The Effects Of Antidepressants In Healthy Volunteers. 
J.Psychopharmacol. 2003; 17:196-203.
5  Honey G, Bullmore E. Human Pharmacological mri. 
Trends Pharmacol.Sci. 2004; 25:366-374.
6  Harmer CJ, Bhagwagar Z, Cowen PJ, Goodwin GM. 
Acute Administration Of Citalopram Facilitates 
Memory Consolidation In Healthy Volunteers. 
Psychopharmacology (Berl) 2002; 163:106-110.
7  Harmer CJ, Shelley NC, Cowen PJ, Goodwin GM. 
Increased Positive Versus Negative Affective 
Perception And Memory In Healthy Volunteers 
Following Selective Serotonin And Norepinephrine 
Reuptake Inhibition. Am.J.Psychiatry 2004; 161:
1256-1263.
8 Van Steveninck AL, Mandema JW, Tuk B et al. 
A Comparison Of The Concentration-effect 
Relationships Of Midazolam For EEG-derived 
Parameters And Saccadic Peak Velocity. Br J Clin 
Pharmacol 1993; 36:109-115.
9 Saletu B, Grünberger J, Anderer P, Linzmayer L, König 
P. On The Cerebro-protective Effects Of Caroverine, 
A Calcium-channel Blocker And Antiglutaminergic 
Drug: Double-blind, Placebo-controlled, EEG-mapping 
And Psychometric Studies Under Hypoxia. Brit.J.Clin.
Pharmacol. 1996; 41:89-99.
10  Van Der Post JP, Noordzij LA, De Kam ML, Blauw 
GJ, Cohen AF, Van Gerven JM. Evaluation Of Tests 
Of Central Nervous System Performance After 
Hypoxemia For A Model For Cognitive Impairment. 
J.Psychopharmacol. 2002; 16:337-343.
11  Broks P, Preston GC, Traub M, Poppleton P, 
Ward C, Stahl SM. Modelling Dementia: Effects 
Of Scopolamine On Memory And Attention. 
Neuropsychologia 1988; 26:685-700.
12 Broocks A, Little JT, Martin A et al. The Infl uence 
 Of Ondansetron And M-chlorophenylpiperazine 
 On Scopolamine-induced Cognitive, Behavioral, 
 
 And Physiological Responses In Young Healthy
 Controls. Biol.Psychiatry 1998; 43:408-416.
13  Gilles C, De Buyl O, Genevrois C, Salama M, 
Mendlewicz J. Specifi city Of Visual Evoked Potentials 
Alterations In Alzheimer’s Disease: Comparison 
With Normal Aging, Depression And Scopolamine 
Administration In Young Healthy Volunteers. Acta 
Neurol.Belg. 1989; 89:226-227.
14  Mauri M, Sinforiani E, Reverberi F, Merlo P, Bono 
G. Pramiracetam Effects On Scopolamine-induced 
Amnesia In Healthy Volunteers. Arch.Gerontol.Geriatr. 
1994; 18:133-139.
15  Preda L, Alberoni M, Bressi S et al. Effects Of Acute 
Doses Of Oxiracetam In The Scopolamine Model Of 
Human Amnesia. Psychopharmacology (Berl) 1993; 
110:421-426.
16  Riedel W, Hogervorst E, Leboux R, Verhey F, Van 
Praag H, Jolles J. Caffeine Attenuates Scopolamine-
induced Memory Impairment In Humans. 
Psychopharmacology (Berl) 1995; 122:158-168.
17  Van Der Does AJ. The Mood-lowering Effect Of 
Tryptophan Depletion: Possible Explanation For 
Discrepant Findings. Arch.Gen.Psychiatry 2001; 
58:200-202.
19 introduction
table 1  Number of tests within individual domains
Neuropsychological domains Neuroleptics Selective Serotonin 
Re-uptake Inhibitors
Benzodiazepines
Achievement 4 0 1
Executive 15 6 11
Attention 24 14 15
Memory 21 9 20
Language 4 0 0
Visual, visuomotor and auditory 25 28 23
Motor 8 6 4
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Abstract
aim The aim was to assess the central nervous system (cns) effects, 
pharmacokinetics and safety of gpi 5693, an inhibitor of a novel cns-
drug target, naaladase which is being evaluated for the treatment of 
neuropathic pain.
methods This was a double-blind, placebo-controlled, exploratory 
study in healthy subjects receiving oral gpi 5693 single ascending doses 
of 100, 300, 750, 1125 mg with a placebo treatment randomly interspersed. 
An open-label, parallel extension examined the effects of food and sex 
on the pharmacokinetics of 750, 1125 and 1500 mg doses. Blood samples 
were collected for pharmacokinetic and biochemical/haematological 
safety analysis, vital signs, ecg and adverse event checks were performed 
regularly up to 48 h postdose. Postdose cns effects were assessed using 
eye movements, adaptive tracking, electroencephalography (eeg), body 
sway and Visual Analogue Scales (vas).
results cns effects were mainly observed after the 1125 mg dose, 
showing a signifi cant decrease of adaptive tracking performance, vas 
alertness and vas mood, and an increase of eeg occipital alpha and 
theta power. Gastro-intestinal (gi) adverse effects were frequent at 
higher doses. No clinically signifi cant changes in vital signs or ecg 
were noted during any of the treatments. The therapeutically relevant 
concentration range (950–11 100 ng ml-1) as determined from animal 
experiments was already reached after the 300 mg dose. cmax after 
the 300 mg and 750 mg dose was 2868 and 9266 ng ml-1 with a t1/2 of 
2.54 and 4.78 h, respectively. Concomitant food intake (with the 750 mg 
and 1125 mg doses) reduced cmax by approximately 66% and auc by 
approximately 40%. With concomitant food intake, the dose-normalized 
cmax also decreased signifi cantly by -5.6 (ci: -2.6 to -8.7) ng ml-1 mg-1. 
The pharmacokinetic variability was largest after the 300 mg and 750 mg 
dose, resulting in a sd of approximately 50% of the cmax.
conclusion naaladase inhibition with gpi 5693 was safe and 
tolerable in healthy subjects. Plasma concentrations that were effective 
in the reversal of hyperalgesia in the chronic constrictive injury animal 
model of neuropathic pain were obtained at doses of 300, 750 and 1125 
mg in the fasted state. Comcomitant food intake reduced cmax and 
auc. cns effects and gi aes increased in incidence over placebo only at 
the 1125 mg dose.
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Introduction
naaladase (also termed glutamate carboxypeptidase ii) is a membrane 
bound metalloprotease that hydrolyses the neuropeptide n-acetyl-
aspartyl glutamate (naag) to n-acetyl-aspartate and glutamate. naag 
acts as an agonist at group ii metabotropic glutamate receptors, and 
is also a mixed agonist/antagonist at the nmda glutamate receptor. 
The functional relevance of naaladase is unknown, but it is thought 
both to terminate the neurotransmitter activity of naag and to liberate 
glutamate from naag, which subsequently acts at the various glutamate 
receptor subtypes. naaladase inhibition is thus primarily expected to 
cause indirect antiglutamatergic effects.* 
gpi 5693 ((r,s)-2-(3-mercaptopropyl) pentanedioic acid) is an orally 
bioavailable, selective and potent naaladase inhibitor.* Rat models 
of peripheral neuropathy suggested that daily oral administration 
of naaladase inhibitors can reduce neuropathic pain signs and 
simultaneously reduce the rate of decline in nerve conduction velocity.* 
Pathology results indicate that naaladase inhibition also protects 
against diabetic-induced axonal atrophy and Wallerian degeneration. 
These data suggest a potential use for gpi 5693 as a treatment for 
neuropathic pain as well as retarding the progression of diabetic 
neuropathy in patients. The indirect antiglutamatergic effects of 
naaladase inhibition in the central nervous system (cns) also suggest a 
role for naaladase inhibition in a host of diseases where glutamate may 
be involved,* but this has not yet been studied extensively.
 Since the physiological role of naaladase is unknown, potential 
cns effects can only be predicted indirectly, e.g. from the various known 
effects of inhibitors of excitatory amino acids on the cns. Currently, no 
behavioural toxicity has actually been observed in animal experiments. 
Since it may be possible to detect subtle cns effects in humans that might 
not be observed in animals, it is important to carefully study the potential 
cns effects of naaladase-inhibition. Also, observed cns effects may 
provide indications of the functional relevance of  naaladase inhibition, 
and provide methods to quantify these effects in future studies.
Drugs affecting glutamatergic neurotransmission can cause a general 
depression of cns activity, including sedation.* It is essential to know if 
signifi cant cns depression occurs, since this may limit applicability of 
the compound during prolonged treatment of neuropathy. There are many 
different methods to quantify cns depression, and saccadic peak velocity 
is one of the most sensitive parameters.* Effects on motor performance 
could also occur with inhibitors of excitatory neurotransmitters. Different 
Ref 1
Ref 2
Ref 3
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motor effects can be quantifi ed using smooth pursuit eye movements, 
adaptive tracking and body sway.*
Some antiglutamatergic drugs have psychotomimetic properties. 
The illicit drug pcp (‘angel’s dust’) and the related anaesthetic agent 
ketamine are direct nmda receptor antagonists with psychotropic 
effects. It is unknown whether these effects are related to glutamatergic 
inhibition, but the subjective effects of subanaesthetic doses of 
ketamine can be quantifi ed and related to central and peripheral drug 
concentrations, using specifi c questionnaires and visual analogue 
scales.* Although gpi 5693 does not possess direct nmda-antagonist 
activity, potential psychotomimetic effects were evaluated for safety. 
In theory, the clinical effects of glutamatergic modulation could be 
measured most sensitively in the realms of attention, motor function 
and subjective changes. In addition, the pharmaco-electro-encephalo-
gram (eeg) provides a sensitive general pharmacodynamic parameter 
of cns penetration and activity.* Glutamatergic agents have caused 
concentration-related changes in eeg-activity in healthy subjects.*
This study represents the fi rst administration of a naaladase 
inhibitor in humans. It aimed to describe the pharmacokinetics and 
safety of gpi 5693, and to determine the central nervous system effects 
of naaladase inhibition concentrations that showed effi cacy in 
neuropathic animal models.
Methods
After approval of the protocol by the Ethical Review Board of the Leiden 
University Medical Centre, 25 healthy male and female subjects (age 
18–45 years) were asked to participate in this exploratory study. After 
giving written informed consent, subjects received a full medical 
examination before entering the study, including a pregnancy test for 
female participants of childbearing potential. Alcohol and xanthine 
use was restricted to two units per day, from two days prior to the 
study day. Furthermore, subjects refrained from alcohol, caffeine and 
xanthine containing foods and beverages 12 h prior to the study days and 
during the study days. Female subjects were instructed to use barrier 
contraceptives. Concomitant medication other than paracetamol was 
not permitted during the study period. 
This was a double-blinded, partially randomized, placebo-controlled, 
ascending dose study of gpi 5693, with minimum washout periods of 
48 h. The study aimed to reach a maximum concentration (cmax) and 
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area under the concentration curve (auc) at the concentrations showing 
reversal of hyperalgesia in experimental animal models.
The study was performed in panels, with interim analyses of 
pharmacokinetics and safety to adapt the design of consecutive panels. 
Four male subjects participating in panel 1 received fasting oral gpi 
5693 doses of 100 mg, 300 mg and 750 mg, with a placebo occasion 
randomly inserted. A fi fth open-label study day was added to this panel 
to investigate the effects of food on the 750 mg dose. After an interim 
analysis, the selected doses for panel 2 (which also consisted of four male 
subjects) were 300 mg, 750 mg, 1125 mg and placebo. Interim analyses 
of the fi rst two panels provided indications for a food effect on gpi 
5693 pharmacokinetics. The safety and tolerability of the drug in men 
allowed inclusion of women in a third open-label panel, investigating 
the tolerability and pharmacokinetics after single oral doses of 1125 and 
1500 mg in fed state for both sexes. No cns effects were measured during 
panel 3 which consisted of six female and six male subjects. 
The eye-movement recording, adaptive tracking, body sway and 
Visual Analogue Scales (vas) were practised before the fi rst study day to 
reduce learning effects during the study. gpi 5693 was administered as 
100 mg and 375 mg capsules after overnight fasting. During all occasions 
of the fi rst two panels without food interaction, eeg, eye movements, 
adaptive tracking, body sway and vas were measured at baseline and 
at 30 min intervals for the fi rst 2 h, and with increasing intervals until 
8 h after drug administration. Ecg, vital signs and adverse events were 
checked regularly and continuous two-lead ecg monitoring was per-
formed for 4 h after drug administration. In the 24–48-h period after dos-
ing, a fecal sample was taken to check for occult blood. Blood sampling 
for haematological and biochemical parameters was done at baseline and 
24 h after dosing. Pharmacokinetic sampling was performed every 10 min 
for the fi rst hour and with increasing intervals until 48 h after drug ad-
ministration. gpi 5693 was measured by means of lc/ms/ms. Plasma gpi 
5693 concentrations were linear from 1 to 2000 ng ml-1 and urine gpi 5693 
concentrations were linear from 10 to 2000 ng ml-1. The average within 
assay cv was 2.5% and the average between assay cv was 1.6%. 
Subjects remained at the study site until 24 h after each dosing. 
A poststudy check-up took place 48 h after their last study day including 
fi nal follow-up of any adverse effects. 
Electroencephalograms were recorded and analysed using ced software 
(Cambridge Eectronics Design, Cambridge, uk), as described previously.* 
eeg recordings were made using silver-silver chloride electrodes, 
fi xed with collodion at Fz, Cz, Pz and Oz, with the same common 
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ground electrode as for the eye movement registration (international 
10/20 system). The electrode resistances were kept below 5 kOhm. All 
recordings were done with the subjects’ eyes closed. eeg signals were 
obtained from leads Fz-Cz and Pz-Oz. The signals were amplifi ed by 
use of a Nihon Kohden ab-621g bioelectric amplifi er (Nihon Kohden 
Corporation, Tokyo, Japan) with a time constant of 0.3 s and a low 
pass fi lter at 100 Hz. Per session eight consecutive blocks of 8 s were 
recorded over a 2-min period. The sampling rate was 1024 Hz. Datablocks 
containing artefacts were identifi ed by visual inspection and these were 
excluded from analysis. Fast Fourier transform analysis was performed 
to obtain the sum of amplitudes in the delta- (0.5–3.5 Hz), theta- (3.5–7.5 
Hz), alpha- (7.5–11.5 Hz) and beta (11.5–30 Hz) frequency ranges. The total 
recording bandwidth was 0–50 Hz.
Recording and analysis of saccadic and smooth pursuit eye 
movements were done with a microcomputerbased system.* 
The equipment used for stimulus display, signal collection and 
amplifi cation was from Nihon Kohden (Nihon Kohden Corporation, 
Tokyo, Japan). Saccadic eye movements were recorded for stimulus 
amplitudes of 15 degrees to either side. Interstimulus intervals varied 
randomly between 3 and 6 s, and 15 saccades were recorded. The average 
values of saccadic peak velocity, latency (reaction time) and inaccuracy 
were used as parameters. For smooth pursuit eye movements the target 
moved sinusoidal at frequencies range from 0.3 to 1.1 Hz, increasing by 
steps of 0.1 Hz. The amplitude of target displacement corresponds to 
20 degrees eyeball rotations to both sides. Four cycles were recorded 
for each stimulus frequency. 
The adaptive tracking test was performed as originally described 
by Borland and Nicholson,* using customized equipment and software 
(Hobbs, 2000, Hertfordshire, uk). The average performance and the 
standard deviation of scores over a 10-min period were used for analysis. 
Adaptive tracking is a pursuit tracking task. A circle moves randomly 
about a screen. The subject is instructed to try to keep a dot inside the 
moving circle by operating a joystick. If this effort is successful, the 
speed of the moving circle increases. Conversely, the velocity is reduced 
if the test subject cannot maintain the dot inside the circle. Performance 
was scored after a fi xed 10-min period. The adaptive tracking test is 
more sensitive to impairment of eye–hand coordination by drugs than 
compensatory pursuit tasks or other pursuit tracking tasks, such as 
the pursuit rotor. The adaptive tracking test has proven to be useful for 
measurement of cns effects of alcohol,* various psychoactive drugs and 
sleep deprivation.*
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The body sway meter allows measurement of body movements in a 
single plane, providing a measure of postural stability. Body sway was 
measured with an apparatus similar to the Wright ataxiameter.* With 
a string attached to the waist, all body movements over a period of 
time were integrated and expressed as mm sway on a digital display. 
The contribution of vision to postural control was eliminated by asking 
subjects to close their eyes. Subjects were instructed to wear the same 
pair of comfortable, low-heeled shoes on each session. Before starting 
a measurement, subjects were asked to stand still and comfortable, 
with their feet approximately 10 cm apart and their hands in a relaxed 
position alongside the body. Subjects were not allowed to talk during the 
measurement. The total period of body-sway measurement was 2 min.
Visual analogue scales as originally described by Norris* were 
used to quantify subjective effects. From these measurements, three 
factors were derived as described by Bond and Lader,* corresponding to 
alertness, mood and calmness. Psychedelic effects were monitored by 
visual analogue scales, translated from scales described by Bowdle et 
al.* since no validated version was available for the Dutch language and 
population. 
All repeatedly measured dynamic variables were characterized using 
maximum change from pretreatment value (emax) and using areas 
under the effect curve (auecs). These auecs were calculated using the 
linear trapezoidal rule and were divided by the corresponding time span 
resulting in a weighted average outcome. Nominal times were used. 
Auecs were calculated over the entire sampling period (12 h) and over the 
fi rst 6 hrs, because most of the response is expected to occur during this 
period.
Descriptive statistics were obtained for each pharmacodynamic 
parameter. Time course as well as derived parameters were summarized 
(using means, standard deviation (sd), min, median, max, n). Derived 
pharmacodynamic parameters were analysed untransformed. eeg 
parameters were analysed as percentage change from prevalue. These 
parameters were analysed, from the fasted occasions only, using analysis 
of variance (anova) accounting for subject and treatment.
Dose-independent parameters (clearance, cmax/dose, auc0–inf /
dose and tmax) were compared between the fasting and fed occasions 
using analysis of covariance with food and subject as factors, dose as 
covariate and including the dose–food interaction. This resulted in a 
predicted linear relationship between dose and the pharmacokinetic (pk) 
parameter for fed and fasted separately. This line was depicted in graphs 
of the individual pk parameters (clearance, cmax/dose, auc0–inf /dose 
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and tmax) plotted against dose, to visualize both dose dependency and 
potential differences between fasted and fed occasions. The line was 
calculated using the reported least square means (at the average admin-
istered dose: 907.5 mg) along with the slopes on dose for the two groups 
(fed/fasted). In absence of a signifi cant dose by food interaction, the 
anova model was recalculated assuming the interaction to be absent 
and in that case the resulting (parallel) lines are shown in the graphs. 
Statistical calculations were performed using spss for Windows 
(spss, Inc., Chicago, il) and sas for Windows v8.1 (sas Institute, Inc., 
Cary, nc, usa). 
The pharmacokinetic parameters were calculated by standard 
noncompartmental analysis using the software package WinNonlin V3.1 
(Pharsight, Inc., Mountainview, ca, usa).
Results
A total of 25 subjects were screened for this study. Twenty-one subjects 
received at least one dose of study medication: four males in panel 1, 
fi ve males in panel 2 and 12 (six males, six females) in panel 3. One 
subject dropped out after the fi rst dose of study medication in panel 2 
for reasons unrelated to the study. All subjects who received at least one 
dose of study medication were included in the safety analysis. Subjects 
who participated in panel 1 (occasion 1–4) and panel 2 were included in 
the pharmacodynamic (cns effect) and pharmacokinetic analysis if they 
had received at least one dose of study medication. The average (sd) 
weight of the participating subjects was 71 (10) kg, the height 178 (9) cm 
and age 23 (3) years. 
The incidence of all adverse experiences judged as ‘treatment related’ 
are summarized in table 1. Most of the treatment-related adverse events 
occurred in the who body system ‘gastro-intestinal disorders’. After 
53 administrations of active drug, 20 (38%) treatment related gastro-
intestinal adverse events were reported. These consisted mainly of mild 
nausea, dyspepsia and refl ux. Incidence of these adverse events was 
similar between placebo, 100 mg, 300 mg, and 750 mg. Incidence of 
these adverse events after the 1125 and 1500 mg dose was greater than 
placebo regardless of dosing in the fed or fasted state (approximately 
50% of the subjects vs. incidence after placebo in 13% of the subjects). 
After concomitant food intake with the 750 mg dose, no gastro-intestinal 
adverse effects were reported. At the higher dose of 1125 mg the incidence 
was identical at the fed and fasted state.
Table 1 – p. 35
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Other frequently reported adverse events were somnolence and 
headache, which were mostly judged as not treatment related (91% and 
86%, respectively). No clinically signifi cant changes in vital signs or ecg 
were noted during any of the treatments. Three positive fecal occult 
blood tests were reported; twice after the 300 mg dose, once after the 
1500 mg dose (fed state) and once after placebo. 
Compared with placebo, small but consistent statistically signifi cant 
cns effects were observed with the highest dose of 1125 mg. As indicated 
by the average time profi le (fi gure 1), eeg occipital alpha power auc-0-6 h 
increased (43.9 (95% confi dence interval (ci): 4.8–83.1)%). Occipital theta 
power auc0-6 h also increased after 1125 mg (17.1 (ci: 0.2–34.1)%).
The effect of gpi 5693 on adaptive tracking performance is shown 
fi gure 2. Adaptive tracking performance auc0-6 h decreased after 1125 
mg (-8.7 (ci:-14.0 to -3.5)%).
The average time profi les for the Bond and Lader visual analogue 
scales are presented in fi gures 3 and 4. 
gpi 5693 1125 mg caused a reduction of the auc0-6 h for vas 
alertness and the vas mood (-9.9 (ci: -19.2 to -0.6) mm and -8.6 
(ci: -16.7 to -0.5) mm, respectively). 
At lower dose levels, inconsistent vas effects were observed which 
did not occur at higher doses and thus did not show a dose relationship. 
The auc0-6 h for body sway after the 300 mg dose was decreased 
compared with placebo (-40.3 (ci: -66.6 to -14.0) mm min-2). The auc0-
6 h of the vas scores for meaning (‘I had the idea that events, objects, 
or other people had particular meaning that was specifi c for me’) and 
anxious (‘I felt anxious’) were decreased after the 300 mg dose (-2.8 
(ci: -4.8 to -0.8) mm and -1.3 (ci: -2.6 to -.0) mm, respectively). 750 mg 
showed a decrease of the vas score for meaning (-2.2 (ci: -4.2 to -0.2) 
(mm). 
No effects were seen on saccadic or smooth pursuit eye movements 
after any of the doses. 
The pharmacokinetic parameters are presented in table 2. The average 
concentration–time profi les of plasma gpi 5693 are presented in fi gure 5. 
The therapeutically relevant concentration range (950–11 100 ng ml-1) as 
determined from animal experiments was already reached in the fi rst 
panel after the 300 mg dose. The pharmacokinetic variability was largest 
after the 300 mg and 750 mg dose, resulting in a sd of approximately 
50% of the cmax. Although no formal testing was performed, and 
pharmacokinetics in females were only studied in the fed state, there was 
no indication of sex differences in pharmacokinetics (third panel).
With concomitant food intake, the cmax decreased from 9266 
Fig. 1 – p. 33
Fig. 2 – p. 33
Fig. 3, 4 – p. 34
Table 2 – p. 36
Fig. 5 – p. 35
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to 3057 and from 15 742 to 5309 (ng ml-1) after the 750 mg and 1125 mg, 
respectively. Food intake also reduced the aucinf from 8855 to 5144 
and from 17 332 to 10 523 (h ng-1 ml-1) for the 750 mg and 1125 mg doses, 
respectively. These food effects were evaluated for these doses, where 
food and dose were used as anova-covariates. The dose-normalized 
cmax decreased signifi cantly by -5.6 (ci: -2.6 to -8.7) ng ml-1 mg-1. 
Food caused a signifi cant reduction of the slope of the relationship 
between dose and auc0–inf. Dose-normalized tmax showed no 
signifi cant food effects. 
The effects of food on pharmacokinetic variability were unclear. 
Although no formal testing was performed, food seemed to reduce the 
variability following the 750 mg dose, from a cv of 50% to a cv of 34% 
for cmax and a cv of 28% to a cv of 24% for auc0–inf. Following the 
1125 mg dose however, food caused a slight increase in the cv for cmax 
(from 25 to 39%) and for auc0–inf (from 26 to 31%).
Discussion
The main aim of this exploratory study was to assess the single-dose 
pharmacokinetics and to evaluate safety and tolerability, including cns 
effects of a newly developed naaladase-inhibitor. In all, fi ve dose levels 
were administered, of which three were also dosed with concomitant 
food intake. 
The pharmacokinetics showed that therapeutically relevant plasma 
concentrations were reached in this study. Although there was some 
pharmacokinetic variability, this will presumably not cause major 
problems in the development of the drug, since the therapeutic range 
was broad and it appears that the upper end of this range can be achieved 
without dose-limiting adverse effects. There were clear effects of food 
on pharmacokinetics, mainly resulting in a lower cmax and auc, which 
should be taken into account when designing a dose schedule for further 
studies. 
The main safety issues after single ascending dose administration of 
gpi 5693 were the relatively high incidence of gastro-intestinal side-
effects, such as nausea and dyspepsia (generally mild and short lasting) 
which appeared to occur more often at higher dose levels. Three subjects 
presented with a positive feces occult blood test, but these were not 
necessarily related to gpi 5693. Firstly, there was no relation to dose 
or to repeated exposure. Secondly, subjects were not required to adhere 
to a strict diet and result could therefore have been false positive. 
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Also, one subject had a positive feces occult blood test following placebo. 
naaladase inhibition per se is not expected to cause gastrointestinal 
effects. The gastrointestinal effects of gpi 5693 could be due to the 
acidic nature of the compound and could be a limiting factor during 
prolonged treatment of neuropathic pain patients with this agent. Firstly, 
gastrointestinal effects may be enhanced during repeated exposure 
with multiple dosing. Secondly, the associated autonomic neuropathy 
in diabetic patients often leads to changes in gastro-intestinal motility. 
A prolonged exposure of the gastric or duodenal epithelium to gpi 
5693 may also increase the incidence of gastrointestinal adverse 
events. Furthermore, if the gut epithelium is affected by gpi 5693, 
pharmacokinetic properties of the drug may be altered.
Central nervous system aes were also reported although the 
incidence was not different following placebo or active treatment. A 
relatively high number of somnolence and headache aes were reported 
after both gpi 5693 and placebo dosing. These effects may be partly due 
to caffeine abstination and disruption of normal daily routines. At the 
highest tested dose (1125 mg) at which central nervous system tolerability 
was evaluated, some cns effects were observed. The performance on 
adaptive tracking declined and the scores of the vas alertness were 
signifi cantly affected, even in the small group of four subjects. These 
effects could be associated with clinically relevant sedation by gpi 
5693. The fi ndings of these cns effects warrant a more extensive cns 
profi ling of the drug with therapeutic dosages, focusing on sedation 
and on the possible development of tolerance to these effects after 
prolonged exposure in a multiple dose study. However, these effects 
also demonstrate cns penetration of the drug. This may be important if 
the expansion of the area of development of this drug includes central 
neurodegenerative diseases. Pharmacokinetic-dynamic modeling was 
not performed because the effects were small and only consistently 
found at the highest dose level.
In summary, gpi 5693 was safe and generally well tolerated at plasma 
exposures that were effective in animal model of neuropathic pain. A 
clear food effect was observed on the pharmacokinetics, reducing cmax 
and auc. Furthermore a relatively high, dose-dependant incidence of 
gastro-intestinal adverse events was observed. Although no signifi cant 
drug related cns adverse events were reported, mild cns effects were 
observed following the highest dose level (at which these were assessed). 
These fi ndings warrant a multiple dose study in healthy subjects in a fed 
state, to further evaluate the pharmacokinetic properties and adverse 
events profi le of gpi 5693, prior to proceeding to patient studies.
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figure 1 Average eeg alpha power. Mean ± sd time-effect profi les of eeg alpha power 
for placebo (•), gpi 5693 100 mg (°), 300 mg (:), 750 mg (;) and 1125 mg (Ç).
figure 2 Average adaptive tracking performance. Mean ± sd time-effect profi les 
of adaptive tracking performance for placebo (•), gpi 5693 100 mg (°), 300 mg (:), 750 mg (;) and 1125 mg (Ç).
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figure 3  Average visual analogue scales alertness. Mean ± sd time-effect profi les 
of visual analogue scales for alertness for placebo (•), gpi 5693 100 mg (°), 300 mg (:), 750 mg (;) and 1125 mg (Ç).
figure 4 Average visual analogue scales mood. Mean ± sd time-effect profi les of visual 
analogue scales for mood for placebo (•), gpi 5693 100 mg (°), 300 mg (:), 750 mg (;) and 1125 mg (Ç).
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figure 5 Average plasma concentrations of gpi 5693. Mean ± sd time-concentration 
profi les after gpi 5693 100 mg (+), 300 mg (s), 750 mg (°), 750 mg (fed) (;), 1125 mg (•), 1125 mg (fed) (:), 1500 mg (fed) (ø).
table 1  Summary of treatment related adverse events
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Body systems (preferred term)
Doses in mg (number of subjects)
100 (4) 300(9) 750(8) 750f (4) 1125 (4) 1125f (12) 1500f (12) Placebo (8)
Body as a whole – General disorders 1 1 4
Fatigue 1 3
Temperature changed sensation 1 1
Central & peripheral nervous system disorders 2 1 1 1
Dizziness 1 1
Headache 2 1
Gastro-intestinal disorders 1 1 2 3 6 7 1
Abdominal pain 1
Diarrhoea 1
Dyspepsia 1 1 1 2 2 2
Eructation 1
Gastro-esophageal refl ux 2 1
Nausea 1 2 2 1
Psychiatric disorders 1 1 3
Insomnia 1
Somnolence 1 3
Skin and appendages disorders 1 1 1
Pruritis 1
Skin reaction localized 1 1
Vision disorders 1
Vision abnormal 1
                  * Dose administered with standardiced meal
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table 2  gpi 5693 summary pharmacokinetic parameters
Dose gpi5693 n cmax (ng/ml) SD tmax (min) sd aucinf (hr*ng/ml) sd T1/2 (hr) sd
100 mg 4 723 201 38 9 684 205 0.87 0.02
300 mg 9 2868 1384 42 10 2733 779 2.54 0.71
750 mg 8 9266 4650 51 53 8855 2498 4.78 2.21
1125 mg 4 15742 3958 45 12 17332 4542 6.05 0.70
750 mg fed 4 3057 1046 45 0 5144 1239 8.83 7.03
1125 mg fed 12 5309 2086 74 33 10523 3292 6.88 6.71
1500 mg fed 12 6822 2229 93 37 15218 3708 8.62 5.48
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Abstract
This study investigates the cns effects of sumatriptan and rizatriptan, 
with temazepam as an active comparator, in healthy female volunteers. 
Sixteen volunteers completed a randomized, double-blind, crossover 
study and on four separate occasions received either 100 mg sumatriptan, 
20 mg rizatriptan or 20 mg temazepam. The main parameters were eye 
movements, eeg, body sway, visual analogue scales and a cognitive test 
battery. Rizatriptan and sumatriptan decreased saccadic peak velocity 
by 18.3 (95% ci: 5.7, 30.8) and 15.0 (2.2, 27.9) °/sec, respectively, about 
half the decrease induced by temazepam (35.0 (22.1, 47.8) °/sec). Body 
sway increased (30% for rizatriptan (16%, 45%) and 14% for sumatriptan 
(1%, 27%), respectively). Temazepam caused larger, similar effects. In 
contrast to temazepam, sumatriptan and rizatriptan decreased reaction 
times of recognition tasks and increased eeg alpha power (signifi cant 
for sumatriptan, 0.477 (0.02, 0.935). Therapeutic doses of sumatriptan 
and rizatriptan caused cns effects indicative of mild sedation. For eeg 
and recognition reaction times the effects were opposite to temazepam, 
indicating central stimulation. 
Introduction
5Ht1b/d agonists are becoming increasingly popular in the treatment 
of migraine attacks. This type of drug is able to activate the 5ht1-like 
receptors on the main cranial vessels, resulting in vasoconstriction and 
thus providing relief of symptoms.* The popularity of the 5ht agonists 
in the acute treatment of migraine is mainly due to the high effi cacy and 
the relatively low rate of side-effects compared with other treatments. 
The fi rst registered 5ht1b/d agonist was sumatriptan, at a recom-
mended oral dose of 50 mg followed by another 50 mg 2 h later in case of 
recurrence of symptoms. Following oral administration sumatriptan has 
a bioavailability of 14%,* which is controlled by dosing to effective con-
centrations. Sumatriptan is metabolized by monoamineoxidase (mao) 
to an inactive n-desmethyl metabolite; the elimination half-life is around 
2 h.* Other triptans quickly followed sumatriptan. Although these trip-
tans demonstrate increased bioavailability over sumatriptan they appear 
to offer few clinical advantages. 
Rizatriptan has been demonstrated to be absorbed more rapidly 
compared with sumatriptan* and has a bioavailability of 40–45% after 
oral administration,* with an elimination half-life of around 2 h.* It is 
metabolized by mao into an active n-desmethyl metabolite and may 
have a longer effect. 
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It has been claimed that rizatriptan has superior effi cacy compared with 
sumatriptan, whereas at therapeutically relevant doses there are indica-
tions that rizatriptan may cause more adverse events, such as dizziness 
or drowsiness, compared with sumatriptan.* The mechanisms involved 
in these adverse events, and the best methods to quantify them, are un-
known. It has long been assumed that triptans were not able to penetrate 
the central nervous system, which might have led to a relatively low 
number of studies and assessments of these types of adverse effects. 
The current study investigated the effects of clinical doses of sumat-
riptan and rizatriptan on the central nervous system, compared with pla-
cebo and temazepam as an active comparator for dizziness and drows-
ness. An array of neuropsychometric parameters was used that has been 
shown to be sensitive to sedative agents.* Additionally, the relationship 
between the plasma concentrations and pharmacodynamics of sumat-
riptan and rizatriptan was evaluated. The study was performed in female 
subjects only, because of the higher prevalence of migraine in females.
Methods
Subjects
After approval of the protocol by the Ethical Review Board of the Leiden 
University Medical Centre, 16 healthy female volunteers were recruited, 
plus one replacement subject. Written informed consent was obtained 
before entering the study. After this the subjects received a full medical 
examination. Drugs were administered to the participants only after a 
negative pregnancy test (Pacifi c Biotech Inc., San Diego, usa) and urinary 
drug-screen (ontrak Rapid Assays for Drug Abuse; Roche (diagnostic 
systems), Mijdrecht, the Netherlands) had been obtained on the 
morning of each study day. Volunteers refrained from nicotine, alcohol 
and caffeine from 48 h prior to each study day until 24 h after dosing. 
Strenuous exercise was to be avoided for 48 h before each study safety 
screen and 12 before and after each dose. Concomitant medication was 
not permitted during each study period. 
Design and procedure
The study was performed as a double-blind, randomized, placebo-
controlled four period cross-over comparative trial with a minimum 
Ref. 6-8
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washout period of 3 days and a maximum washout period of 1 week. 
The study medication contained sumatriptan 50 mg tablets, rizatriptan 
10 mg encapsulated tablets, temazepam 20 mg capsules and placebo 
tablets and capsules. Rizatriptan and temazepam were encapsulated into 
identical hard gelatine capsules. On each study day subjects received 
either: a sumatriptan 50 mg tablet and a placebo capsule followed by the 
same treatment after 2 h; rizatriptan 10 mg capsule and a placebo tablet 
followed by the same treatment after 2 h; a placebo tablet and capsule 
followed by temazepam 20 mg capsule and a placebo tablet after 2 h; or 
a placebo tablet and capsule, followed by the same treatment after 2 h. 
The triptans were administered according to clinical practice for repeated 
dosing. Temazepam was administered at 2 h to have a comparable tmax 
for temazepam and the triptans (3–5 h after initial dose). 
All tests (except the cognitive test battery) and blood sampling were 
performed before the intake of medication and at the following times 
after the fi rst intake: 20, 40 min, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10 and 12 h. The 
cognitive test battery was executed in the 3–5-h period after the fi rst 
administration of the study drug. Adverse events were checked regularly 
with openended questions (‘How do you feel?’). Before the intake 
of medication (around 09.15) A light standard breakfast was served. 
Standard lunch and dinner were served 5 and 8 h post-dose.
Pharmacodynamics
eye movement analysis Recording and analysis of saccadic and 
smooth-pursuit eye movements was performed with a microcomputer-
based system, as described previously.* The equipment used for stimulus 
display, signal collection and amplifi cation was from Nihon Kohden 
(Nihon Kohden Corporation, Tokyo, Japan). Saccadic eye movements 
were recorded for stimulus amplitudes of 15 degrees to either side. 
Interstimulus intervals varied randomly between 3 and 6 s, 15 saccades 
were recorded. The average values of saccadic peak velocity, latency 
(reaction time) and inaccuracy were used as parameters. For smooth-
pursuit eye movements the target moved sinusoidally at frequencies 
ranging from 0.3 to 1.1 Hz, increasing by steps of 0.1 Hz. The amplitude 
of target displacement corresponds to 20 degrees eyeball rotations to 
both sides. Four cycles were recorded for each stimulus frequency.
electroencephalograms Electroencephalograms were recorded 
and analysed using ced software (Cambridge Electronics Design, 
Ref. 12
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Cambridge, uk), as described previously.* eeg recordings were made 
using silver-silver chloride electrodes, fi xed with collodion at Fz, Cz, 
Pz and Oz, with the same common ground electrode as for the eye 
movement registration international 10/20 system). The electrode 
resistances were kept below 5 kOhm. All recordings were done with the 
subjects’ eyes closed. eeg signals were obtained from leads Fz-Cz and 
Pz-Oz. The signals were amplifi ed by use of a Nihon Kohden ab-621g 
bioelectric amplifi er (Nihon Kohden Corporation) with a time constant of 
0.3 s and a low pass fi lter at 100 Hz. Eight consecutive blocks of 8 s were 
recorded per session over a 2-min period. The sampling rate was 1024 
Hz. Datablocks containing artefacts were identifi ed by visual inspection 
and these were excluded from analysis. Fast Fourier transform analysis 
was performed to obtain the sum of amplitudes in the delta (0.5–3.5 
Hz), theta (3.5–7.5 Hz), alpha (7.5–11.5 Hz) and beta (11.5–30 Hz) frequency 
ranges. The total recording bandwidth was 0–50 Hz. 
body sway Body sway was measured using an apparatus similar to the 
Wright ataxiameter,* which adds up the amplitude of body movement 
transferred through a string that is attached to the waist (apparatus: 
tno/nipg, Leiden, the Netherlands). Measurements of sagittal body 
sway (forwards/backwards) were made for 2 min with the eyes closed 
while standing on an unstable surface consisting of a 10-cm foam pad 
covered with a rigid plateau. The subjects were standing comfortably 
with their feet slightly apart and arms along their body.
visual analogue scales Visual analogue scales as originally 
described by Norris* were used to quantify subjective effects. Three 
factors corresponding to alertness, mood and calmness were derived 
from these measurements.*
Cognitive test battery
Cognitive performance was tested using the ‘FePsy’ software package 
(Instituut voor Epilepsiebestrijding, Heemstede, the Netherlands)*. This 
system contains a battery of computerized tests of different complexity 
measuring diverse cognitive skills. The battery has been extensively 
validated in epilepsy patients.* The following tests were performed: 
- Simple auditory and visual reaction time, measuring attention.
- The binary choice task, a more complex reaction time task measuring  
 information processing and response inhibition.
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- The visual searching task, which evaluates the visual (complex) 
information processing and perceptual–mental strategies. The main 
parameter of the visual searching task was the number of errors, 
the secondary endpoint was the mean searching time of correct 
response.*
- The card sorting task, which assesses abstraction ability, 
conceptualization, failure to maintain set and perseverance.*
- Serial recognition of words and fi gures and simultaneous recognition 
of words and fi gures, which are recognition and short-term memory 
tasks.
- The corsi block tapping test,* a direct recall memory test.
Pharmacokinetics
Blood samples were drawn from an intravenous cannula inserted into 
a forearm vein. The blood samples were immediately centrifuged after 
collection at 4°c at 1000 g and the plasma was separated. The plasma 
samples were frozen at -20°C and stored until analysis. The plasma 
samples were analysed by the department of international bioanalysis 
(GaxoSmithKline, Ware, uk) using solid phase extraction in combination 
with liquid chromatography tandem mass spectrometry (lc-ms-ms) for 
sumatriptan and rizatriptan. For temazepam, the plasma samples were 
analysed by Simbec Research tld (Merthyr Tydfi l, Wales) using a gas 
chromatography method. 
Sample times were related to the time of (fi rst) dose (for study drugs 
administered twice). Pharmacokinetics for all drugs were assessed using 
non-compartmental methodology as implemented in WinNonlin V2.1 
(Pharsight Corporation, Mountainview, California, usa). For each subject 
and each treatment the following pharmacokinetic parameters were 
determined: maximum plasma concentration (cmax), the time at which 
the maximum concentration was reached, relative to dosing (tmax), 
the terminal halfl ife (t1/2) and the area under the plasma concentration-
time curve up to the last quantifi able concentration (auclast) and 
extrapolated to infi nity (aucinf). Descriptive statistics were reported 
for each pharmacokinetic parameter. The results for sumatriptan and 
rizatriptan were compared with the literature and with data on fi le to 
verify that the bioavailability was not altered by the reformulation. 
Ref. 19, 20
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Statistics
All repeatedly measured dynamic variables were characterized using 
changes from pre-treatment value expressed as areas under the effect 
curve (auecs). These auecs were calculated using the linear trapezoidal 
rule and were divided by the corresponding timespan, resulting in a 
time-weighted average outcome. Auecs were calculated over the entire 
sampling period (12 h) and over the fi rst 6 h because most of the response 
was expected to occur during this period. Results are only reported 
relative to baseline over the 0–6-h period. The cognitive test results 
were compared among treatments using standard analysis of variance 
methods. The primary contrasts were sumatriptan vs. rizatriptan, 
sumatriptan vs. placebo and rizatriptan vs. placebo, calculated within the 
anova model. The contrast with temazepam was used in an exploratory 
fashion, providing a frame of reference for the cns effects of sumatriptan 
and rizatriptan. The results are presented as average differences with 
95% confi dence intervals (95% ci) unless indicated otherwise.
The relationship between concentrations and effects was assessed by 
plotting the effect vs. the interpolated concentration. The interpolated 
concentration was used because of a time difference between blood 
samples and dynamic parameters. Placebo correction was implemented 
by subtracting the response during the placebo occasion from the 
response during active treatment at corresponding nominal times on an 
individual basis. The relationships between interpolated concentrations 
and placebo corrected spv and log body sway were assessed by calcu-
lating linear concentration-effect relationships using nonlinear mixed 
effect modelling (nonmem version V; nonmem Project Group, ucsf, 
California, usa). This procedure analyses all curves collectively while 
preserving differences between individuals. Different slope and intercept 
estimates for the different drugs were implemented. Additive intra- and 
interindividual error models were used and parameters were estimated 
using fi rst order conditional estimation (foce) with the ‘interaction’ 
option. The signifi cance of slope parameters was assessed by calculating 
95% confi dence intervals using the reported standard errors.
Results
Sixteen subjects were initially recruited. One subject repeated a 
dosing period, due to a non-treatment-related adverse event that led 
to discontinuation of the third study day. One subject was replaced 
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because of a non-serious adverse event during the third study day. The 
mean age of the 17 participants was 21.4 years (range 18–28). Body mass 
index (weight (kg)/length (m)2) was below 30 for all participants. The 
pharmacodynamic results are based upon 16 subjects who completed all 
treatment periods and one subject who completed two dosing periods. 
The pharmacokinetic results are based upon plasma concentrations of 17 
subjects for rizatriptan and 16 subjects for sumatriptan and temazepam. 
The safety analysis was performed on all 17 subjects that received one or 
more treatments. 
Adverse events
In all treatment groups sedation (40%), headache (19%) and dizziness 
(9%) were recorded most. Drug-related adverse events, as judged by 
the investigator, were also mainly sedation (75%), headache (13%) 
and dizziness (11%). No large differences were seen between the 
different treatments, but temazepam appeared to induce slightly more 
sedation of moderate intensity than the other treatments (table 1). 
Events were generally mild and did not require treatment. Two subjects 
experienced moderate adverse events (fl u-like symptoms) that led to the 
discontinuation of a trial day. During those events paracetamol was used 
for symptomatic treatment.
Pharmacodynamics
eye movements Both rizatriptan and sumatriptan caused a small 
but statistically signifi cant reduction in saccadic peak velocity of -18.3 
(-30.8, -5.7) °/s (mean difference, 95% confi dence interval) and -15.0 
(-27.9, -2.2) °/s, respectively, compared with placebo. This was about half 
the effect of temazepam, which caused a reduction of -35.0 (-47.8, 
-22.1) °/s (fi g. 1). The difference of 3.3 (-9.6, 16.1) °/s between the two 
triptans was not statistically signifi cant. The triptans did not have 
signifi cant effects on saccadic latency or inaccuracy. Temazepam showed 
a clear but non-signifi cant effect on the smooth-pursuit eye movements. 
Both triptans did not alter smooth-pursuit eye movements compared 
with placebo.
electroencephalograms Sumatriptan caused a statistically 
signifi cant increase in alpha power compared with placebo for the 
Table 1 – p. 53
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frontal leads (0.477 (0.020, 0.935) µv/min). Rizatriptan showed a non-
signifi cant increase in alpha power for the frontal leads (0.366 (-0.081, 
0.812) µv/min). The average time-effect profi les of temazepam suggested 
a decrease of frontal and occipital alpha power, but this did not reach 
statistical signifi cance relative to placebo (-0.399 (-0.856, 0.58), -0.439 
(-1.171, 0.292) µv/min, frontal and occipital leads, respectively) (fi g. 2a). 
The mean difference and confi dence intervals for frontal leads alpha 
power are displayed graphically in fi g. 2b. Temazepam showed a non-
signifi cant elevation of frontal beta power (0.142 (-0.025, 0.309) µv/min). 
No effect of temazepam or the triptans was seen on the occipital beta 
amplitude. There were no signifi cant changes in delta power for any of 
the treatments compared with placebo. A non-signifi cant decrease of 
frontal (-0.319 (-0.654, 0.017) µv/min) and occipital (-0.271 (-0.577, 0.035) 
µv/min) theta power was observed for temazepam compared with 
placebo.
body sway The blinded review of body sway data indicated that body 
sway needed to be analysed on a log-scale. Both triptans caused small 
statistically signifi cant increases in body sway compared with placebo 
(fi g. 3). Rizatriptan caused an increase of 30 (16, 45)% and sumatriptan 
had a smaller effect of 14 (1, 27)%. By comparison, temazepam caused an 
increase in body sway of 31 (17, 47)%. There was a statistically signifi cant 
difference between the two triptans of 15 (2, 29)% (p=0.022). 
visual analogue scales Temazepam gave a clear decrease of the 
vas alertness score of 4.35 (0.03, 8.68) cm compared with placebo. The 
triptans did not have any effect on vas for alertness. No differences were 
seen in mood and calmness comparing the different treatments with 
placebo and the triptans with each other.
Cognitive test battery
simple auditory and visual reaction time The reaction time 
tests were performed with the dominant and the non-dominant hand. 
Temazepam caused an increase in mean auditive and visual reaction 
times for the dominant (51.8 (31.4, 72.1) and 35.9 (15.5, 56.4) ms) and the 
non-dominant hand (47.8 (32.3, 63.3) and 69.7 (24.3, 115.1) ms, respectively) 
compared with placebo. Rizatriptan and sumatriptan both caused 
an increase of mean auditive and visual reaction times. This was not 
signifi cant for the dominant hand, but rizatriptan caused a signifi cant 
Fig.2a - p. 54
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increase in the mean auditive reaction time for the non-dominant hand 
(20.9 (5.7, 36.1) ms) compared with placebo. A signifi cantly longer reaction 
time for rizatriptan compared with sumatriptan was found for the mean 
auditive reaction times of the non-dominant hand (18.2 (3.0, 33.4) ms).
binary choice task The mean reaction times for the binary choice 
task were signifi cantly affected following temazepam. There was an 
increase compared with placebo of 99.5 (46.2, 152.8) ms. Rizatriptan and 
sumatriptan caused much smaller, non-signifi cant increases in the mean 
reaction times. 
computerized visual searching task Temazepam caused 
a signifi cant increase in the number of errors (0.85 (0.17, 1.53) items), 
the main parameter of the visual searching task, and prolonged the 
mean searching time for the correct responses (by 1.44 (0.37, 2.51) s). 
Sumatriptan and rizatriptan had no signifi cant effects compared with 
placebo or each other.
simultaneous and serial recognition of words and 
figures For simultaneous recognition of words, a signifi cant increase 
in reaction times of correct responses of 0.34 (0.08, 0.60) s during 
temazepam treatment was observed. Also, for this task a signifi cant 
reduction in the number of correct responses was seen for temazepam 
compared with placebo (2.02 (0.55, 3.49) items). Compared with 
temazepam, the average number of correct items during sumatriptan 
and rizatriptan treatments decreased slightly but not signifi cantly. 
However, for simultaneous recognition of words the reaction times 
for the correct responses decreased signifi cantly for both sumatriptan 
(0.31 (0.04, 0.58) (s) and rizatriptan (0.26 (0.00, 0.52) (s) compared to 
placebo. The reaction times for correct responses during temazepam 
treatment increased signifi cantly compared with placebo for both 
simultaneous recognition of fi gures (0.67 (0.23, 1.11) (s) and the serial 
recognition of words (0.45 (0.23, 0.66) (s). No effect of temazepam was 
found on the number of correct responses of both tests. Both triptans 
showed no effect on the reaction times or numbers of correct responses. 
No signifi cant effect of temazepam, rizatriptan or sumatriptan was 
observed on the serial recognition of fi gures. 
corsi block tapping task and card sorting test 
No signifi cant effect of temazepam, rizatriptan or sumatriptan 
was observed on the corsi block tapping task or card sorting test.
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Pharmacokinetics
Pharmacokinetic parameters are presented in table 2. A recent 
pharmacokinetic study reported cmax after rizatriptan 10 mg orally as 
28.6±13.5 ng/ml.* Thus, cmax was found to be approximately 14% lower 
after the fi rst dose in the current study, with encapsulated rizatriptan. 
In the same study tmax was reported as 42±12 min,* which is 56 min 
earlier than in the current study. Thus, encapsulation of rizatriptan 
caused a delay in absorption compared with the tablet formulation 
as presented in recent literature.
The pharmacokinetic properties of sumatriptan and temazepam 
were consistent with those presented in the literature. Dynamic 
measurements were performed after the second dose and around cmax 
for the second dose of all treatments.
Pharmacokinetic–pharmacodynamic modelling
Pharmacokinetic–pharmacodynamic relationships were investigated for 
all repeated measurements that showed a signifi cant difference between 
both triptans and placebo, i.e. saccadic peak velocity (spv) and log body 
sway. 
For saccadic peak velocity corrected for placebo, the average slopes 
((°/s)/(ng/ml)) and their 95% confi dence intervals (ci) were as follows: 
sumatriptan -0.168 (-0.37, 0.04), rizatriptan -0.494 (-0.79, -0.20) and 
temazepam -0.164 (-0.21, -0.12). Thus, no signifi cant concentration-effect 
relationship was shown for sumatriptan, in contrast to rizatriptan and 
temazepam.
For log body sway corrected for placebo, the average slopes ((log 
mm/2 min)/(ng/ml)) and their 95% confi dence intervals (ci) were as 
follows: sumatriptan 0.76 (-0.39, 1.91), rizatriptan 2.98 (1.40, 4.56) and 
temazepam 0.495 (0.34, 0.65). As for saccadic peak velocity, a signifi cant 
concentration-effect relationship was shown only for rizatriptan and 
temazepam. 
Discussion
Until recently, it has been assumed that triptans do not penetrate 
the central nervous system. However, the current study showed that 
sumatriptan and rizatriptan had effects on several central nervous 
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system measurements. Both triptans reduced saccadic peak velocity, 
which is indicative of a mild sedative drug effect. The increase in body 
sway and the increases in simple auditive and visual reaction times 
during sumatriptan and rizatriptan treatment support this fi nding. 
The effects of these triptans were generally smaller and less consistent 
than those of temazepam. For instance, the decrease in saccadic peak 
velocity caused by sumatriptan and rizatriptan was only half that 
caused by a moderately sedative dose of temazepam. Sedation caused 
by a 5ht1b/d agonist is rarely reported in human studies and could be 
of clinical importance. Sedative drug effects of sumatriptan have been 
demonstrated during safety studies in cynomolgus monkeys after 
administration of very high doses of 20 and 40 mg/kg.* In a recent 
meta-analysis of oral triptans, the incidence of cns effects (consisting 
among others of agitation, confusion, dizziness and somnolence) was
reported around 4% after sumatriptan 50 mg and around 9% for 
rizatriptan 10 mg.*
The apparent difference in effect size between sumatriptan and 
rizatriptan was small. Rizatriptan appeared to have a greater effect on 
the measurements than sumatriptan. This difference between these 
triptans only became signifi cant for body sway and some of the cognitive 
tests. Rizatriptan cns responses in this study may have been have been 
underestimated as rizatriptan encapsulation appears to have caused a 
decrease in expected cmax of around 14%, and a delay in tmax of about 
56 min, compared with pharmacokinetic data available for rizatriptan.*
Cognitive testing showed clear neurocognitive effects of temazepam. 
The drug primarily caused an increase in reaction times for the different 
tests, an effect that is well known for benzodiazepines and other sedative 
agents.* There are indications that benzodiazepines interfere primarily 
with procural and/or storage of information.* This is supported by our 
fi ndings. Temazepam decreased the number of correct responses on the 
simultaneous recognition of words and increased the number of errors 
on the visual searching task. Triptan effects on cognition and eeg were 
partly different from those of temazepam, suggesting slightly enhanced 
impulsivity. First, sumatriptan (and rizatriptan nonsignifi cantly) both 
caused an elevation of frontal-central alpha power. Such an increase 
in alpha power is compatible with a state of relaxed wakefulness.* As 
expected, temazepam caused a decrease in alpha power, which was non-
signifi cant in this case but has been described repeatedly.* A similar 
observation, an increase with the triptans and decrease with temazepam, 
was made in occipital-central theta power. This may be explained by 
subharmonic alpha waves that present as theta waves, a phenomenon 
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which is often seen in young people’s eegs. However, it must be noted 
that the relationship between states of alertness and frontal alpha power 
is complex.
Secondly, both sumatriptan and rizatriptan caused a small but 
signifi cant decrease in reaction times for the simultaneous recognition 
of words, while the number of correct responses declined (though not 
signifi cantly). These effects are opposite to temazepam, which caused 
a signifi cant increase of reaction times, consistent with moderate 
sedation. These fi ndings may be caused by a potentially class-specifi c 
effect of sumatriptan and rizatriptan on information or decision 
processes. A change in strategy under infl uence of these triptans may 
be responsible for the decrease in reaction times: instead of choosing 
for accuracy subjects may have favoured speed. The same changes in 
decision processes were not observed for other reaction time tasks 
(e.g. the visual searching task and the card sorting task). In contrast 
to the word recognition task, these tasks give feedback on the accuracy 
(but not the velocity) of the responses, which may have stimulated 
accuracy. 
The enhanced speed and reduced accuracy suggests that sumatriptan 
and rizatriptan stimulate impulsivity, although the effects were very 
small. This may explain why they were seen in only one test of the 
cognitive test battery: simultaneous recognition of words is regarded 
as one of the most diffi cult memory tests in the battery, and could 
therefore be more sensitive to a slight impairment. On the other hand, 
this isolated fi nding may be spurious.
Previous reports of other 5ht1 agonists, like buspirone and 
umespirone, have shown mixtures of sedative and stimulant effects.* 
Buspirone showed a subjective sedative effect on analogue rating scales, 
impaired memory and increased reaction times for cognitive tests. 
Umespirone also increased reaction times. Stimulant effects such as an 
increase in subjective alertness and a decrease in reaction times were 
observed for buspirone* and improvements in word recognition and 
mood were observed for umespirone* Our observations on the 5ht1b/d 
agonist-triptans are partly compatible with these fi ndings.
Recently, there is increasing evidence that triptan penetration 
into the central nervous system is not only responsible for some of 
the adverse effects, but also contributes to the relief of migraine 
symptoms. The mechanisms of action could be the inhibition of activity 
of the trigeminal nucleus caudalis activity* or the decrease of cortical 
spreading depression as occurs in the early onset of a migraine attack.* 
Sumatriptan was also shown to normalize eeg changes associated with 
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migraine, such as an increase in the theta and delta range and a decrease 
in the alpha and beta range.*
In summary, these results show that sumatriptan and rizatriptan 
cause small but clear effects on the central nervous system. These effects 
may differ from those caused by the benzodiazepine temazepam. They 
may be due to subtle changes in information and decision processing, 
compatible with enhanced impulsivity. The effects of rizatriptan appear 
to be slightly larger than for sumatriptan, although in most cases this 
did not reach statistical signifi cance. The difference may have been 
decreased by an alteration of rizatriptan pharmacokinetics as a result 
of encapsulation. In any case, the cns-effects of both sumatriptan and 
rizatriptan were small in comparison to those of 20 mg temazepam, 
and do not seem to compromise clinical tolerability to any appreciable 
extent. Although this study was performed in a small number of subjects 
with many parameters and does not univocally establish cns effects of 
sumatriptan and rizatriptan, these results could be regarded as a guide 
for further studies.
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figure 1 Average time-effect curve of the used drugs and saccadic eye movements 
peak velocity.
table 1  Summary of main adverse events (number reported).
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Main adverse events Placebo oral 
(n = 17)
Sumatriptan 
(n = 17)
Rizatriptan 
(n = 17)
Temazepam 
(n = 16)
Any event 30 29 27 25
Any drug related event 13 13 13 17
Neurological event 19 16 20 23
Drug related neurological event 13 11 13 17
Sedation 8 9 11 14
Headache 3 1 2 1
Dizziness 3 1 0 2
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figure 2a Average time-effect curve for eeg alpha power (fc and po leads).
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figure 2b Mean difference from placebo and 95% confi dence intervals of eeg alpha 
power.
figure 3 Average time-effect curve for log-transformed body sway.
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table 2  Pharmacokinetic parameters.
Parameters Sumatriptan Rizatriptan Temazepam
Geometric mean (95% confi dence intervals)
Cmax  (ng/ml) 1
st Dose 28.5 (19.9-40.7) 22.7 (18.2-28.3) na
2nd Dose 40.6 (34.1-48.3) 36.8 (31.6-42.8) 423 (364-493)
AUC0-inf   (ng/ml*hr) 238 (200-284) 197 (173-224) 2600 (2100-3210)
t1/2 (min) 111 (101-121) 105 (95-116) 350 (285-430)
Mean ± SD (range)
Tmax  (min) 1
st Dose 94 ± 24 (60-120) 98 ± 26 (40-120) na
2nd Dose 148 ± 79 (50-230) 89 ± 47 (50-230) 86 ± 50 (20-230)
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Abstract
Previous single-dose studies have shown clear blood pressure-lowering 
effects of a potential sustained release (sr) profi le of rilmenidine, with 
concentration-dependent effects on the central nervous system. The 
aim of this study was to evaluate potential changes in concentration–
effect–relationships for these central nervous system effects during 
a 4-week treatment period with an experimental sr formulation of 
rilmenidine 3 mg once daily in 15 mild-to-moderate hypertensive 
patients. The central nervous system effects of the treatment were 
evaluated using saccadic eye movements for sedative effects and visual 
analogue scales for subjective effects on alertness, mood and calmness. 
Measurements for pharmacokinetic and pharmacodynamic evaluations 
were performed on the fi rst day of the treatment period and repeated 
after 1 week and 4 weeks of treatment. Drug concentrations increased 
during the study, whereas treatment related reductions in saccadic peak 
velocity (spv) remained similar on all three study days. The slopes of the 
concentration–effect–curves for spv remained unchanged throughout 
the study, while the intercepts tended to increase as a result of increased 
pre-dose values. Similar effects were observed for visual analogue scales 
for alertness: pre-dose values increased signifi cantly during the study, 
while the size of the treatment responses (slopes) remained unaltered. 
The reasons for these adaptations cannot be determined but may include 
drug tolerance and habituations to study procedures. Blood pressure 
control remained stable and adequate throughout the study. 
Introduction
Rilmenidine [2-(dicyclopropylmethyl)-amino-2-oxazoline] is a centrally 
acting anti-hypertensive with binding selectivity to the I1 imidazoline 
receptors over α2-adrenoceptors (Beau et al., 1988; Verbeuren et al., 
1990; Institut de Recherches Internationales Servier (iris), 1993; Yu et al., 
1996). It has dose (concentration)-dependent blood pressure lowering 
effects above 0.5 subjects. Rilmenidine is registered in several European 
countries at a recommended dose of one tablet (1 mg) once or twice daily. 
Clinical experience indicates that with 1 mg dosing blood pressure control 
might not be maintained for 24 h per day in all patients. In a study of 
146 patients with hypertension (diastolic blood pressure between 95 
and 115 mmhg), trough level blood pressure control was considered 
inadequate in 56% of subjects after 4 weeks of treatment (De Cort et 
al., 1993). An unspecifi ed number of these patients became adequately 
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controlled after increasing the dosing frequency to 1 mg twice daily. 
This dosage regimen is less acceptable during chronic treatment. 
On the other hand, elevating the dose of once-daily administration 
may increase the incidence of peak concentration-related side-effects, 
such as sedation and dry mouth (xerostomia) (Dollery et al., 1988). 
 A sustained release formulation of the drug could maintain 
plasma levels in between a minimum effective (anti-hypertensive) 
concentration and a maximum non-sedative peak level. In addition 
to the plasma concentrations, the rate of increase of concentration 
may also infl uence the effect. The classic example is provided by 
Kleinbloesem et al. (1987) who demonstrated that a high rate of increase 
of nifedipine concentrations did not lead to a blood pressure reduction 
in healthy volunteers, in contrast to a low rate of increase of nifedipine 
concentrations. However, a previously performed study showed no 
infl uence of the rate of infusion of rilmenidine on both blood pressure 
and central nervous system effects (visual analogue scales and saccadic 
eye movements) (de Visser et al., 2001a). The current study was performed 
after several studies had investigated the design of an optimal slow 
release profi le (de Visser et al., 2001a,b, 2002). From these studies, it was 
concluded that a 3 mg sustained release formulation would have the 
optimal profi le for adequate blood pressure control with an improved 
side-effect profi le. Because many centrally active drugs show some 
tolerance development to side-effects during prolonged treatment, the 
current study aimed to investigate the effects of a 4-week treatment 
with a 3 mg sustained release formulation on the pharmacokinetic/
pharmocodynamic (pk/pd) relationships between rilmenidine plasma 
concentrations and central nervous system effects (saccadic eye 
movements and visual analogue scales). Tolerance to these effects would 
be indicated by a reduced slope of the pk/pd relationship with saccadic 
eye movements and/or visual analogue scales. Increased intercepts of 
these relationships might also be an indication of tolerance, but this 
is more diffi cult to interpret because of the possible contributions of 
habituation to study procedures and other factors.
Methods
Design
This was a phase ii, single-centre, open, non-controlled study without 
direct individual benefi t for patients. Screening assessment took place 
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within 17 days before rilmenidine treatment. Patients were acquainted 
with the experimental methods and conditions in a short training session 
taking place within 1 week before rilmenidine treatment. Eligible patients 
were then withdrawn from their own anti-hypertensive treatment 
and switched directly into a 4-week 3 mg O.D. rilmenidine sustained 
release (sr) treatment. The withdrawal was gradual for ß-blockers, and 
immediate for other anti-hypertensive agents but, in all cases, as short as 
possible to prevent loss of blood pressure control. Measurements for pk/
pd evaluation were performed on the fi rst day (d1–d2) of the rilmenidine 
treatment period and repeated after 1 week (d8) and 4 weeks (d29) of 
treatment. At the end of the 4-week rilmenidine treatment period, 
patients were reallocated to their own anti-hypertensive treatment.
Subjects
Diagnosed hypertensive subjects (males and females), treated with at 
least one and a maximum of two different anti-hypertensive drugs, 
provided their signed informed consent to participate in the study. After 
a general health screen (during which relevant additional conditions were 
excluded, including causes for secondary hypertension), eligible patients 
were enrolled in the study. 
Treatments
Rilmenidine sr was presented as white round-shaped fi lm coated tablets 
containing 3 mg of active medication. Patients were requested to take 
one tablet of rilmenidine every morning under fasting conditions, with 
approximately 150 ml of water, 30 min before breakfast. Patients were 
instructed to take their study medication regularly (between 07.00 h and 
09.00 h in the morning). Patients were instructed to maintain a diary, 
where intake of study medication was to be recorded. 
Blood pressure 
Blood pressure was measured after the patient had been sitting quietly 
for at least 10 min, pre-dose and repeatedly post-dose on each of the 
three study days. All measurements were carried out with an automated 
sphygmomanometer (Nihon Kohden mpv 1072, Tokyo, Japan).
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Visual analogue scales
Visual analogue scales as originally described by Norris (1971) have been 
used previously to quantify subjective effects of benzodiazepines (van 
Steveninck et al., 1991). From these scales, three factors can be derived, 
as described by Bond et al., 1974, corresponding to alertness, mood and 
calmness. Increased scores on these scales indicate enhanced subjective 
feelings of alertness, mood (in general) and calmness. These visual 
analogue scales were practised at a training session (three times), and 
measured pre-dose and every 1 h for 12 h after dosing, on each of the 
three study days.
Saccadic eye movements
Saccadic eye movements have been used previously to quantify drug 
effects of rilmenidine (de Visser et al., 2001A) and clonidine (Harron et al., 
1995). Saccadic eye movements were practised at a training session (three 
times), and measured pre-dose and every 1 h for 12 h after dosing, on each 
of the three study days, with an additional measurement after 24 h for 
the fi rst dosing. Recording of eye movements was performed in a quiet 
room with ambient illumination. There was only one patient per session 
in the same room. Recording and analysis of saccadic eye movements 
was conducted with a microcomputer-based system for sampling and 
analysis of eye movements (Van Steveninck et al., 1999). The equipment 
used for stimulus display, signal collection and amplifi cation was from 
Nihon Kohden (Nihon Kohden Corporation, Tokyo, Japan). Disposable 
silver-silver chloride electrodes (Medicotest n-oo-s, Olstykke,Denmark) 
were applied on the forehead and beside the lateral canthi of both 
eyes of the patient for registration of the electro-oculographic signals. 
Skin resistance was reduced to less than 5 ko before application of the 
electrodes. Head movements were restrained using a fi xed head support. 
The target consisted of an array of light emitting diodes on a bar, fi xed 
at 50 cm in front of the head support. Saccadic eye movements were 
recorded for stimulus amplitudes of ± 15° to either side. Fifteen saccades 
were recorded for each stimulus amplitude with interstimulus intervals 
varying randomly between 3 and 6 s. Average values of latency (i.e. 
reaction time), saccadic peak velocity and inaccuracy of all artifact-free 
saccades were used as parameters. Saccadic inaccuracy was calculated as 
the absolute value of the difference between the stimulus angle and the 
corresponding saccade, expressed as a percentage of the stimulus angle. 
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Blood sampling
Patients were randomly allocated to one of the following investigation 
schedules for pk/pd evaluation. 
days 1–2 Schedule 1: pre-dose and 1, 4, 7, 10 and 24 h after dosing or 
schedule 2: pre-dose and 2, 5, 8, 11 and 24 h after dosing or schedule 3: 
pre-dose and 3, 6, 9, 12 and 24 h after dosing. 
days 8 and 29 Schedule 1: pre-dose and 1, 4, 7 and 10 h after dosing or 
schedule 2: pre-dose and 2, 5, 8 and 11 h after dosing or schedule 3: pre-
dose and 3, 6, 9 and 12 h after dosing. 
Blood samples for rilmenidine assay (9 ml) were obtained in lithium 
heparin-containing polypropylene tubes. Blood samples were drawn from 
an i.v. cannula (inserted into the arm opposite to the one where blood 
pressure was measured), which was kept patent using a heparin-nacl 
solution. Blood samples were taken after discarding the contents of the 
cannula. At the 24-h time point on day d2, blood was collected using a 
vacuette with a venapuncture. 
Analyses
pharmacokinetics Rilmenidine plasma levels were measured by 
using a gas chromatographic/mass spectrometric method (Ung et al., 
1987). Rilmenidine pk was modelled using a one-compartment model 
with first order absorption and a lag-time using nonmem version 
V software (nonmem Project Group, ucsf, San Francisco, ca, usa) 
using the first order conditional estimation method with interaction. 
Residual error was modelled as a combination of a constant coefficient 
of variation component and an additive component. Individual empirical 
Bayes estimates for absorption half-life, elimination half-life, clearance 
and lag-time were determined for all occasions separately, and predicted 
individual rilmenidine concentration profiles were obtained using these 
estimates.
pharmacodynamics Areas under the curve were calculated for 
saccadic eye movement data and visual analogue scale scores using the 
linear trapezoidal rule on (expected) protocol times (auecs). These auecs 
were subsequently divided by the corresponding time span resulting in 
a weighted average response. Additionally, the minimum measurement 
was determined with the associated actual time point for parameters 
with a clear response. In the case of multiple minima, the first occurrence 
63 chapter 3 – pharmacokinetic/dynamic assessment of tolerance to central nervous 
 system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients
was taken. No corrections for baseline response were implemented for 
either auecs or emin, because the baseline results could be subject to 
changes during treatment. 
Response measurements (auec, emin, tmin) were compared 
between the 3 days using paired student’s t-tests without correction for 
multiple comparisons because of the limited number (n = 3) of contrasts 
and because all contrasts are sensible and clearly address the main 
objectives of the study. 
pk/pd Using the predicted rilmenidine concentrations, a linear 
concentration–effect model with additive residual error was applied to 
saccadic peak velocity and vas alertness scores without use of an effect 
compartment, because individual graphs did not indicate the need for 
a more complex model (e.g. delay or nonlinearity in the concentration–
effect relationship). Parameter estimates for slopes and intercepts were 
obtained using nonmem with the fi rst order conditional estimation 
method. Estimates were obtained for the parameters on day 1 and 
changes were estimated from the value on day 1 to the value on day 8 
and from the value on day 1 to the value on day 29 value. Signifi cance of 
changes was assessed by calculating 95% confi dence intervals for the 
difference estimates using two times the reported se of the estimates.
Data management and additional calculations were performed using 
sas for Windows V 8.2 (sas institute, inc., Cary, nc, usa).
Results
Subjects
Fifteen (seven male, eight female) hypertensive patients were 
randomized to one of the blood sampling schedules. Their ages were in 
the range 41–65 years with a (mean ± sd, 51.3 ± 7.2 years). All patients had 
mild-to-moderate essential hypertension, and received one or two anti-
hypertensive agents (angiotensin-converting enzyme inhibitors 33.3%, 
ß-blockers 26.7%, diuretics 26.7%, angiotensin ii inhibitors 26.7%, 
calcium antagonists 6.7%, combined form (ß-blocker and diuretic) 6.7% 
of the study population). Two patients suffered from arthrosis and these 
patients used allowed concomitant medication (Ibuprofen 400 mg prn). 
Baseline systolic/diastolic blood pressures on medication at screening 
(before switching to rilmenidine) were in the range 128/68–165/98 mmhg.
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Safety assessments
No serious or severe adverse events were reported. The most frequently 
reported adverse events were sleepiness, dry mouth and headache, 
which occurred in 93%, 60% and 46.7% of the patients, respectively. 
Most adverse events were of a mild intensity. No clinically signifi cant 
abnormalities were found for any of the safety laboratory measurements. 
Pharmacokinetics
The concentration-time profi le on days 1, 8 and 29 are shown in fi g. 1. 
The following population mean (approximate se of population mean ± 
sem) pharmacokinetic parameters were estimated: elimination half-life 
567 min [72.0 min, inter-individual coeffi cient of variation (iicv) 65%], 
absorption half-life 270 min (44.7 min, iicv 81%), clearance 0.457 L/min 
(0.0292, Iicv 40%) and a lag time of 165 min (4.61, Iicv 0%).
Blood pressure
Patients switched rapidly from their own antihypertensive treatment(s) 
to rilmenidine. The mean (sd) pre-dose blood pressures on day 1 were 
131.7/76.6 (12.1/7.9) mmhg. On day 29, the mean (sd) pre-dose systolic/
diastolic blood pressure was 140.5/80.6 (21.0/10.3) mmhg.
Saccadic eye movements
The effects of prolonged treatment on the auecs of saccadic peak 
velocity (spv), reaction time (rt) and inaccuracy are shown in table 1. 
The average curves for saccadic peak velocity (spv) on days 1, 8 and 29 
are presented in fi g. 2. The primary endpoint of saccadic peak velocity 
(spv auec) showed no signifi cant changes during 4 weeks of treatment 
with rilmenidine sr 3.0 mg od. The minimum spv values during days 
1, 8 and 29 of treatment were comparable, with mean ± sd values of 
413.2 ± 48.2, 415.4 ± 53.7 and 401.5 ± 63.0 degrees/s, respectively. Hence, 
these data provide no indications for tolerance development. There 
are clear indications for a treatment effect that is comparable among 
the three treatment days. The average minimum values (emin) on the 
three treatment days all represent decreases in excess of 15%, which is 
Fig. 1 , 2 – p. 69
Table 1 - p. 71
Fig. 2 – p. 69
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well over the level of clinical significance of 10% below baseline (van 
Steveninck et al., 1999) Associated with a decrease in spv observed 
after the loss of one night of sleep. The other two parameters (reaction 
time and inaccuracy) did not show any significant effects, except for a 
decrease in auec inaccuracy for days 8 and 29 compared to day 1.
Visual analogue scales
The auecs of vas alertness, mood and calmness are represented in table 
1. The average curves for visual analogue scale alertness on days 1, 8 and 
29 are shown in fi g. 3. Signifi cant increases in subjective alertness, mood 
and calmness were observed from day 1 to day 8 and from day 1 to day 
29. No signifi cant changes were observed from day 8 to day 29. The vas 
baseline values all increased from day 1 to day 8 and from day 1 to day 29.
pk/pd
pk/pd parameter estimations for vas alertness and spv are shown in 
table 2. The average pk/pd relationships are shown in fi g. 4 for spv and 
fi g. 5 for vas alertness. Both parameters (vas and spv) showed linear 
concentration–effect relationships. No signifi cant changes in slopes 
between days were observed for vas or spv, indicating that the central 
nervous system-effect of rilmenidine per unit concentration remained 
unaltered. The intercept for the spv pk/pd relationships did not change 
signifi cantly from day 1 to either day 8 or day 29. The intercept of the vas 
alertness scale increased signifi cantly after day 1: the difference between 
day 8 and day 1 was 12.5 (4.5 ± 20.5) mm and the difference between day 
29 and day 1 was 13.0 (2.9 ± 23.1) mm.
Discussion
This study was part of a series of investigations, designed for the 
development of an optimal controlled release formulation of the 
centrally active antihypertensive agent rilmenidine. Previous studies 
showed clear concentration-dependent effects on blood pressure and 
the central nervous system of a potential sustained release profi le of 
rilmenidine (de Visser et al., 2001a,b, 2002). Furthermore, these studies 
suggested that the optimal therapeutic window would be 4–6 ng/ml. 
Table 1 - p. 71
Fig. 3 – p. 70
Table 2 – p. 72
Fig. 4, 5 – p. 70, 71
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Although effective, these concentrations have been shown to produce 
some changes in saccadic eye movements and visual analogue scales, 
which could be consistent with the clinical phenomenon of sedation 
(van Steveninck et al., 1991). These effects could become less pronounced 
during prolonged treatment due to tolerance development (van 
Steveninck et al., 1997). The aim of the current study was to evaluate 
potential changes in pk/pd-relationships for these central nervous 
system effects during a 4-week treatment period with rilmenidine sr 3 
mg od.
The design of the study was based on two assumptions. First, a rapid 
switch from prestudy antihypertensives to rilmenidine was considered 
unlikely to affect the central nervous system effects. A rapid switch could 
affect blood pressure control that, soon after the switch, would still be 
partly affected by the interrupted prestudy treatment and would not be 
individually optimized. However, adequate long-term blood pressure 
control has already been established with rilmenidine (Ostermann et 
al., 1988), and this was not the aim of our study. The second assumption 
was that pk/pd analyses reduce the need for a placebo-control. Any 
major placebo response would dilute the relationship between the drug 
concentration and the pharmacodynamic parameter. Hence, a clear 
concentration–effect–relationship was considered a strong argument 
for drug-dependency of the parameter. pk/pd analyses were essential 
for the aims of the study because they can be used to quantify changes 
in sensitivity to the drug and the development of tolerance. For linear 
concentration–effect–relationships, changes can occur in the slope 
and/or the intercept of the concentration–effect curve. A decreased 
slope signifi es that the same concentration range produces a less 
pronounced response. For example, in this case, the effect at the highest 
observed concentration is decreased due to desensitization or dynamic 
counter-regulation. An increase in the intercept signifi es that the entire 
concentration-effect curve is right-shifted. Elevated pre-dose values will 
usually lead to an increased intercept of the concentration–effect curve. 
Rilmenidine concentrations accumulated signifi cantly during the 4-
week period, whereas central nervous system-effects did not increase. 
This is an indication of tolerance, which is also demonstrated in the 
concentration–effect–relationships for both spv and vas alertness 
scores. Figures 4 and 5 clearly show a parallel rightward shift of the 
concentration–effect curves (i.e. an increase in intercepts without any 
change in slopes). This increase could be largely attributed to an increase 
in pre-dose alertness. The treatment responses remained unchanged 
with rising rilmenidine concentrations. The mechanisms behind these 
Fig. 4, 5 – p. 70, 71
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changes are unclear. Pharmacological adaptations can cause an increased 
pre-dose effect (e.g. rebound after drug withdrawal), but this has not 
been reported for rilmenidine, and is particularly unlikely considering the 
accumulation (rather than withdrawal) of the drug with this sr profi le. 
Pharmacological tolerance to the central nervous system effects of 
rilmenidine would primarily (or at least additionally) be expected to cause 
a reduction in the slopes of the concentration–effect relationships, which 
was not observed in this study. Therefore, explanations for the observed 
alterations do not appear to be purely pharmacological. Methodological 
causes can be considered, related to learning effects or habituation to 
the study procedures. If causes for the adaptations were methodological, 
this would also be expected in a placebo group. However, a recent 4-
week placebo-controlled trial with the imidazoline antihypertensive 
moxonidine did not reveal any changes in the placebo treated group 
(Kemme et al., 2003). The concentration–effect–relationships in the 
moxonidine-group displayed clear changes in intercepts but not in slopes 
that are comparable to the fi ndings of the current study. This suggests 
that the gradual increase in predose alertness is drug-class specifi c. 
These changes are reminiscent of long-term adaptations observed with 
monoaminergic antidepressant treatments. Imidazoline agents show 
an increase in extracellular noradrenaline in the prefrontal cortex (Nutt 
et al., 1997), and this could explain the observed increase in attention 
(Middelton, 1996). The neuropharmacological effects of imidazoline 
agents and their therapeutic potentials for psychiatric disorders warrant 
further study (Nutt et al., 1997).
In conclusion, this study has shown an improvement in subjective 
pre-dose alertness (and mood and calmness) during prolonged 
rilmenidine treatment, whereas adequate blood pressure control was 
maintained throughout the 4-week treatment period.
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figure 1  Average rilmenidine concentration-time profi les at days 1, 8 and 29 
(mean ± sd).
figure 2 Average saccadic peak velocity-time profi les at days 1, 8 and 29.
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figure 3  Average visual analogue scale alertness-time profi les at days 1, 8 and 29.
figure 4  Average pk/pd relationship between predicted rilmenidine concentrations 
and saccadic peak velocity.
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figure 5 Average pk/pd relationship between predicted rilmenidine concentrations 
and vas alertness.
table 1 Time-corrected auec’s (0–12 h) for all pharmacodynamic parameters. 
Data are shown as mean (sd) and contrasts with 95% confi dence intervals (95% (ci) 
between treatment days (*p < 0.05).
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Day 1 Day 8 Day 29 Day 1 - Day 8 Day 1 - Day 29 Day 8 - Day 29
Mean 
(sd)
Mean 
(sd)
Mean 
(sd)
Mean 
(95% ci)
Mean 
(95% ci)
Mean 
(95% ci)
Saccadic peak 
velocity (deg/sec)
458.9 
(41.7)
458.9 
(44.4)
456.5 
(48.1)
0.0 
(-12.1, 12.1)
2.4 
(-17.1, 21.9)
2.4 
(-13.6, 18.4)
Saccadic reaction 
time (ms)
236 
(21)
229 
(21)
231 
(22)
7.1 
(-0.5, 14.7)
4.7 
(-3.7, 13.1)
-2.4 
(-9.0, 4.2)
Saccadic 
inaccuracy (%)
9.46 
(3.19)
8.39 
(2.62)
8.56 
(2.86)
1.06 
(0.38, 1.75) *
0.89 
(0.10, 1.69) *
-0.17 
(-0.65, 0.31)
vas alertness (mm)
72.1 
(13.5)
77.4 
(12.6)
78.1 
(12.7)
-5.36 
(-8.16, -2.56) *
-6.04 
(-9.18, -2.89) *
-0.68 
(-3.43, 2.08)
vas mood (mm)
78.9 
(12.0)
81.4 
(10.9)
82.4 
(11.7)
-2.45 
(-4.23, -0.66) *
-3.52 
(-5.60, -1.44) *
-1.07 
(-2.82, 0.68)
vas calmness (mm)
79.9 
(7.6)
83.9 
(7.4)
84.5 
(6.9)
-3.95 
(-5.92, -1.99) *
-4.61 
(-7.25, -1.96) *
-0.65 
(-2.69, 1.39)
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table 2  pk/pd parameters using empirical Bayes estimates for saccadic peak 
velocity and vas alertness. Data are population average, se of the population average 
(mean), 95% ci and inter-individual variability as standard deviation (IIsd).
Mean sem 95% cl iisd
Saccadic peak velocity
Slope day 1 (deg.sec-Ang-A.ml) -6.66 1.63 -9.9 / -3.4 4.77
Change to day 8 -0.0870 2.35 -4.9 / 4.6
Change to day 29 -0.286 2.96 -6.2 / 5.6
Intercept day 1 (deg.sec-A) 476 9.69 457 / 495 37.5
Change to day 8 16.2 12.6 -9.0 / 41.4
Change to day 29 9.34 18.4 -27.5 / 46.1
Residual variability (sd) 26.1
VAS alertness
Slope day 1 (mm.ng-A.ml) -0.828 0.519 -1.9 / 0.2 2.06
Change to day 8 -1.37 1.00 -3.4 / 0.6
Change to day 29 -1.32 1.08 -3.5 / 0.8
Intercept day 1 (mm) 75.5 3.47 68.6 / 82.4 9.42
Change to day 8 12.5 4.02 4.5 / 20.5
Change to day 29 13.0 5.06 2.9 / 23.1
Residual variability (sd) 7.17
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Abstract
objectives The primary aim was to demonstrate that moxonidine, 
given in an experimental sustained release (sr) formulation, had no 
clinically relevant central nervous system (cns) effects after 4 weeks of 
treatment. A clinically relevant cns effect was predefi ned as more than 
45° s-1 reduction in saccadic peak velocity (spv), corresponding to the 
effects of one night’s sleep deprivation.
methods In a randomized, double-blind fashion, 35 patients with mild 
to moderate essential hypertension received placebo run-in medication 
for 2 weeks, followed by 4 weeks’ moxonidine sustained release (1.5 mg 
o.d.) or placebo. On the fi rst day and 1 and 4 weeks following the start of 
treatment, blood pressure was measured and cns effects were assessed 
using spv, visual analogue scales and eeg.
results On day 1 there was a signifi cant, but not clinically relevant, 
reduction in the time-corrected area under the effect curve (auec) for 
spv in the moxonidine group compared with placebo [difference of 38° 
s-1; 95% confi dence interval (ci) 23, 52]. This difference was no longer 
signifi cant after one (9° s-1; 95% ci -17, 35) and 4 weeks (6.9° s-1; 95% ci 
-16, 30). Visual analogue scales for alertness showed similar results. A 
decrease in eeg α- and ß-power and an increase in delta-power were only 
found on day 1 of moxonidine treatment. The auec for systolic/diastolic 
blood pressure relative to placebo was 23 (95% ci 17, 29)/13 (9, 16) mmhg 
lower on day 1 and remained reduced by 20 (11, 30)/12 (6, 17) and 15 (6, 25)/9 
(3,15) mmhg after 1 and 4 weeks’ moxonidine treatment.
conclusions Four weeks’ treatment with an experimental sr 
formulation resulted in tolerance to cns effects (equivalence to placebo) 
while blood pressure-lowering effects remained adequate. The tolerance 
to cns effects was already observed after 1 week of treatment.
Introduction
Moxonidine is a centrally acting antihypertensive agent, which binds 
selectively and with high affi nity to the imidazoline-I1 receptor in the 
ventrolateral medulla of the brainstem and the kidney.* This receptor is 
thought to play an important role in central blood pressure regulation. 
Ref. 1
75 chapter 4 – central nervous system effects of moxonidine experimental sustained 
 release formulation in patients with mild to moderate essential hypertension
Stimulation of I receptors induces sympatho-inhibition in the periphery, 
refl ected by a lowering of blood pressure, heart rate, and plasma 
noradrenaline levels.* Moxonidine also binds to the ß 2-receptor in the 
medulla oblongata, albeit to a lesser extent than to the imidazoline-
I1 receptor.* Stimulation of the α2-receptor in the nucleus coeruleus 
appears to induce the side-effects of centrally acting antihypertensive 
drugs, such as sedation and dry mouth.* The agonistic activity of 
moxonidine on α2-receptors is low in comparison with other fi rst-
generation centrally acting antihypertensive agents like clonidine and 
methyldopa.* The improved tolerability of moxonidine compared with 
these drugs appears to be related to this difference in receptor activity.*
The sedative properties of many drugs like benzodiazepines* or 
partial α2 agonists like clonidine and rilmenidine* have been evaluated 
previously with measurements of saccadic eye movements and Visual 
Analogue Scales (vas). Sedation is typically accompanied by a drop in 
saccadic peak velocity (spv), as well as a decrease in subjective alertness 
as measured with vas scores. During prolonged treatment with drugs like 
benzodiazepines, development of tolerance to the sedative effects has 
been shown.* So far, tolerance development to central nervous system 
(cns) drug effects has not been studied for imidazoline I1 agonists. This 
tolerance development may improve the clinical acceptability during 
prolonged treatment with centrally acting antihypertensive drugs. 
In this study, the cns effects of moxonidine were investigated using 
an experimental sustained release (sr) formulation during prolonged 
treatment of patients with mild to moderate hypertension. The aim was 
to demonstrate that moxonidine had no clinically relevant effect on 
the spv after 4 weeks of treatment, compared with placebo. A clinically 
relevant effect on the spv was predefi ned as an effect which is found 
after 24 h of sleep deprivation.* Secondary objectives were to assess the 
subjective effects (visual analogue scales of Bond and Lader), effects 
on two-lead pharmaco-eeg (fast Fourier analysis), blood pressure and 
heart rate. In addition, the relationship between moxonidine plasma 
concentration and its effects on spv, visual analogue scales for alertness 
and blood pressure were modelled.
Methods
The study was conducted according to the principles of the Declaration 
of Helsinki and in accordance with the guideline for Good Clinical 
Practice. The study protocol was approved by the Committee on Medical 
Ref. 2
Ref. 2
Ref. 2
Ref. 2,3
Ref. 4-6
Ref 7, 8
Ref. 9
Ref. 8
Ref. 10
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Ethics of Leiden University Medical Centre. All patients were included 
after giving written informed consent. This was a randomized, parallel 
study in which patients received placebo run-in medication for 2 weeks 
in a single-blind fashion, followed by a double-blind 4-week treatment 
with moxonidine using an experimental sr formulation of 1.5 mg o.d. 
or placebo. After screening and approval by their own physician, eligible 
patients entered a variable washout period of up to 8 weeks, in which 
their own antihypertensive treatment was withdrawn. As soon as a 
diastolic blood pressure of 90–104 mmhg had been reached and the 
patient was off antihypertensive medication for at least 2 weeks, the 
patient entered the placebo run-in period, during which the patients 
were acquainted with the experimental methods and conditions during a 
short training session. Patients with a diastolic blood pressure of 90–104 
mmhg without previous antihypertensive treatment could directly enter 
the single-blind placebo run-in period. Patients whose blood pressure 
increased above 120 mmhg after withdrawal of their antihypertensive 
medication were excluded from further participation. At the end of the 
run-in period eligible patients were randomized to one of the study 
treatments: moxonidine or placebo. Patients were studied on the fi rst 
day of allocated randomized treatment, and at 1 and 4 weeks following 
the start of treatment. After the fi nal study day, medication was tapered 
off to 0.5 mg o.d. for 3 days. The patients were instructed to take their 
study medication regularly at breakfast with liquids. Compliance was 
checked by tablet counting. Suffi cient compliance was assumed when 
the study drug intake was within 80–120% of the planned intake. The 
moxonidine sr dose was based on the maximum dose intended to be 
developed, to be able to investigate the course of effects of the highest 
dose likely to be used in clinical practice.
On the study days, the patients arrived at the facility in the morning 
in a fasted state. Inclusion/exclusion criteria were checked, if applicable 
a pregnancy test (cards o.s.®h.c.g.-urine test kits; Pacific Biotech, 
Inc., San Diego, ca, usa) was performed and the urine was checked 
for use of illicit or sedative drugs (amphetamines, cocaine, morphine, 
tetrahydrocannabinol, barbiturates and benzodiazepines using 
Abuscreen ontrak®Rapid Assays for Drug Abuse; Roche Diagnostic 
Systems, Mijdrecht, the Netherlands). In addition, an alcohol breath 
test was performed with a Lion Alcol Meter (taxa meter, Amsterdam, 
the Netherlands). After cannulation of a forearm vein and attachment 
of scalp, periorbital and ecg electrodes, patients received a light 
standardized breakfast, and were allowed a 30-min adaptation period 
in quiet surroundings. Randomized trial medication was administered 
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(t=0 h) after a baseline blood sample (drug-assay) had been drawn, and 
after two (t=-0.5 and 0 h) baseline measurements of heart rate, blood 
pressure, saccadic eye movements, pharmaco-eeg and vas. These 
measurements were repeated every half hour for the fi rst hours, and 
every hour from 3 to 10 h.
Measurements
The blood pressure measurements were made using an automated 
oscillometric blood pressure monitor (mpv1072; Nihon Kohden,Tokyo, 
Japan), which displays an average value for two sequential (duplicate) 
measurements at each time point. All measurements were made after 
the patient had been in a semirecumbent position for at least 5 min. 
Recording of eye movements was performed in a quiet room with 
ambient illumination. Recording and analysis of saccadic eye movements 
was conducted with a microcomputer-based system for sampling and 
analysis of eye movements (Customized ced Software; Cambridge 
Electronic Design, Cambridge, uk) as described previously.* 
The equipment used for stimulus display, signal collection and 
amplifi cation was from Nihon Kohden. Disposable silver–silver chloride 
electrodes (Medicotest n-oo-s, Olstykke, Denmark) were applied on 
the forehead and beside the lateral canthi of both eyes of the patient 
for registration of the electrooculographic signals. Skin resistance was 
reduced to <5 ko before application of the electrodes. Head movements 
were restrained using a fi xed head support. The target consisted of an 
array of light-emitting diodes on a bar, fi xed at 50 cm in front of the head 
support. Saccadic eye movements were recorded for stimulus amplitudes 
of ±15° to either side. Fifteen saccades were recorded for each stimulus 
amplitude with interstimulus intervals varying randomly between 3 and 
6 s. Average values of latency (= reaction time), spv and inaccuracy of all 
artefact-free saccades were used as parameters. Saccadic inaccuracy was 
calculated as the absolute value of the difference between the stimulus 
angle and the corresponding saccade, expressed as a percentage of the 
stimulus angle. 
eeg registrations were made as described previously*, using 
silver–silver chloride electrodes, fi xed with collodion at median frontal 
(Fz), median central (Cz), median parietal (Pz) and median occipital (Oz), 
with the same common ground electrode as for the eye movement 
registration (international 10/20 system). The electrode resistances were 
kept below 5 ko. eeg signals were obtained from leads Fz-Cz and Pz-Oz. 
Ref. 7, 10
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The signals were amplifi ed by use of a Nihon Kohden ab-621g bioelectric 
amplifi er with a time constant of 0.3 s and a low pass fi lter at 100 Hz. For 
the fast Fourier analysis, data collection and analysis were performed 
using customized ced software (Cambridge Electronics Design). Per 
session, eight consecutive blocks of 8 s were recorded. The signal was ad-
converted using a ced 1401 laboratory interface (Cambridge Electronics 
Design) and electronically stored for subsequent analysis. Data blocks 
containing artefacts were identifi ed by visual inspection and these were 
excluded from analysis. Fast Fourier analysis was performed to obtain 
the sum of amplitudes in the delta (0.5–3.5 Hz), theta (3.5–7.5 Hz), alpha 
(7.5–11.5 Hz) and beta (11.5–30 Hz) frequency ranges.
Visual analogue scales were used as described by Bond and Lader* 
and Norris.* From the lines three factors were derived, corresponding 
to alertness, mood and calmness.
Blood samples for drug assay were collected using lithium heparin-
containing polystyrene tubes (Vacuette; Greiner, Alphen a/d Rijn, the 
Netherlands) and centrifuged immediately after sampling for 10 min 
at 4°c and 1500 g. Plasma was stored at -20°c until shipment and drug 
analysis. Drug concentrations were measured using hplc/ms with 
atmospheric pressure chemical ionization at oneida research services 
(Whitesboro, ny, usa). Validation range was 0.050–8.000 ng ml-1, 
accuracy and precision were < 14% and < 4%.
Calculations and statistical analysis
Data from all subjects were used in the analysis, including the dropouts 
during treatment with randomized trial medication. The primary 
statistical analysis was aimed at differences between the two study 
treatments at day 29 (after 4 weeks’ treatment) in overall effects on spv. 
The overall effect was characterized by calculating the area under the 
effect curves (auec) over 10 h and dividing this area by the corresponding 
time span. An analysis of covariance was performed with the value prior 
to initial drug administration (on day 1) as covariate. A one-sided t-test 
using the mean square error from the ancova was used for testing one-
sided equivalence of the spv response at day 29. Clinical equivalence 
was predefi ned to be proven, if the upper value of the 90% confi dence 
interval of the difference was below 45° s-1. This difference is found after 
one night of sleep deprivation and can be considered to be a maximally 
acceptable sedative effect.* All secondary parameters were analysed 
using an analysis of covariance. For the estimates of the treatment 
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differences, 95% confi dence intervals (cis) were calculated. All parameters 
are given as time-corrected auecs as a representation of the average 
effect over the day.
spv, vas alertness and diastolic blood pressure concentration–effect 
relationships were investigated using nonlinear, mixed effect modelling 
as implemented in nonmem (Version 5; nonmem Project Group, ucsf, 
ca, usa). This methodology analyses all occasions simultaneously: all 
subjects are described using the same structural model, and mean and 
interindividual variability estimates are generated for the entire popula-
tion.* Signifi cance of parameters was assessed by comparing models 
with and without the specifi c parameter(s) using a likelihood ratio test, 
where a conservative p-value of 0.001 was used to compensate for the 
large sample normal approximation. In order to correct for the placebo 
response, the average placebo vs. time profi le was calculated over all pla-
cebo subjects and subtracted from the individual moxonidine responses 
at corresponding protocol times. The relationship was described using 
a simple linear model. In order to relate concentrations to effects, linear 
interpolation was used. This was implemented in nonmem by adding, for 
each data point, the corresponding slope and intercept of the interpola-
tion line for that particular segment. This makes it possible to assess and 
estimate the need for an effect compartment to model the possible delay 
between concentrations and effects. Concentration–effect parameters 
were estimated assuming a parameter value for day 1 and a within-subject 
deviation (with a fi xed and random component) for days 8 and 29. Fixed 
and/or random components were subsequently eliminated using the like-
lihood ratio test. An effect compartment was implemented in all cases.
eeg data were analysed after log transformation because of clear 
indications of skewness and only log eeg results were reported. All other 
variables were analysed untransformed.
Results
Subjects
Two patients dropped out during the placebo run-in period, one 
because of an adverse event (depression) and one because of frequent 
benzodiazepine use. Thirty-fi ve patients were randomized into the 
doubleblind treatment period: 16 to moxonidine sr and 19 to placebo. 
Demographics and baseline characteristics of the subjects who started 
randomized trial medication are summarized in table 1. Two patients 
Ref. 13
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in the moxonidine sr group dropped out: one patient after 1 week’s 
treatment because of adverse event (dizziness), and one patient after 
day 1 because of a serious adverse event (aorta dissection leading to 
hospitalization and death). This serious adverse event was regarded as 
unrelated to the study drug. In the placebo group, also two patients 
dropped out: one patient because of severe hypertension and one patient 
because of depression, both after day 1.
Adverse events
A total of 30 patients (86%) reported treatment-emergent adverse 
events. The most frequently reported adverse events were somnolence 
and dry mouth. On the fi rst treatment day, somnolence was reported by 
all 16 subjects on moxonidine sr (100%) and by 10/19 patients (58%) in 
the placebo group, and dry mouth by 10 patients (63%) In the moxonidine 
group, vs. two patients (11%) on placebo. After 4 weeks of treatment, the 
number of moxonidine-treated patients reporting sedation had dimin-
ished to 9/16 (56%), compared with 7/19 (37%) on placebo. At that time, 
dry mouth was noted by 7/16 patients on moxonidine sr (44%) and 2/19 
on placebo (11%).
Compliance
The median percentage of tablets taken during treatment was 100.0% 
(range 96.0–105.6%) In the moxonidine treatment group, and 100.0% 
(95.5–114.3%) In the placebo group.
Saccadic peak velocity
The spv profi le showed a clear treatment-related curve for all moxonidine 
sr treatment study days (fi gure 1). On day 1 the time-corrected auec 
for peak velocity was signifi cantly lower in the moxonidine sr group 
(38° s-1; 95% ci 23, 52). However, as predose moxonidine baseline values 
increased, the moxonidine treatment profi le shifted upwards, and the 
difference with placebo was no longer present on day 8 (difference 9° s-1;
95% ci -17, 35) and day 29 (difference 7° s-1; 95% ci -16, 30). The upper 
value of the 90% ci (-12, 26) was well below 45° s-1, the predefi ned level 
of clinical signifi cance*. The two treatments were therefore considered 
Fig. 1 – p. 87
Ref. 10
81 chapter 4 – central nervous system effects of moxonidine experimental sustained 
 release formulation in patients with mild to moderate essential hypertension
equivalent with respect to the auec curve for spv after 4 weeks of 
treatment. No signifi cant differences were observed for accuracy and 
reaction times (data not shown).
Visual analogue scales
Analogously to the spv profi le, the alertness vas showed a treatment-
related curve for all moxonidine sr treatment study days (fi gure 2). The 
time-corrected alertness auec was signifi cantly lower on day 1 in the 
moxonidine sr group (6.7 mm; 95% ci 0.2, 13.2). As predose baseline 
vas alertness increased and the profi le shifted upwards, this difference 
disappeared on day 8 (difference of 5.4 mm; 95% ci -2.6, 13.5) and day 
29 (difference of 0.9 mm; 95% ci -8.3, 10.1). No signifi cant differences 
between the moxonidine sr and placebo groups were observed with 
respect to the mood and calmness auecs (data not shown).
Electroencephalogram
No clear treatment profi les were observed for eeg parameters. 
Signifi cant differences between treatment groups were shown for all 
mid-parietal–occipital (PzOz) leads. In the moxonidine sr group on 
day 1, log transformed auec of total α- and ß-power was signifi cantly 
lower (difference 0.08, 95% ci 0.005, 0.16; and 0.12, 95% ci 0.01, 0.23, 
respectively), while total delta-power was signifi cantly higher (difference 
-0.10; 95% ci -0.20, -0.01). These differences were not observed on day 
8 and day 29, nor were there signifi cant differences between study days 
(data not shown). The log transformed auec of total theta-power was 
higher in the moxonidine sr group on day 8 and day 29 (difference -
0.16, 95% ci -0.33, -0.001; and -0.21, 95% ci -0.40, -0.03, respectively). 
No signifi cant differences between treatment groups were observed 
for any of the mid-frontal-central (FzCz) lead eeg parameters. The log 
transformed auec of total teta-power (FzCz lead) on day 1, however, came 
close to a signifi cant increase for the moxonidine sr group compared 
with placebo (difference -0.15; 95% ci -0.31, 0.003).
Fig. 2 – p. 88
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Blood pressure and heart rate
Systolic and diastolic blood pressure profi les showed clear treatment 
profi les on all study days (fi gures 3 and 4). Mean (95% ci) systolic auecs 
were signifi cantly lower in the moxonidine sr group on all study days: 
23 (17, 29), 20 (11, 30) and 15 (6, 25) mmhg difference for days 1, 8 and 29. 
Also the mean (95% ci) diastolic blood pressure auecs were signifi cantly 
lower in the moxonidine sr group on all study days: 13 (9, 16), 12 (6, 17) and 
9 (3, 15) mmhg difference for days 1, 8 and 29. Only on day 8 was predose 
(trough) diastolic blood pressure signifi cantly lower in the moxonidine 
sr group compared with placebo (difference 5.3 mmhg; 95% ci 0.2, 
10.5). Average heart rate did not show a treatment-related response (not 
shown).
Pharmacokinetics
The moxonidine time profi les were clearly the result of an extended 
release oral formulation. Average moxonidine concentration profi les 
shifted upwards on day 8 and day 29 as baseline values increased 
(fi gure 5). The area under the curve (auc) increased 18% (95% ci 2, 37) 
from day 1 to day 8 and the auc increased 14% (95% ci -1, 33) from day 
1 to day 29. The maximum concentration increased 19% (95% ci 6, 34) 
from day 1 (2.6 ± 0.7 ng ml-1) to day 8 (3.1 ± 1.1 ng ml-1) and 20% (95% ci 
6, 35%) from day 1 to day 29 (3.1 ± 0.8 ng ml-1). The time to maximum 
concentration (4 h 28 min on day 1 and 3 h 26 min on day 29) did not 
change signifi cantly between study days.
Concentration–effect modelling
Concentration–effect modelling was performed by linearly interpolating 
the concentration profi le and by linking these concentrations to 
the effects. In the concentration–effect graphs the average effect 
(moxonidine minus placebo effect) is plotted against the corresponding 
average interpolated moxonidine concentration. All effects tended to lag 
behind relative to the plasma concentrations. This hysteresis was dealt 
with by assuming a hypothetical effect compartment, characterized 
by an equilibration half-life that describes the speed with which 
plasma concentrations would be equilibrated with effect compartment 
concentrations if the drug was to be infused at a constant rate. 
Fig. 3,4 – p. 88, 89
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Saccadic peak velocity
For spv the best fi t was given by a model including an effect 
compartment where the equilibration half-life (58 min; 95% ci 39, 77) and 
slope (-22.9° S-1 ng-1 ml; 95% ci -4, -42) were similar between study days 
(fi gure 6). From day 1 to 8 and 29 the profi le shifted upwards, leading to 
an increase in intercept of 36° s-1 (95% ci 30, 41) from day 1 to day 8 
and an increase of 41°s-1 (95% ci 26, 55) from day 1 to day 29.
vas alertness
For vas alertness, the best model was analogous to spv. The slope (-3.9 
mm ng-1 ml; 95% ci -1.6, -6.2) and equilibration half-life (43 min; 95% ci 
10, 76) did not differ between occasions (fi gure 7). Only the intercept was 
different between occasions: a nonsignifi cant increase of 3.0 mm (95% ci 
-1.3, 7.3) from day 1 to day 8 and a signifi cant increase of 6.6 mm (95% ci 
3.6, 9.6) from day 1 to day 29.
Diastolic blood pressure
For diastolic blood pressure, no shift of the concentration–delta diastolic 
blood pressure curve was observed, but the profi le levelled off on day 
8 and day 29 (fi gure 8). The best fi t was given by a model in which only 
the slope was signifi cantly different between study days. Estimated 
equilibration half-life was 86 min (95% ci 52, 119) and intercept was -0.15 
mmhg (95% ci -4.5, 4.2). The slope decreased 4.4 mmhg ng-1 ml (95% ci 
2.3, 6.6) from day 1 to day 8 and 3.2 mmhg ng-1 ml (95% ci 0.3, 6.1) from 
day 1 to day 29. 
Discussion
This study showed that after 4 weeks of treatment, moxonidine 1.5 mg 
o.d. given in an experimental sr formulation was equivalent to placebo 
for the overall effects on spv, an objective measure of alertness. On each 
study day, a treatment-related decrease in spv relative to predose values 
at each study day was observed, but only on the fi rst day of moxonidine 
sr treatment was the spv auec signifi cantly lower compared with 
placebo. As a result of an upward shift of the curve, the average effects 
Fig. 6 – p. 90
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of moxonidine sr on spv were at placebo level after 8 and 29 days of 
treatment. Although its face validity is not very high, spv is one of the 
most reproducible and sensitive measures of sedation.* No method 
applicable in drug research is available that shows direct relationships 
to clinical consequences of sedation, like reduced working performance 
or increased accident rates. The spv results were corroborated by similar 
fi ndings with visual analogue scales for alertness, which have a higher 
face validity. The subjective vas score for alertness showed treatment-
related curves, which shifted upwards during treatment. The eeg results 
further support these observations, as only on day 1 were signifi cant 
effects consistent with cns depression observed.* All these results point 
to the development of tolerance to the cns effects of moxonidine 1.5 mg. 
It should be noted that the recommended starting dose for moxonidine 
is considerably lower than the dosage used in this study. The observed 
cns effects for the fi rst treatment day are therefore likely to be smaller 
during normal clinical use. Both the average subjective and objective 
cns effects on day 1 returned to placebo levels within the fi rst week 
of treatment, although treatment-related decreases in spv and vas 
were still present after 1 and 4 weeks. These observations are further 
clarifi ed by concentration–effect modelling. The slope of the modelled 
effect remained unchanged, indicating that the response to moxonidine 
was similar on all study days. However, the concentration–effect 
curves shifted upwards during treatment, resulting in net cns effects 
comparable to placebo.
The increase in baseline alertness as shown by two independent 
measures of alertness (spv and vas) indicates that after 1 and 4 weeks of 
treatment the patients in the Moxonidine sr group became more alert 
in the morning before receiving their daily dose. This phenomenon has 
not been observed previously during treatment with moxonidine, and 
its causes are unclear. The cns effects of moxonidine are thought to be 
mainly due to weak α2 receptor agonism, which decreases central norad-
renergic activity.* An increase in alertness during treatment with α2 ago-
nists could be the result of a hyperresponsiveness of central noradren-
ergic pathways during prolonged treatment.* However, such a putative 
central noradrenergic increase did not seem to affect blood pressure. 
Systolic and diastolic blood pressure showed clear treatment 
effects in the moxonidine sr group, with a lowering of blood pressure 
to nonhypertensive levels. Despite this clear treatment effect, predose 
blood pressure did not differ between the treatment groups, except for 
a lower diastolic blood pressure in the moxonidine sr group on day 8. 
Thus, 24-h effective control of systolic and diastolic blood pressure was 
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not fully maintained with a single dose of this experimental moxonidine 
sr formulation. However, it has to be considered that the study was not 
powered to detect clinically meaningful blood pressure effects at trough. 
Further improvement of the extended release profi le could increase the 
trough levels of 0.7 ng ml-1 observed on day 29, and also reduce the mean 
maximum concentrations of 3.1 ng ml-1 that were found in this study.
Moxonidine plasma concentrations increased by 14–18% compared with 
day 1, but the average blood pressure remained unchanged throughout 
the 4-week treatment period. Modelling showed a small decrease in 
slopes of the concentration–effect curves, which may be interpreted as 
an indication of tolerance. Tolerance is often observed among agonist-
stimulated, g-protein-coupled receptors, such as the i1-receptor. 
On the other hand, no rebound hypertension has been reported after 
the discontinuation of moxonidine treatment,* arguing against such 
a phenomenon. Systemic counter-regulation could be a more plausible 
explanation, considering the strong antihypertensive effects of this 
moxonidine dose, as exemplifi ed by an average maximum systolic/
diastolic blood pressure reduction of 36/21 mmhg on day 1 (fi gures 3 
and 4). In view of the sustained antihypertensive effects, the lack 
of further blood pressure reduction despite increasing moxonidine 
concentrations may be regarded as clinically nonsignifi cant. 
In conclusion, this study showed that after 4 weeks of treatment, 
moxonidine sr 1.5 mg o.d. is equivalent to placebo for average cns 
effects. Treatment–effect curves over the day and modelling of the 
pharmacodynamic and pharmacokinetic data provided indications 
of an increased alertness at predose (trough level) after 1 and 4 weeks 
treatment.
This study was sponsored by solvay pharmaceuticals, Weesp, the 
Netherlands.
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 4  central nervous system effects of moxonidine experimental sustained 
release formulatio  in patients with mild to moderate essential hypertension
table 1 Demographic characteristics and baseline variables
figure 1 Mean ± sd saccadic peak velocity profi les for the moxonidine sustained release 
(sr) (•) and placebo (°) treatment groups during study day 1, day 8 and day 29. Each profi le represents a different study day; measurements were performed from predose (fi rst two 
data points) until 10 h postdose.
Moxonidine SR
(n=16)
Placebo
(n=19)
Age (years)a 55 (34-71) 56 (35-78)
Numbers /% per age group:
< 50 6 / 38 3 / 16
50 – 59 3 / 19 9 / 47
) 60 7 / 44 7 / 37
Sex (n, Male / female) 7/9 10/9
Weight (kg)a 78 (59-102) 81 (61-105)
Height (cm)a 172 (160-190) 172 (158-186)
Body Mass Index (kg/m2)a 26 (22-37) 28 (21-38)
Systolic blood pressureab 157 (135-189) 161 (146-178)
Diastolic blood pressureab 91 (72-106) 91 (77-100)
Heart rateab 71 (60-86) 72 (56-91)
Ethnic origin (n/%) Caucasian 15 / 94 19 / 100
Negroid 1 / 6 0 / 0
a given as means (range)
b pre-dose value at fi rst study-day
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figure 2 Mean ± sd visual analogue scale (vas) alertness profi les for the moxonidine 
sustained release (sr) (•) and placebo (°) treatment groups during study day 8 and day 29. Each profi le represents a different study day; measurements were performed from predose 
(fi rst two data points) until 10 h postdose.
figure 3 Mean ± sd systolic blood pressure profi les for the moxonidine sustained 
release (sr) (•) and placebo (°) treatment groups during study day 1, day 8 and day 29. Each profi le represents a different study day; measurements were performed from predose 
(fi rst two data points) until 10 h postdose.
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figure 4 Mean ± sd diastolic blood pressure profi les for the moxonidine sustained 
release (sr) (•) and placebo (°) treatment groupsduring study day 1, day 8 and day 29. Each profi le represents a different study day; measurements were performed from predose (fi rst 
two data points) until 10 h postdose.
figure 5 Mean ± sd moxonidine plasma concentration profi les during study day 1, day 
8 and day 29. Each profi le represents a different study day; measurements were performed 
from predose (fi rst two data points) until 10 h postdose.
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figure 6 Delta (placebo minus moxonidine response) saccadic peak velocity profi les 
vs. interpolated moxonidine concentration. The broken line represents the modelled 
profi le for day 1 (with average original data, °), the solid lines represent the modelled profi le for days 8 and 29.
figure 7 Delta (placebo minus moxonidine response) visual analogue scale (vas) 
alertness vs. interpolated moxonidine concentration. The broken line represents the 
modelled profi le for day 1 (with average original data, °), the solid lines represent the modelled profi le for days 8 and 29.
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figure 8 Delta (placebo minus moxonidine response) diastolic blood pressure vs. 
interpolated moxonidine concentration. The broken line represents the modelled profi le 
for day 1 (with average original data, °), the solid lines represent the modelled profi le for days 8 and 29.
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chapter 5  drug class specific composite effects on saccadic 
 peak velocity, visual analogue scales and   
  electroencephalography
J. Van Der Post, R.C. Schoemaker, A.F Cohen & J.M.A. Van Gerven; 
Centre For Human Drug Research, Leiden, The Netherlands
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Abstract
aims This study aims to explore whether drug (class) specifi c 
relationships are present between saccadic peak velocity (spv), Visual 
Analogue Scales (vas) and electro-encephalography (eeg).
methods From studies that were performed at centre for human drug 
reasearch (chdr) data was included that had showed a statistically 
signifi cant treatment effect on spv, and included either vas or eeg 
measurements or both in the evaluation of a range of cns active drugs. 
All data were analysed simultaneously, resulting in a population average 
estimate for slope and intercept and estimates of the inter-individual 
variability in parameters. Analysis was performed using linear mixed 
effect modelling. Two models (estimation of a a common slope and 
intercept for all drugs, estimation of a different slope for each drug 
with a reference slope for placebo) were tested. These two models were 
statistically compared using a likelihood ratio. Differences in slope from 
placebo with approximate 95% confi dence intervals (ci) were calculated, 
allowing an assessment of difference in slopes between the different 
drugs.
results Delta spv-delta vas relationship showed a mean slope 0.125 
(95% ci of 0.110/0.140). The difference in minimum value of the objective 
function between the two models (with and without separate slopes for 
the different drugs) was 56.5 (p<0.001, likelihood rato test with 10 degrees 
of freedom (df)). The most clear discrimination between drugs could be 
observed for spv relationships with beta Fc, alpha Po and theta Fc. The 
difference in minimum value of the objective function between the two 
models was 144.55 for beta Fc (p<0.001, 10 df), 79.55 for alpha Po (p<0.001, 
8 df) and 55.79 (P<0.001, 8 df).
conclusions Combining the diferent slopes of the spv-vas and spv-
eeg relationships, a drug class specifi c picture emerges. With decreasing 
spv, benzodiazepines/propofol show a strong subjective response on 
vas, increase beta Fc power and decrease alpha and theta power. The 
serotoninergic drugs show only a small vas response and increase alpha 
and theta power. The imidazoline modulators show a vas response above 
serotoninergic drugs but under benzodiazepines, and decrease alpha 
power and increase theta power. 
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Introduction
There is a high level of interest in biomarkers in the pharmaceutical 
industry, which is faced with the ever-increasing cost of research and 
development, and with growing pressure to accelerate the rate of 
bringing new drugs to the marketplace. Appropriate use of suitable 
biomarkers can facilitate this proces. A biomarker is a characteristic 
that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses 
to a therapeutic intervention. In general, biomarkers can be used for 
the following applications: as a diagnostic tool (for the identifi cation 
of those patients with a disease or abnormal condition), as a tool for 
staging a disease or classifi cation of the extent of disease, as an indicator 
of disease prognosis or for prediction and monitoring of clinical response 
to an intervention.
Biomarkers are perhaps most useful in the early phases of drug 
development, when measurement of clinical endpoints may be too time-
consuming or cumbersome to provide timely proof of concept or dose-
ranging information. Ideally, the attributes of a biomarker should include 
the following*: clinical relevance, sensitivity and specifi city to treatment 
effects, reliability, practicality and simplicity.
This investigation focusses on biomarkers for pharmacological 
activity of central nervous system (cns) active drugs in phase 1 
development. The identifi cation of biomarkers in this area poses 
specifi c problems. The overwhelming amount of different tests (or tests 
variants) used by different research groups makes it diffi cult to identify 
even basic test characteristics such as sensitivity, and severely limits 
the reproducability of fi ndings. This compromises the ideal biomarker 
attributes of sensitivity and reliability. In addition, the specifi city of 
these biomarkers seems to be low. The clinical relevance of tests results 
is also often diffi cult to assess: most cns biomarkers are used during 
a broad evaluation of adverse cns effects, and seldomly focuss on the 
intended pharmacological effect.
Showing cns activity of drugs can be informative on another level 
than assessing adverse reactions. Potentially, a marker can be sensitive 
to a certain receptor modulating effect (such as plasma prolactin for 
d2-antagonistic activity) or effects on a specifi c neurotransmitter (such 
as plasma cortisol for serotoninergic action, or memory impairment 
for achetylcholine inhibition). These markers are not necessarily 
pathophysiologically close to a clinical endpoint, but can demonstrate 
a certain mechanism of action. An important shortcoming of these, 
Ref. 1
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although sensitive, ‘single biomarkers’ (one test, one measurement) 
is their frequent lack of specifi city. Frequently drugs will show similar 
results on a marker, although their pharmacological properties vary 
widely. 
A potentially more fruitful approach could be to identify a 
combination of sensitive markers that show a specifi c co-dependence to 
a drug (or preferably a drug class) action. If such a ‘composite biomarker’ 
can be identifi ed, it could allow establishing ‘biomarker templates’ 
of drug classes with specifi c receptor binding profi les or mechanisms 
of action. It is important to realize that these composite markers will 
initially not allow a strong link to the pathophysiology of a disease or 
intended clinical effect. However, it will allow compounds with a new 
or unknown mechanism of action to be placed in a relation to existing 
drugs, based on their effects on this composite marker. This could 
guide further evaluation of the cns effects of such a drug, based on the 
cumulative knowledge of existing drugs. 
Recent structured literature evaluation of tests used in neuroleptic* 
and anxiolytic* drug development as well as studies on drugs from other 
drug classes (studies presented in tables 1&2) showed that saccadic peak 
velocity (spv), Visual Analogue Scales (vas) and electroencephalography 
(eeg) are frequently used and are sensitive to a wide range of drugs. This 
study aims to explore whether drug (class) specifi c relationships are 
present between spv, vas and eeg. 
Methods
Study selection
The studies all included spv and either vas or eeg measurements or 
both. The data used was selected from studies that were performed 
at chdr during the past 20 years. The drugs under investigation and 
the number of study occasions for studies that had both spv and vas 
measurements are presented in table 1. The same data is presented in 
table 2 for drugs that had both spv and eeg measurements.
Saccadic eye movements
Saccadic peak velocity as used in our experiments is the maximum 
velocity that the eye ball reaches while following a light that jumps 
Ref. 2
Ref 3
Table 1, 2 – p. 106, 107
Table 1 – p. 106
Table 2 – p. 107
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on a horizontal bar. The head of the subject is fi xated in a headrest. 
Recording and analysis of saccadic eye movements was done with 
a microcomputer-based system.* The equipment used for stimulus 
display, signal collection and amplifi cation was from Nihon Kohden 
(Nihon Kohden Corporation, Tokyo, Japan). Saccadic eye movements 
were recorded for stimulus amplitudes of 15 degrees to either side. 
Interstimulus intervals varied randomly between 3 and 6 seconds, and 
fi fteen saccades were recorded. The average values of saccadic peak 
velocity were used as parameters. 
Visual analogue scales
Visual analogue scales as originally described by Norris* were used to 
quantify subjective effects. The factors corresponding to alertness were 
derived from these measurements.* These consisted of 7 of the total of 
16 scales. The direction corrected mean score in mm of these scales was 
used.
Electroencephalography
Electroencephalograms were recorded and analysed using ced software 
(Cambridge Electronics Design, Cambridge, uk), as described previously.* 
eeg recordings were made using silver-silver chloride electrodes, 
fi xed with collodion at Fz, Cz, Pz and Oz, with the same common 
ground electrode as for the eye movement registration (international 
10/20 system). The electrode resistances were kept below 5 kOhm. All 
recordings were done with the subjects’ eyes closed. eeg signals were 
obtained from leads Fz-Cz and Pz-Oz. The signals were amplifi ed by 
use of a Nihon Kohden ab-621g bioelectric amplifi er (Nihon Kohden 
Corporation, Tokyo, Japan) with a time constant of 0.3 seconds and a 
low pass fi lter at 100 Hz. Per session eight consecutive blocks of eight 
seconds were recorded over a 2 minute period. The sampling rate was 
1024 Hz. Datablocks containing artefacts were identifi ed by visual 
inspection and these were excluded from analysis. Fast Fourier transform 
analysis was performed to obtain the sum of amplitudes in the delta- 
(0.5-3.5 Hz), theta- (3.5-7.5 Hz), alpha- (7.5-11.5 Hz) and beta (11.5-30 Hz) 
frequency ranges. The total recording bandwidth was 0-50 Hz.
Ref. 4
Ref 5
Ref. 6
Ref. 7
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Statistical analysis
Studies were included in the analysis that showed a statistically 
signifi cant treatment effect on spv, and included either vas or eeg 
measurements or both. Vas and eeg were related to spv because spv 
has shown to be the most sensitive test for a wide range of cns active 
drugs.* Relating vas and eeg test results to spv, thus normalising results 
to spv, allows comparison of spv-vas and spv-eeg relationships for 
different drugs and dosages. 
The spv profi les were linearly interpolated to obtain interpolated 
spv measurements for corresponding vas measurements. The value 
just prior to drug administration was used as pre-value and pre-values 
were subtracted for both spv and vas measurements, resulting in 
changes from baseline (deltaspv and deltavas). The spv measurements 
were always close to the eeg measurements and were therefore shifted 
slightly to the corresponding eeg measurements. The value just prior 
to drug administration was used as pre-value and pre-values were 
subtracted for both spv and eeg measurements, resulting in changes 
from baseline (deltaspv and deltaeeg). Data analysis was performed 
using spss for Windows V10.1.4 (spss, inc., Chicago, il).
spv-vas, spv-eeg relationships Each individual’s relationship 
between spv and vas or eeg was described using a straight line. More 
complex relationships did not result in improvement of fi t. Instead 
of estimating all individual linear regressions, all data were analysed 
simultaneously, resulting in a population average estimate for slope and 
intercept and estimates of the inter-individual variability in parameters. 
The advantage of simultaneous estimation is that this allows a single 
test to determine if the relationship is the same for all the different 
drugs. This analysis was performed using linear mixed effect modelling 
with nonmem Version v software (nonmem Project Group, ucsf, ca), 
where ‘fi rst order conditional estimation’ was employed. For each set 
of parameters, two models were estimated. The fi rst model estimated 
a common slope and intercept for all drugs and the second estimated a 
different slope for each drug (a reference slope for placebo and changes 
in slope (from placebo) for the different drugs were determined). These 
two models were statistically compared using the likelihood ratio test 
that compares the difference in minimum value of the objective function 
between the two models with a chi-square distribution. Differences in 
slope from placebo with approximate 95% confi dence intervals (using 
2*sem) were calculated, allowing an assessment of difference in slopes 
between the different drugs.
Ref. 2, 3
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Results
spv-vas relationships
Linear mixed effect modelling used to estimate slope and intercept of 
the delta spv-delta vas relationship showed a mean slope of 0.125 with 
a 95% confi dence interval of 0.110/0.140. The 95% confi dence interval 
for the slope indicates a highly signifi cant relationship between the two 
measures. Subsequently, relationships were simultaneously estimated 
for the different drugs and placebo. The difference in minimum value 
of the objective function between these two models (with and without 
separate slopes for the different drugs) was 56.5 which is signifi cant at 
p<0.001 using the likelihood rato test with 10 degrees of freedom. This 
proves that the different drugs have different slopes for the delta spv-
delta vas relationship. Regression estimates for the different drugs are 
presented in fi gure 1.
spv-eeg relationships
The most clear discrimination between drugs could be observed for spv 
relationships with beta Fc, alpha Po and theta Fc. Using the likelihood 
rato test, the difference in minimum value of the objective function 
between these two models (with and without separate slopes for the 
different drugs) was 144.55 for beta Fc (p<0.001, 10 degrees of freedom), 
79.55 for alpha Po (p<0.001, 8 degrees of freedom (df)) and 55.79 (p<0.001, 
8 df). This proves that the different drugs have different slopes for 
the spv-eeg relationships. Regression estimates of these spv-eeg 
relationships for the different drugs are presented in fi gures 2-4. 
spv-eeg-vas relationships
Drugs were grouped into three classes; benzodiazepines, serotoninergic 
drugs and imidazoline receptor modulators. The mean slope ranges 
for the drug classes are presented in table 3. The composition of these 
drug classes differs for each column, since not all measurements were 
available for all the different drugs. Only three studies included all 
measurements (spv, vas, eeg), which did not allow for discriminant 
analysis. 
Fig. 1 – p. 104
Fig 2, 3, 4 – p. 104, 105
Table 3 – p. 108
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Discussion
The delta spv-delta vas relationships showed a strong correlation 
between the two measures for all drugs that had a decreasing effect 
on spv. However, the drugs appear to have a clear differential effect. 
With a comparable effect size on spv, the slopes for benzodiazepines 
(lorazepam, temazepam) seemed to be largest (fi gure 1, table 3). The 
slopes for the imidazoline receptor modulators (rilmenidine, moxonidine) 
were lower than those of the benzodiazepines, followed by the slopes 
for serotoninergic drugs (suma- and rizatriptan). This indicates that spv 
changes can lead to a different subjective notion of decreased alertness.
The interpretation of these results does have a number of pitfalls. 
First of all, the study information that the participating subjects received, 
may have led to the difference in subjective alertness scores. The 
information will usually state what the treatment indication for a drug 
is, and will inform subjects on the expected side effects. For a number 
of studies, the study medication consisted of benzodiazepine and 
placebo treatment in a cross-over design. The subjective interpretation 
of decreased alertness by subjects in such a study may lead to a stronger 
vas response if they know one of the drugs is a hypnotic (temazepam) or 
anxiolytic (lorazepam). Furthermore, although most studies used healthy 
volunteers (mostly between 18-40 years), the populations used in the 
studies may have been heterogenous, which could infl uence subjective 
scores. 
The relatively small slope of the benzodiazepine diazepam combined 
with the large effect size on spv, indicated a non-linear and potentially 
sigmoidal relationship between spv and vas (no increase of vas with 
increasing spv change). However, examination of individual spv-vas 
relationships for diazepam showed no evidence of non-linearity.
In conclusion, the consistency in methodology (identical for all 
studies, all studies were performed in one centre) and the highly 
signifi cant difference in slopes for the drugs, warrants the presumption 
of a unique spv-vas relationship for different drugs or perhaps drug 
classes.
The relationship between spv and eeg showed clearly different 
slopes for bezodiazepines/propofol, serotoninergic drugs (suma- 
and rizatriptan, m-cpp) and the imidazoline receptor modulators 
(rilmenidine, moxonidine). spv-beta Fc relationships showed a large 
positive slope for temazepam, midazolam and propofol, with comparable 
small slopes for the other drugs (fi gure 2, table 3). The specifi c effect of 
benzodiazepines and propofol on beta Fc is well documented (9-14), and 
Fig. 1 / Table 3 – 
p. 104 / 108
Fig. 2 / Table 3 – 
p. 104 /108
Ref. 9, 10, 11, 12, 13, 14
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confi rmed in this study. For the spv-alpha Po relationships a positive 
slope is observed with the serotoninergic drugs, contrasting with the 
negative slope for the other drugs (fi gure 3, table 3). m-cpp actually 
increases spv and decreases alpha power, leading to a positive slope for 
the spv-alpha Po relationship. The spv-theta Fc relationship showed a 
contrast between the benzodiazepines/propofol and the other drugs, 
showing a negative slope for the fi rst and a positive slope for the latter 
(fi gure 4, table 3). 
Combining the different slopes of the spv-vas and spv-eeg 
relationships, a drug class specifi c picture emerges (table 3). With 
decreasing spv, benzodiazepines/propofol show a strong subjective 
response on vas, increase beta Fc power and decrease alpha and theta 
power. The serotoninergic drugs show only a small vas response and 
increase alpha and theta power. The imidazoline modulators show a vas 
response above serotoninergic drugs but under benzodiazepines, and 
decrease alpha power and increase theta power.
Unfortunately only three studies included both spv, vas and eeg.
 A larger number of overlapping studies would allow a discriminant 
analysis that could quantify the discriminating power of the combination 
of these measures. Although this is an exploratory study, the presented 
results should be viewed as a stimulant to include spv, vas and eeg in 
the evaluation of cns active drugs in phase 1 research. Ideally, more data 
on composite effects, also of other relatively receptor specifi c drugs, will 
be generated. If the observed composite effects on these measures is 
thus prospectively validated, they may allow drugs with (partly) unknown 
mechanisms of action to be compared to the ‘composite biomarker 
templates’ of receptor specifi c drugs.
Fig. 3 / Table 3 – p. 106
Fig. 4/ Table 3 – p. 106
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figure 1 Regression estimates for the different drugs; endpoints (on the x-axis) 
correspond to 95% of the deltaspv values for that drug.
figure 2 Regression estimates for the different drugs; endpoints (on the x-axis) 
correspond to 95% of the delta spv values for that drug.
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figure 3 Regression estimates for the different drugs; endpoints (on the x-axis) 
correspond to 95% of the delta spv values for that drug.
figure 4 Regression estimates for the different drugs; endpoints (on the x-axis) 
correspond to 95% of the delta spv values for that drug.
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table 1 Studies (refs. or drug) and number of occasions used for delta spv-delta vas 
relationships.
Treatments (study reference) {number of study occasion}
Placebo
(15) {13}, (16) {10}, (8) {9}, (17) {63}, (18) {53}, (19) {17} 
(partial gaba agonist) {13}
Sumatriptan (19) {16}
Rizatriptan (19) {16}
Rilmenidine (8) {18}, (rilmenidine) {43}
Partial gaba-agonist (partial gaba agonist) {12}
Alcohol (15) {12}
Lorazepam (20) {28}, (partial GABA agonist) {14}
Temazepam (20) {48}, (16) {19}, (19) {15}
Moxonidine (18) {44}
Diazepam (15) {13}
Bretazenil (15) {13}
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table 2 Studies (refs. or drug) and number of occasions used for delta spv-delta eeg 
relationships.
5 drug class sp cific composite effects on saccadic peak velocity, visual 
analogue scales a d electroencephalography
Treatments (study reference)  {number of study occasion}
Placebo (9;21) {9}, (22) {11}, (10;11) {19}, (propofol) {10)} (8) {9}, (18) {53}, (19) {14}
Sumatriptan (19) {16}
Rizatriptan (19) {16}
Rilmenidine (8) {18}
Ro 486791 (10) {30}
Ro 488684 (11) {30}
Temazepam (9;21) {35}, (23;24) {21}, (19) {15}
Moxonidine (18) {44}
Midazolam (10;11) {20}, (propofol) {22}
Propofol (propofol) {23}
m-cpp (25) {27}
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table 3 Slope ranges of the different drug classes for spv, eeg beta fc, theta fc and 
alpha po.
slope ranges
drug class spv eeg  beta Fc eeg  theta Fc eeg  alpha Po
benzodiazepines 0.0912 / 0.2338 0.0035 / 0.0164 -0.0043 / -0.0023 -0.0105 / -0.0194
imidazoline 
modulators
0.1077 / 0.1331 0.0032 / 0.0054 0.0045 / 0.0050 -0.0247 / -0.0084
serotoninergic drugs 0.0805 / 0.1072 0.0012 / 0.0034 0.0034 / 0.0035 0.0118 / 0.0150
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chapter 6   evaluation of tests of central nervous system 
 performance after hypoxemia for a model 
 for cognitive impairment
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Abstract
The sensitivity of several neurophysiological and cognitive tests to 
different levels of hypoxia was investigated. Cerebral hypoxia in healthy 
volunteers may be a disease model for dementia or other forms of brain 
dysfunction. Twelve healthy subjects were included in a randomized, 
single-blind, placebocontrolled, three-period cross-over trial. They 
received three air/n2 gas mixtures via mask breathing [aimed at 
peripheral oxygen saturation (spo2) values of > 97% (placebo), 90% 
and 80%, with normal end-tidal co2. Central nervous system effects 
were tested regularly for 130 min by saccadic and smooth pursuit 
eye movements, electro-encephalogram, visual analogue scales and 
cognitive tests. Treatments were well tolerated. Compared to spo2 90%, 
spo2 80% reduced saccadic peak velocity by 16.4 °/s [confi dence interval 
(ci) –26.3, –6.4], increased occipital delta power by 14.3% (ci 3.6, 25.1), 
and signifi cantly increased most cognitive reaction times. spo2 80% 
also decreased correct responses for the binary choice task and serial 
word recognition [–1.3 (–2.2, –0.3) and –3.5 (–6.2, –0.8), respectively] 
compared to spo2 90%. Cognitive performance was decreased by spo2 
80% and increased by spo2 90% compared to placebo. Sensitive effect 
measurements can be identifi ed for these interventions. The applicability 
as a model for cognitive impairment should be investigated further.
Introduction
Many investigators have found cerebral hypoxia to have an effect 
on cognitive performance as well as on several neurophysiological 
measures. Much of this research has been conducted in the fi elds of 
mountaineering and aviation physiology (Denison et al., 1966; Clark et al., 
1983; Jason et al., 1989; Regard et al., 1989; Kida and Imai, 1993; Bonnon et 
al., 1995). More recently, it has been recognized that hypoxemia-induced 
cognitive impairment and neurophysiological changes share similarities 
with the fi ndings in dementia of both the vascular and degenerative 
subtypes (Saletu et al., 1991a,b; Saletu et al., 1992). This has led to the 
suggestion that hypoxic conditions in healthy volunteers may be used 
as a model for cognitive impairment (Saletu and Grunberger, 1984). 
To date, no widely applicable model for cognitive impairment is 
available. Although other pharmacological models have been suggested 
(Patel and Tariot, 1991), currently the most used method for inducing 
cognitive impairment is a challenge with scopolamine, a muscarine 
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receptor antagonist. Scopolamine has been shown to increase delta and 
theta power and decrease alpha and beta frequencies in the electro-
encepahalogram (eeg) of healthy young volunteers (Ebert and Kirch, 
1998). The drug also increases reaction times and generally impairs 
tasks with minimal memory requirements, without showing effects 
on word recognition and delayed word recall (Ebert and Kirch, 1998). 
Furthermore, the administration of scopolamine induces sedative 
effects, accommodation disturbances and dryness of the mouth. 
These characteristics limit the use of the scopolamine model in several 
ways.
First, induced symptoms do not overlap completely with those of 
cognitive impairment resulting from Altzheimers’ disease. This may 
be partly due to the fact that other neurotransmitter systems, apart 
from acetylcholine, are also involved in cognition and memory (Ellis and 
Nathan, 2001). Moreover, scopolamine-induced cognitive impairment 
may in part be caused by sedation. In addition, the scopolamine model 
has proven useful during the development of cholinergic drugs, although 
its applicability for drugs with other mechanisms of action is doubtful. 
The hypoxemia model would potentially allow the testing of 
treatments for cognitive impairment, without the disadvantages of 
drug interaction. In contrast to the scopolamine model, the induced 
cognitive defi cit will possibly be more widespread and less specifi c to 
one neurotransmitter system. Also, sedation does not appear to be an 
important symptom, which possibly clarifi es the interpretation of the 
results.
Most studies have shown that cerebral hypoxia induces eeg changes, 
such as an increase in delta, theta and fast-beta waves, and a decrease 
in alpha activity (Kraaier et al., 1988; Saletu et al., 1990; Van der Worp et 
al., 1991). Similar changes are found in dementia both of the vascular 
and degenerative subtypes. Furthermore, a deterioration of cognitive 
performance, such as a decline in recognition and recall reminiscent of 
Alzheimer’s dementia, has also been reported under cerebral hypoxia 
(Crow and Kelma, 1971; Berry et al., 1989; Noble et al., 1993; Bonnon et al., 
1995). It is still unclear which tests are the most sensitive to evaluate 
the effects of cerebral hypoxia on cognitive and psychomotor functions. 
The relationship between the levels of hypoxemia and the impairment 
of central nervous system (cns) function is also unknown. 
The aim of this study was to investigate the potential of hypoxemia 
as a model for cognitive impairment, by evaluating the effect of different 
levels of hypoxemia on a selection of cognitive and neurophysiological 
tests.
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Methods
Subjects
After approval of the protocol by the Ethical Review Board of the Leiden 
University Medical Center, 12 healthy volunteers were asked to participate 
in the study. After providing their written informed consent, subjects 
received a full medical examination before entering the study. A training 
session for mask breathing was performed as part of their eligibility 
assessment. The cns test battery was practised to reduce learning 
effects during the study. Subjects refrained from alcohol, caffeine and 
xantine containing foods and beverages 12 h prior to the study day and 
during the study days. Concomitant medication other than paracetamol 
or oral contraceptives was not permitted during the study period. A light 
standard breakfast was served before the start of the experiment. After 
the experiment, subjects were allowed to go home if all vital signs were 
back to normal and stable and signifi cant adverse events had subsided. 
Design and procedure
The study was designed as a blinded, randomized, placebo-controlled 
three-period cross-over trial with a minimum washout period of 2 days. 
Starting at approximately the same time each study day (approximately 
09.30 h) subjects breathed an air/n2 gas mixture through a well-fi tted 
facemask (vbm Medizintechnik gmbh, Sulz a.N., Germany), which 
maintained their peripheral spo2 at either > 97% (placebo, normal 
air breathing) or decreased their spo2 percentages to 90% or 80% 
for a duration of 2 h 10 min. The air/n2 gas mixtures were adapted 
continuously to the peripheral spo2 percentagages (Peripheral 
Saturation meter, Life scope ec bsm-1101k, Nihon Kohden, Tokyo, Japan) 
by a single investigator, who was not involved in other study procedures. 
All other investigators and the study subject remained blinded to 
the administered gas mixture and the oxygen saturation levels. Eye 
movements, eeg and Visual Analogue Scale (vas) scores were performed 
at baseline and at the following time points after reaching the hypoxemic 
plateau phase: 0 h 00 min, 0 h 30 min, 1 h 00 min, 1 h 30 min, 2 h 00 min, 
2 h 10 min and 2 h 20 min (after the subjects spo2 was back and stable at 
baseline levels). The cognitive test battery was conducted intermittently 
between 10 min and 1 h and 50 min during breathing of the gas mixture. 
One-lead electro-cardiogram, heart rate, peripheral spo2, and end-tidal 
co2 were monitored continuously and recorded at intervals.
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cns function tests
cognitive test battery Cognitive performance was tested using the 
‘FePsy’ software package (Instituut voor Epilepsiebestrijding,Heemstede, 
the Netherlands) (Alphers and Aldenkamp, 1994). This system contains a 
battery of computerized tests of different complexity measuring diverse 
cognitive skills.
memory tasks To evaluate memory function, serial and simultaneous 
recognition of words and fi gures, which are recognition and short 
memory tasks, were evaluated. For serial recognition, six words/four 
fi gures are presented in serial order, at 1 s per word with a 250-ms 
interval. After a delay of 2 s, one of these words/fi gures is presented for 
recognition, and the subject is instructed to indicate the presentation 
order in the study phase. Recall of the order of stimuli was required for 
recognition. For simultaneous word/fi gure recognition, six words/four 
fi gures are presented simultaneously for 6 s. After a delay of 2 s, six 
words/four fi gures are presented. The subjects are asked to indicate 
which of these words/fi gures was presented earlier.
The Corsi Block Tapping task was used to assess direct recall. This test 
is constructed according the principles of the original corsi block tapping 
task (Nelson et al., 2000), and assesses nonverbal memory span. In this 
test, nine buttons appear on a screen. Three buttons fl ash in serial order 
in a tempo of one per second. Subjects are instructed to indicate the 
order in which the buttons appear. After each correct response, one extra 
button is presented until two consecutive trials fail. The ‘span’ is the 
maximum correct number of buttons. 
To address visual (complex) information processing and perceptual-
mental-strategies, the visual searching task was performed. It consists 
of fi nding a grid pattern out of 24 that matches the one in the centre of 
the screen. The target pattern is marked by an arrow on the right side 
and is selected by typing the correct number from the keyboard. After 
12 presentations, the surrounding grids change. The subject is asked 
to react as fast as possible. The main parameter of the visual searching 
task was the number of errors, the secondary endpoint was the mean 
searching time of correct response (Goldstein et al., 1973; Demita and 
Johnson, 1981).
The wisconsin card sorting task was an adaptation of the 
original wisconsin card sorting task, assessing abstraction ability, 
conceptualization, failure to maintain set and perseveration (Anderson 
et al., 1991). The four stimuli cards are shown on the top row of the 
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screen. The deck of 128 response cards is shown on the bottom row. The 
subject is instructed to sort the cards. The categories (colour, number or 
form) are not communicated. The subject has to type the number of the 
stimulus card he thinks the response card belongs to. The response card 
is then placed beneath the stimulus card. Hereafter, the subject receives 
feedback from the computer by showing ‘correct’ or ‘incorrect’ on the 
screen and an accompanying high or low beep. After identifi cation of the 
correct category, the sorting strategy is changed. The test proceeds until 
six shifts of categories have taken place or until the deck of response 
cards is exhausted. Main parameters are: total number of errors and 
number of persisting errors.
reaction times To measure attention, simple auditory and visual 
reaction times were performed. Stimulus exposure endures until a 
response (space bar) is given. The subject is asked to react as quickly as 
possible. The inter-stimulus interval is randomly varied from 2.5–4 s.
For both the dominant and the non-dominant hand, 30 stimuli are 
presented. The main parameters are average response latency and the 
standard deviation of all scores. 
The binary choice task, which is a more complex reaction time task, 
was added to measure information processing and response inhibition. 
Attention and speed of information processing are evaluated. Either a red 
or a green block is displayed in random order in either the left or the right 
half of the screen. The subject reacts by pushing a button on either side 
of the keyboard, corresponding to the position of the coloured block on 
the screen. The test is self-paced and continuous, which implies that a 
response is immediately followed by substitution of another block in the 
same or the opposite position. Sixty stimuli are presented during 1 min. 
The main parameters are the number of correct responses, mean reaction 
time of correct response and the sd of correct responses.
Neurophysiological tests
eye movements Saccadic eye movements have been shown to be 
very sensitive to sedation, specifi cally saccadic peak velocity, in studies 
on sleep deprivation and sedative compounds (van Steveninck et al., 
1991; Harron et al., 1995; Steveninck et al., 1999). Smooth pursuit eye 
movements are altered in a number of neuropsychiatric diseases (e.g. 
schizophrenia and stroke), and are also affected by sedative agents such 
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as barbiturates and alcohol (van Steveninck, 1993; van Steveninck et al., 
1997). The sensitivity to cerebral hypoxia remains to be assessed. 
Recording and analysis of saccadic and smooth pursuit eye 
movements was performed with a microcomputer-based system (van 
Steveninck et al., 1989). The equipment used for stimulus display, signal 
collection and amplifi cation was obtained from Nihon Kohden. Saccadic 
eye movements were recorded for stimulus amplitudes of 15° to either 
side. Interstimulus intervals varied randomly from 3–6 s, and 15 saccades 
were recorded. The average values of saccadic peak velocity, latency 
reaction time) and inaccuracy were used as parameters. For smooth 
pursuit eye movements the target moved sinusoidal at frequencies 
ranging from 0.3–1.1 Hz, increasing by steps of 0.1 Hz. The amplitude of 
target displacement corresponds to 20° eyeball rotations to both sides. 
Four cycles were recorded for each stimulus frequency.
electro-encephalograms Electro-encephalograms were recorded 
and analysed using ced software (Cambridge Electronics Design, 
Cambridge, uk), as described previously (Steveninck et al., 1999). eeg 
recordings were made using silver-silver chloride electrodes, fi xed with 
collodion at Fz, Cz, Pz and Oz, with the same common ground electrode 
as for the eye movement registration (international 10/20 system). The 
electrode resistances were maintained below 5 kOhm. All recordings were 
carried out with the subjects’ eyes closed. eeg signals were obtained 
from leads Fz–Cz and Pz–Oz. The signals were amplifi ed by use of a Nihon 
Kohden ab-621g bio-electric amplifi er with a time constant of 0.3 s and a 
low pass fi lter at 100 Hz. Per session, eight consecutive blocks of 8 s were 
recorded over a 2-min period. The sampling rate was 1024 Hz. Datablocks 
containing artefacts were identifi ed by visual inspection and these were 
excluded from analysis. Fast Fourier transform analysis was performed 
to obtain the sum of amplitudes in the delta- (0.5–3.5 Hz), theta- (3.5–7.5 
Hz), alpha- (7.5–11.5 Hz) and beta (11.5–30 Hz) frequency ranges. The total 
recording bandwidth was 0–50 Hz.
Subjective assessments
visual analogue scales Visual analogue scales, as originally 
described by Norris (Norris, 1971), were used to quantify subjective 
effects. Three factors corresponding to alertness, mood and calmness 
were derived from these measurements (Bond and Lader, 1976). 
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Statistical analysis
All data were analysed by factorial one-way analysis of variance 
(anova), with subject, treatment and study day as factors. Contrasts 
between treatments and between study days were calculated within 
the anova model and are presented with 95% confi dence intervals. 
For saccadic peak velocity, saccadic accuracy, saccadic latency, vas 
alertness, vas mood and vas calmness, area under the effect curves 
(auec) were calculated using the linear trapezoidal rule on the protocol 
times from prevalue to the fi nal value. For the eeg variables, the auec 
of the percentage change from baseline was calculated. auecs were 
divided by the corresponding time span, resulting in weighted averages. 
Calculations were performed using the spss statistical software package 
(Version 9.0.1, spss inc., Chicago, il, usa).
Results
Fifteen subjects, nine males and six females (aged 19–27 years, with 
normal weight to height ratio), were enrolled in the study. Twelve 
subjects completed all three treatment periods, and were included in 
the dynamic analysis. Two female and one male subject dropped out 
of the study due to adverse events, and were replaced. All subjects who 
had one or more treatments were included in the safety analysis.
Adverse events
The adverse events seen in this study were mainly headache and mild 
drowsiness (table 1). Most of the adverse events (52%) and treatment 
related adverse events (70%) were seen during spo2 80%. Three 
subjects dropped out of the study due to non-serious adverse events: 
one female subject experienced tachy-dysrhythmia and anxiety during 
spo2 90%, one male subject experienced a sinus tachy dysrhythmia and 
blackouts during spo2 80% and one female subject did not tolerate the 
mask breathing during the Placebo occasion. All adverse events abated 
immediately after interruption of mask-breathing.
Table 1 – p. 126
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spo2 and end-tidal co2
The peripheral spo2 of > 97%, 90% and 80%, aimed for on individual 
study days was reached accurately and remained stable throughout the 
study period (98.7 ± 0.8%, 90 ± 0.9%, 80.3 ± 1.2%, respectively). Return 
to normal spo2 was reached almost instantaneously after the oxygen 
concentration in the gas mixture was returned to 21%. End-tidal co2 
remained stable at baseline levels throughout the study period (table 2).
Blood pressure and heart rate 
No difference in systolic or diastolic blood pressure was observed 
between any of the treatments. An increase in heart rate occurred during 
the spo2 90% and 80%, which appeared to mirror the level of hypoxemia 
(fi g. 1).
Cognitive effects
Generally, the observed cognitive effects were small and showed an 
improvement under spo2 90% and a deterioration under spo2 80%.
recognition of words and figures A signifi cant reduction 
in the number of correct responses for serial recognition of words was 
observed during spo2 80% compared to spo2 90% [mean difference 
–3.5, confi dence interval (ci) –6.2, –0.8)]. No noteworthy effects were seen 
on serial recognition of fi gures, simultaneous recognition tasks or any of 
their reaction times.
binary choice task A signifi cantly smaller number of correct 
responses was observed during spo2 80% compared to spo2 90% 
(mean difference –1.25, ci –2.17, –0.33). The mean difference of incorrect 
responses was larger during spo2 80% compared to spo2 90% (mean 
difference 101.3, ci 19.5, 183.0). During spo2 80%, the reaction time for 
incorrect responses was signifi cantly longer (mean difference 99.9, ci 
18.5, 181.3) (ms). The sd of incorrect responses was larger (mean difference 
13.3, ci 0.6, 25.9), compared to spo2 90%. 
Table 2 – p. 126
Fig. 1 – p. 124
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simple auditory and visual reaction times Compared to 
placebo, spo2 90% caused a decrease in mean difference auditory 
reaction times for the dominant hand (mean difference –13.2, ci –1.5, 
–24.9) (ms). Compared to spo2 90%, spo2 80% increased mean auditory 
reaction time for the dominant hand (mean 31.8, ci 0.8, 62.9) (ms) and 
caused a longer mean difference auditory reaction time for the non-
dominant hand (mean difference 18.4, ci 2.9, 33.9) (ms). A longer (mean 
difference 40.1, ci 12.6, 67.5) (ms) mean difference visual reaction time for 
the non-dominant hand was also observed for spo2 80% compared to 
spo2 90%.
other cognitive tests No signifi cant effects were seen on the 
visual searching task, the card-sorting task or the corsi block tapping 
task. 
Neurophysiological effects
eye movements spo2 80% caused a small reduction in peak velocity 
(mean difference –7.6, ci –17.5, 2.4) (°/s) compared to placebo. spo2 
90% caused a non-signifi cant increase in saccadic peak velocity (mean 
difference 8.8, ci –1.2, 18.8) (°/s) compared to placebo. The difference in 
saccadic peak velocity of 16.4 (ci 26.3, 6.4) (°/s) between spo2 90% and 
80% was statistically signifi cant (fi g. 2). No effects on saccadic accuracy, 
latency and smooth pursuit eye movements were seen after both spo2 
80% and 90%.
electro-encephalograms 80% spo2 caused an increase in 
occipital delta power compared to placebo and 90% spo2 [mean 
difference 10.7, ci 0.3, 21.1 and mean difference 14.3, ci 3.6, 25.1 (%) 
respectively] (fi g. 3A). Also, an increase in occipital theta power occurred, 
compared to 90% Spo2 (mean difference 9.9, ci –5.4, 25.3) (%) was 
found. Small decreases in frontal alpha power, compared to placebo and 
90% spo2 [mean difference –8.4, ci –19.7, 3.0 and mean difference –9.2, 
ci –20.6, 2.2 (%), respectively] were seen (fi g. 3B).
spo2 90% caused a decrease in occipital delta and theta power 
compared to placebo (mean difference –3.6, ci –14.4, 7.2 and mean 
difference –7.2, ci –22.5, 8.1 (%), respectively]. No effects of spo2 80% 
and 90% were seen on occipital alpha power, frontal and occipital beta 
power, frontal delta power and frontal theta power.
Fig. 2 – p. 124
Fig. 3a – p. 125
Fig. 3b – p. 125
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Subjective effects
visual analogue scale No signifi cant differences were seen in 
alertness, mood and calmness on comparing the different spo2 levels. 
Discussion
This study aimed to explore the effects of two levels of hypoxemia on 
cns function in healthy human volunteers, and to identify sensitive 
tests to measure these effects. Although small, a number of effects of 
hypoxemia on cns function have been observed. 
 Because this was an exploratory study with a small number of 
subjects, and a large number of tests, these effects may be spurious. 
However, although in general these effects were small, a consistent 
picture emerged from these results. The main contrasts were seen 
between spo2 90% and spo2 80%.
spo2 80% seemed to decrease cognitive performance, in contrast 
to the increase observed under spo2 90%, with placebo in-between. 
A decrease in the number of correct responses was found for the serial 
recognition of words and for the binary choice task when spo2 80% was 
compared to spo2 90%. Generally, reaction times increased under spo2 
80% and decreased under spo2 90%.
spo2 80% caused cognitive effects that differed from those observed 
during sedation, either by pharmacological intervention or sleep 
deprivation (Saletu et al., 1991A; Visser et al., 2001). In mild sedation, 
an increase in reaction times is expected, while the number of correct 
responses for cognitive tasks will remain unchanged. In contrast, the 
current study showed a combination of an increase in reaction time 
and a decrease in correct responses, which was also reported previously 
in a hypoxemia study in human volunteers (Noble et al., 1993). This seems 
to indicate that hypoxia does not simply cause a ‘slowing’ of the brain, 
but affects memory and decision making processes.
This study showed an improvement in cognitive performance above 
normal values under mild hypoxemia (spo2 90%) similar observations 
have been made previously. Acute exposure to mild hypoxia, a fractional 
inspiratory oxygen concentration of 14.5% (comparable to spo2 90%) 
has improved a simple measure of cognitive performance above normal 
values (Schlaepfer et al., 1992).
Neurophysiological tests showed similar results. spo2 90% appears 
to have a general stimulant effect on cns function as opposed to 
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spo2 80%, which seems to be slightly impairing. This is indicated by 
a reduction in saccadic peak velocity under spo2 80% compared to 
placebo. This can be regarded as a very mild sedative effect, less than 
would be observed after one night of sleep deprivation (Steveninck 
et al., 1999). However, the absence of signifi cant effects on subjective 
ratifng scales for alertness would argue against a clear sedative effect 
(Saletu et al., 1991A; Saletu et al., 1992). This lack of subjective effects 
is in accordance with the fi nding that, even with severely hypoxic 
aircraft pilots, feelings of somnolence are rarely reported prior to loss 
of consciousness (Brown, 1994). The slight elevation in saccadic peak 
velocity compared to placebo that was observed with spo2 90%, 
suggests an improvement of alertness (Steveninck et al., 1999). 
The study showed an increase in eeg occipital delta power (endrenyi 
and zha, 1994; Sheiner, 1994) and a decrease of alpha power (levy, 1994), 
which is comparable to fi ndings in Altzheimers’ disease. spo2 90%, 
however, caused an increase in alpha power compared to placebo, 
suggesting an improvement in alert wakefulness. An increase in delta 
and theta power and a decrease in alpha power can also indicate 
hyperventilation (Van der Worp et al., 1991). This is unlikely to have caused 
the eeg changes in our study, since end-tidal co2 values were not 
decreased by the hypoxemic conditions. These results are in agreement 
with previous reports, in which increases in delta eeg activity and 
decreases in alpha activity were observed in healthy volunteers during 
hypobaric hypoxia (Kraaier et al., 1988; Saletu et al., 1990; Van der Worp et 
al., 1991).
The observed activation and increased performance during spo2 
90% could be the result of a functional adaptation to the effects 
of mild hypoxia; if cognitive function is only slightly affected, the 
impairment could be noticed, and consequently overcompensated by 
the subjects. Similar effects have been reported with benzodiazepines 
(van Steveninck et al., 1991) and after sleep deprivation (Steveninck et al., 
1999). Alternatively, this might also arise from cns dysinhibition under 
mild hypoxia. Furthermore, the sensitivity of different neurotransmitter 
systems in the brain could differ for various levels of hypoxia, resulting in 
the observed bidirectional effect of hypoxemia.
Hypoxemia down to 80% spo2 over an extended period of time 
appears to be generally well tolerated by healthy young volunteers. Most 
of the adverse events, comprising mainly headache and drowsiness, were 
mild and ceased usually within minutes of ending the mask breathing. 
The three subjects that dropped out due to nonserious adverse events 
appeared to have intolerability to the test procedures, resulting in tachy-
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dysrhythmia and anxiety. A 25% dropout rate could seriously affect the 
effi cient use of this model. However, more careful training of subjects 
on the ability to breathe through a mask could potentially avoid these 
events. The increase in heart rate was the only observed effect on vital 
signs, and remained within normal limits (60–100 b.p.m.) for most 
subjects. Hypocapnia was excluded as a contributor to either the adverse 
or the cns effects of the procedure. 
In conclusion, it appears that a number of cognitive (auditory and 
visual reaction times, binary choice task and serial recognition of words) 
and neurophysiological (saccadic eye movements, eeg) are sensitive to 
the effects of hypoxemia. The effects seem to be most outspoken on 
simple and complex reaction times. In our study, hypoxemia showed 
only limited cognitive effects, and the main contrasts were found 
between spo2 80% and 90%. This could set a limit to the usefulness 
of hypoxemia as a model for cognitive impairment. An elderly (target) 
population may show a different more unidirectional response to 
hypoxemia. A repetition of this study in this population could also 
increase the effect size, due to a diminished capacity for compensation. 
122  biomarkers in early phase development of central nervous system drugs
references
Alphers W C J, Aldenkamp A P (1994) FePsy, The Iron Psyche. 
Manual 5.0. Publisher, Publisher’s Location
Anderson s W, Damasio H, Jones R D, Tranel D (1991) 
Wisconsin Card Sorting Test Performance As 
A Measure Of Frontal Lobe Damage. J Clin Exp 
Neuropsychol 13: 909–922
Berry D T, Mcconnell J W, Phillips B A, Carswell C M, 
Lamb D G, Prine B C (1989) Isocapnic Hypoxemia 
And Neuropsychological Functioning. J Clin Exp 
Neuropsychol 11: 241–251
Bond A, Lader M (1976) Self-concepts In Anxiety States. Br J 
Med Psychol 49: 275–279
Bonnon M, Noel-jorand M C, Therme P (1995) Psychological 
Changes During Altitude Hypoxia. Aviat Space Environ 
Med 66: 330–335
Brown P (1994) Pupil Test For Alheimer’s. New Sci 5 
Clark C F, Heaton R K, Wiens A N (1983) Neuropsychological 
Functioning After Prolonged High Altitude Exposure In 
Mountaineering. Aviat Space Environ Med 54: 202–207
Crow T J, Kelman G R (1971) Effect Of Mild Acute Hypoxia On 
Human Short-term Memory. Br J Anaesth 43: 548–552
Demita M A, Johnson J H (1981) The Validity Of A Compu-
terized Visual Searching Task As An Indicator Of Brain 
Damage. Behav Res Meth Instrument 13: 592–594
Denison D M, Ledwith F, Poulton E C (1966) Complex 
Reaction Times At Simulated Cabin Altitudes Of 5000 
Feet And 8000 Feet. AErosp Med 37: 1010–1013
Ebert U, Kirch W (1998) Scopolamine Model Of Dementia: 
Electroencephalogram Findings And Cognitive 
Performance. Eur J Clin Invest 28: 944–949
Ellis K A, Nathan P J (2001) The Pharmacology Of Human 
Working Memory Int J Neuropsychopharmacol 4: 
299–313
Endrenyi L, Zha J (1994) Comparative Effi ciencies Of 
Randomized Concentration- And Dose-controlled 
Clinical Trials Clin Pharmacol Ther 56: 331–338
Goldstein G, Welch RB, Rennick PM, Shelly Ch (1973) The 
Validity Of A Visual Searching Task As An Indicator Of 
Brain Damage. J Consult Clin Psychol 41: 434–437
Harron D W, Hasson B, Regan M, Mcclelland R J, King D J 
(1995) Effects Of Rilmenidine And Clonidine On The 
Electroencephalogram, Saccadic Eye Movements, And 
Psychomotor Function. J Cardiovasc Pharmacol 26 
(Suppl.): S48–s54
Jason G W, Pajurkova E M, Lee R G (1989) High-
altitude Mountaineering And Brain Function: 
Neuropsychological Testing Of Members Of A Mount 
Everest Expedition. Aviat Space Environ Med 60: 
170–173
Kida M, Imai A (1993) Cognitive Performance And Event-
related Brain Potentials Under Simulated High 
Altitudes. J Appl Physiol 74: 1735–1741
Kraaier V, Van Huffelen A C, Wieneke G H (1988) 
 Quantitative EEG Changes Due To Hypobaric 
Hypoxia In Normal Subjects. Electroencephalogr Clin 
Neurophysiol 69: 303–312
Levy G (1994) Pharmacologic Target-mediated Drug 
Disposition. Clin.pharmacol.ther 56: 248–252
Nelson R E, Dickson A L, Banos J H (2000) An Automated 
Administration Of Corsi’s Block-tapping Test. Percept 
Motor Skills 91: 578–580
Noble J, Jones J G, Davis E J (1993) Cognitive Function 
During Moderate Hypoxaemia. Anaesth Intens Care 
21: 180–184
Norris H (1971) The Action Of Sedatives On Brain Stem 
Oculomotor Systems In Man. Neuropharmacology 
10: 181–191
Patel S, Tariot P N (1991) Pharmacologic Models Of 
Alzheimer’s Disease. Psychiatr Clin North Am 14: 
287–308
Regard M, Oelz O, Brugger P, Landis T (1989) Persistent 
Cognitive Impairment In Climbers After Repeated 
Exposure To Extreme Altitude. Neurology 39: 210–213
Saletu B, Grunberger J (1984) The Hypoxia Model In 
Human Psychopharmacology: Neurophysiological 
And Psychometric Studies With Aniracetam i.v. Hum 
Neurobiol 3: 171–181
Saletu B, Grunberger J, Anderer R (1990) On Brain 
Protection Of Codergocrine Mesylate (Hydergine) 
Against Hypoxic Hypoxidosis Of Different Severity: 
Double-blind Placebo-controlled Quantitative EEG 
And Psychometric Studies. Int J Clin Pharmacol Ther 
Toxicol 28: 510–524
Saletu B, Anderer P, Paulus E (1991a) EEG Brain Mapping In 
Diagnostic And Therapeutic Assessment Of Dementia. 
Alzheimer Dis Assoc Disord 5: 57–75
Saletu B, Paulus E, Linzmayer L (1991b) Nicergoline In 
Senile Dementia Of Alzheimer Type And Multi-
infarct Dementia: A Double-blind, Placebo-
controlled, Clinical And EEG Erp Mapping Study. 
Psychopharmacology 117: 385–395
Saletu B, Anderer P, Fischhof PK, Lorenz H, 
Barousch R, Bohmer F (1992) EEG Mapping And 
Psychopharmacological Studies With Denbufylline In 
Sdat And Mid. Biol Psychiatry 32: 668–681
Schlaepfer T E, Bartsch P, Fisch H U (1992) Paradoxical 
Effects Of Mild Hypoxia And Moderate Altitude On 
Human Visual Perception. Clin Sci (Colch) 83: 633–636
Sheiner L B (1994) A New Approach To The Analysis Of 
Analgesic Drug Trials, Illustrated With BroMFenac 
Data Clin Pharmacol Ther 56: 309–321
Steveninck A L, Berckel B N M, Schoemaker H C, Breimer 
D D, Gerven J M A, Cohen A F (1999) The Sensitivity 
Of Pharmacodynamic Tests For The Central Nervous 
System Effects Of Drugs On The Effects Of Sleep 
Deprivation. J Psychopharmacol 13: 10–17
123 chapter 6 – evaluation of tests of central nervous system performance after 
 hypoxemia for a model for cognitive impairment
Van Der Worp H B, Kraaier V, Wieneke G H, Van Huffelen A C 
 (1991) Quantitative EEG During Progressive Hypocarbia 
And Hypoxia. Hyperventilation-induced EEG Changes 
Reconsidered. Electroencephalogr Clin Neurophysiol 
79: 335–341
Van Steveninck A L (1993) Methods Of Assessment Of 
Central Nervous System Effects Of Drugs In Man 
Thesis. State University, Leiden
Van Steveninck A L, Cohen A F, Ward T (1989) A 
Microcomputer Based System For Recording And 
Analysis Of Smooth Pursuit And Saccadic Eye 
Movements Br J Clin Pharmacol 27: 712–713
Van Steveninck A L, Schoemaker H C, Pieters M S, Kroon 
R, Breimer D D, Cohen A F (1991) A Comparison Of The 
Sensitivities Of Adaptive Tracking, Eye Movement 
Analysis And Visual Analog Lines To The Effects 
Of Incremental Doses Of Temazepam In Healthy 
Volunteers. Clin Pharmacol Ther 50: 172–180
Van Steveninck A L, Wallnofer A E, Schoemaker R C, Pieters 
M S, Danhof M, Van Gerven J M, Cohen A F (1997) A 
Study Of The Effects Of Long-term Use On Individual 
Sensitivity To Temazepam And Lorazepam In A Clinical 
Population. Br J Clin Pharmacol 44: 267–275
Visser S J D, Post V D J, Pieters M s M, Cohen A F, Gerven J M 
A (2001) Biomarkers For The Effects Of Antipsychotic 
Drugs In Healthy Volunteers. Br J Clin Pharmacol 51: 
119–132 
124  biomarkers in early phase development of central nervous system drugs
figure 1 Average heart rates. Mean ± sd time-effect profi les of heartrate for spo2 
80% (•), 90% (°) and 100% (:).
figure 2 Average saccadic peak velocity. Mean ± sd time-effect profi les of saccadic 
peak velocity for spo2 80% (•), 90% (°) and 100% (:).
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figure 3a Average occipital delta power. Mean ± sd time-effect profi les of occipital delta 
power for spo2 80% (•), 90% (°) and 100% (:). (b) 
figure 3b Frontal alpha power. Mean ± sd time-effect profi les of frontal alpha power for 
spo2 80% (•), 90% (°) and 100% (:).
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table 1  Adverse events for different spo2.
table 2  End-tidal co2 percentages.
Adverse events 100%
n = 15 
90% 
n = 14
80%
 n = 13
Any event 8 8 17
Any treatment related event 1 5 14
Headache 3 1 5
Drowsiness 3 3 5
Treatment pre-treatment 
mean ± sd
during treatment
mean ± sd
post-treatment
mean ± sd
HbSaO2 80% 5.4 (0.3) 5.1 (0.3) 4.9 (0.3)
HbSaO2 90% 5.3 (0.2) 5.1 (0.3) 5.0 (0.3)
HbSaO2 100% 5.3 (0.2) 5.2 (0.3) 5.1 (0.3)
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Abstract
This study aimed to evaluate eye blinking as a marker for central dopami-
nergic activity by investigating the effects of sulpiride (d2-antagonist) 
and lisuride (d2-agonist) on spontaneous eye blinks. Twelve healthy sub-
jects were included in a randomized, double-blind, placebo-controlled, 
three-period crossover trial. They received sulpiride 400 mg, lisuride 
0.2 mg and placebo on different occasions. Eye blinks, prolactin, fi nger 
tapping, eye movements and visual analogue scales were measured at 
baseline and regularly for 12 h after administration. No effect of sulpiride 
or lisuride was observed on the number of eye blinks. Sulpiride caused an 
increase in prolactin (643 U/ml) [confi dence interval (ci) 549–737). Lisuride 
caused a decrease in smooth pursuit eye movements (–4.1%) (ci –7.3 
to –0.9) and visual analogue scales for mood (–2.1 mm) (ci –3.7 to –0.4). 
Spontaneous eye blink rate was not affected by sulpiride and lisuride, 
which makes eye blinking not suitable as a marker for central d2 activity. 
Introduction
Spontaneous eye blinking occurs in humans approximately 15 000 times 
per day, 15–20 times per minute in a quiet relaxed state. The biological 
function of eye blinking is to keep the cornea healthy by enabling a layer 
of moisture to form continuously. The rate of blinking is also closely re-
lated to psychological factors. If a task requires continuous visual atten-
tion, such as reading, the blink rate decreases. Due to strong emotional 
responses, stress (such as performing under time pressure) or having to 
perform when fatigued, the blink rate increases (Karson et al., 1981B). 
Patients suffering from parkinson’s disease or supra nuclear palsy 
tend to have a decreased spontaneous eye blink rate compared to a 
healthy population (Karson et al., 1984A,b). By contrast, patients with an 
acute psychotic episode often show an increased eye blink rate as well 
as an aberrant blinking pattern (Mackintosh et al., 1983; Kitamura et al., 
1984; Helms et al., 1985; Lovestone, 1992). These clinical observations of 
patients with diseases involving central dopaminergic neurotransmission 
have led to the suggestion of spontaneous eye blink rate as a putative 
marker for central dopamine activity.
Dopaminergic pharmacotherapy also appears to affect eye blink rate. 
Patients treated with dopamine precursors or agonists have an increased 
spontaneous eye blink rate. Dopamine antagonistic medication, such 
as several antipsychotics, decreases blinking frequency (Karson et 
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al., 1981a; Karson et al., 1982; Kleinman et al., 1984). Experiments with 
dopamine agonists in primates have confi rmed these observations 
(Karson et al., 1981C; Elsworth et al., 1991; Lawrence et al., 1991; Kleven 
et al., 1996). Few studies in healthy volunteers have been performed to 
investigate the effect of dopaminergic drugs on spontaneous eye blink 
rate. Apomorphine demonstrates an increasing effect on blink-rate in 
healthy volunteers (Blin et al., 1990). If a relationship exists, spontaneous 
eye blinking may provide a measure for the dopaminergic activity of new 
drugs, as well as a clinical tool for individual adjustment of dopaminergic 
drug dosage in patients with Parkinson’s disease or schizophrenia. 
Ideally, a useful marker should meet several requirements. First, a 
clear response of the biomarker to a therapeutic dose of a dopaminergic 
drug. Second, a clear, consistent response across studies (from different 
groups). Third, a dose (concentration)–response relationship of the drug 
and the marker. Finally, a plausible relationship between the biomarker 
and the pharmacology of the dopaminergic should also exist. The present 
study focuses on the fi rst requirement. 
The involvement of the d2-receptor in spontaneous eye blinking is 
well documented, both by patient treatment data as well as in animal 
experiments (Karson et al., 1981A; Karson et al., 1982; Lawrence et al., 1991; 
Kleven et al., 1996). The drugs that were used in this study were matched 
on d2-receptor selectivity. Sulpiride is a selective post-synaptic d2-
receptor antagonist (although, in lower doses, it can act as a pre-synaptic 
d2-antagonist) and lisuride is a post-synaptic d2-receptor agonist, with 
some weak d1-antagonistic activity. The kinetic profi les of these drugs 
are fairly compatible. The drugs were administered at twice the clinically 
accepted starting dose, aimed at reaching clinically signifi cant plasma 
concentrations.
Prolactin was measured as a reference marker for d2 antagonism. 
Physiological pituitary prolactin secretion is inhibited by dopamine, and 
dopamine receptor antagonism induces a prolactin response. Indeed, 
a correlation can be observed between the affi nity of a drug for the d2 
receptor and the prolactin inducing property (Visser et al., 2001). The d2 
antagonist used in this study was expected to produce a maximal prolac-
tin response of approximately 11 times baseline plasma concentrations 
(De Koning et al., 1995). Lisuride was expected to lower prolactin levels 
slightly, depending on pre-treatment values. Eye blinking can also be 
affected by changes in attention. Although rarely used to evaluate do-
paminergic drugs in healthy volunteers (Visser et al., 2001), saccadic eye 
movements have been shown to be very sensitive to sedation, specifi -
cally saccadic peak velocity, in studies on sleep-deprivation and sedative 
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compounds (van Steveninck et al., 1991; Harron et al., 1995; Steveninck et 
al., 1999) Smooth pursuit eye movements are altered in a number of neu-
ropsychiatric diseases (e.g. schizophrenia and stroke), and are also affect-
ed by sedative agents such as barbiturates and alcohol (van Steveninck, 
1993). Both types of eye movements were measured in this study. 
Although not very sensitive, fi nger tapping has been used frequently 
in the evaluation of neuroleptic drugs in healthy volunteers (Visser 
et al., 2001), and was also measured in the current study. In addition, 
subjective drug effects were rated with Visual Analogue Scales (vas) for 
alertness, mood and calmness. Some sensitivity to dopaminergic effects, 
particularly neuroleptics, has been demonstrated (Visser et al., 2001).
Methods
Subjects
After approval of the protocol by the Ethical Review Board of the Leiden 
University Medical Centre, 12 healthy volunteers were asked to participate 
in the study. After providing their written informed consent, subjects 
received a full medical examination before entering the study. The eye 
blink rate and eye-movement recording were practised to reduce learning 
effects during the study. Subjects refrained from alcohol, caffeine and 
xanthine containing foods and beverages from 12 h prior to the study 
day and during the study days. Concomitant medication other than 
paracetamol was not permitted during the study period. 
Design and procedure
The study was designed as a double-blinded, completely counterbalanced 
within-subjects repeated measures experiment, with a minimum wash-
out period of 2 days. Each study day at approximately 10.00 h, subjects 
received a capsule containing either sulpiride 400 mg, lisuride 0.2 mg or 
placebo. Eye blinks, eye movements, fi nger tapping and visual analogue 
scale scores were measured twice at baseline. Single measurements were 
performed at 45 min and each following hour until 12 h after drug admin-
istration. Blood samples for prolactin were drawn at 30 min and each fol-
lowing 30 min until 3 h, then every 1 h until 6 h and, fi nally, every 2 h until 
12 h after drug administration. Safety assessments consisted of elec-
trocardiograms, blood pressure and a general enquiry into the subjects’ 
wellbeing pre-dose and at 3 h and 6 h after drug administration. 
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Eye blink recording 
Eye blink rate was determined under tranquil conditions, with comfort-
able room temperature and normal humidity. The subject was measured 
in a comfortable position. Head movements were limited by instructing 
the subject to lean their heads against the headrest of the chair. The 
subject was instructed not to talk during the measurement, and to relax 
but not to fall asleep. Subjects were told that they could not close their 
eyes. The measurements were taken while the subjects were asked to 
look at a television monitor for a 5-min period, which was showing a vir-
tual aquarium scene. The aquarium scene was used to provide a neutral 
eye focusing point. It does not require continuous visual attention and 
does not provoke strong emotional responses during the measurements, 
since these factors can infl uence the eye blink rate. The moving speed of 
fi shes was low to avoid saccadic eye movements during gazing. A previ-
ous pilot study showed this to be the optimal measurement duration and 
circumstances. In this study, six subjects were measured under identical 
conditions over an 8-h period with 30min intervals. Minimal effect sizes 
were calculated assuming a two-sided t-test with six subjects, a power of 
80% and α = 0.05. The 0–8-h values were used for a minimal effect size 
for a parallel study and the 0–4-h and 4–8-h (compared within subjects) 
to obtain a minimal effect size for a crossover study. A recording duration 
of more than 5 min did not decrease the minimal effect size.
Measurement electrodes were affi xed to the upper and lower rim 
of the left orbita. The ground electrode was placed in the midline, 
between the eyebrows. Blinks were recorded electronically. Analysis of 
the recorded blinks was performed online with a microcomputer and 
specialized software. Blinks were recognized as peaks of bipolar waves 
with a duration of less than 1 s. The main parameters were the number 
of blinks over a 5-min period, the average blink interval and the sd of 
the blink interval.
Finger tapping
Tapping is one of the computerized tests for cognitive functions of the 
FePsy (‘the iron psyche’) (Alphers et al., 1994), a system for automated 
(neuro)psychological testing. The test has been adapted from the 
Halstead Reitan Test Battery (Choca et al., 1997), and evaluates motor 
activation and fl uency. Speed of fi nger tapping is measured for the 
index fi nger for both the dominant and nondominant hand; a session 
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contains fi ve performances of 10 s for each hand (e.g. 10 × 10 s). Feedback 
on performance is given by a counter in the centre of the screen, while the 
amount of taps of each 10-s trial is shown at the bottom of the screen. The 
space bar is used as tapping device. The volunteer is instructed to tap as 
quickly as possible. The mean tapping rate and the sds for the dominant 
and non-dominant hand are used for statistical analysis.
Prolactin
Whole blood was drawn every study day in a Beckton & Dickinson 
(Erembodegem-Aalst, Belgium) Haemogard® edta-tube, tilted, and 
immediately stored on ice water (4 °c). Within 1 h, it was centrifuged at 
4 °c for 10 min at 2000 g. Plasma was stored directly at –20 °c. Plasma 
prolactin was measured by enzymeassay using the Elisa System 300 
(Minneapolis, mn, usa).
Eye movements
Recording and analysis of saccadic and smooth pursuit eye movements 
was performed with a microcomputer-based system (van Steveninck et 
al., 1989). The equipment used for stimulus display, signal collection and 
amplifi cation was from Nihon Kohden (Nihon Kohden Corporation, Tokyo, 
Japan). Saccadic eye movements were recorded for stimulus amplitudes of 
15° to either side. Interstimulus intervals varied randomly between 3 s and 
6 s, and 15 saccades were recorded. The average values of saccadic peak 
velocity, latency (reaction time) and inaccuracy were used as parameters. 
For smooth pursuit eye movements, the target moved sinusoidal at 
frequencies range from 0.3–1.1 Hz, increasing by steps of 0.1 Hz. The 
amplitude of target displacement corresponds to 20° eyeball rotations 
to both sides. Four cycles were recorded for each stimulus frequency. The 
parameter derived from these measurements is the percentage of time 
that the subjects’ eyes are in smooth pursuit of the target.
Visual analogue scales
Visual analogue scales as originally described by Norris (1971) were used to 
quantify subjective effects. Three factors corresponding to alertness, mood 
and calmness were derived from these measurements (Bond et al., 1976).
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Statistical analysis
Treatment orders were balanced in a latin square design and assignment 
of subjects to treatment orders occurred at random. All withdrawals 
were replaced by subjects receiving the same randomization order. 
The pharmacodynamic analyses was performed in the per protocol 
population. The safety analysis was reported for all subjects who have 
fi nished at least one occasion with an active treatment. 
All subjects who completed at least two occasions were investigated. 
A blinded data review of primary variables (eye blink number, interval and 
sd, prolactin, fi nger tapping) was performed after entry of all data, and 
decisions pertaining to missing, unused or spurious data were recorded. 
Overall drug effects were quantifi ed using time-corrected areas under 
the effect curves (auecs divided by the corresponding time span) over 
0–6 h and 0–12 h. These measures were compared between treatments 
using factorial analysis of variance with subject, treatment and occasion 
as factors and pre-treatment values as covariates. If a covariate was 
included, least square means were used to present the treatment 
response. The following contrasts were defi ned within the anova model: 
(i) placebo versus sulpiride; (ii) placebo versus lisuride and (iii) lisuride 
versus sulpiride. 
Contrasts are presented with 95% confi dence intervals (ci); no 
corrections for multiple comparisons were implemented because the 
study was not designed to prove differences between treatments but to 
assess the size of effects.
Results
Thirteen male subjects (aged 19–40 years, mean 24 years), were enrolled 
in the study. Twelve subjects completed all three treatment periods, and 
were included in the dynamic analysis. One subject dropped out for non-
study related reasons and was replaced. All subjects who had one or more 
treatments were included in the safety analysis.
Adverse events 
The adverse events observed in this study were mainly somnolence (n = 
9), fatigue (n = 5), headache (n = 8) and nausea (n = 3). In general, most 
adverse events occurred during the lisuride treatment. This was mainly 
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due to the higher incidence of somnolence (lisuride, n = 6; sulpiride, n = 
4; placebo, n = 3) and nausea (solely during the lisuride treatment). The 
nausea resulted in moderate vomiting on two occasions. Most other 
adverse events were mild. All adverse events subsided before the subjects 
returned home at the end of a study day. No changes in vital signs or 
electrocardiogam were noted during any of the treatments. 
Spontaneous eye blinking
As expected, the number of eye blinks showed a large interindividual 
variability. The raw number of eye blinks for the different treatments over 
time are presented in fi gure 1. Analysis of variance with pre-treatment 
values as covariate showed no treatment differences between the 
treatments or between treatments and placebo. The sd of the blink 
interval showed similar results.
Prolactin
A clear and signifi cant increase of the auc compared to placebo was 
observed for sulpiride over the 0–6-h and 0–12-h periods: 917 U/ml 
(ci 773–1060) and 643 U/ml (ci 549–737), respectively (fi g. 2, Top panel). 
The decrease of lisuride compared to placebo over these periods did 
not reach statistical signifi cance: –74 U/ml (ci –217 to 69) and –39 U/ml 
(ci –133 to 54), respectively (fi g. 2, Lower panel).
Finger tapping
No effect of any of the treatments was observed on fi nger tapping for 
the dominant or non-dominant hands, or on the sd of these measures. 
Eye movements
The smooth pursuit percentages over time for the different treatments 
are presented in fi gure 3. No differences of the treatments compared to 
placebo or between treatments were observed for saccadic peak velocity, 
accuracy or latency. A decrease the auc of percentage smooth pursuit 
occurred for lisuride over the 0–6-h and 0–12-h periods: –4.2% (ci –7.5 to 
–0.9) and –4.1% (ci–7.3 to –0.9), respectively. 
Fig. 1 – p. 138
Fig. 2 – p. 138
Fig. 2 – p. 138
Fig. 3 – p. 139
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Visual analogue scales
The vas for alertness and mood both showed a treatment effect for 
lisuride. The scores for the different treatments over time are presented 
in fi gures 4 and 5. Lisuride decreased the vas scores for mood over the 
0–6-h and 0–12-h periods: –2.7 mm (ci –4.7 to –0.7) and –2.1 mm (ci –3.7 
to –0.4), respectively. The decrease of vas alertness scores over these 
periods did not reach statistical signifi cance: –3.8 mm (ci –8.2 to 0.6) and 
–3.8 mm (ci –8.5 to 0.9), respectively. 
Discussion
This study did not show any indication of effect of sulpiride or lisuride on 
the number of spontaneous eye blinks or on the sd of its interval. This 
is not in accordance with previous studies, indicating spontaneous eye 
blink rate as a putative marker of central dopamine activity (Karson et 
al., 1981A,c, 1982, 1984; Blin et al., 1990; Elsworth et al., 1991; Lawrence et 
al., 1991; Kleven et al., 1996). Several explanations can be given for these 
fi ndings. First, no infl uence of dopamine on spontaneous eye blink rate 
may exist. Publications of negative results could be underrepresented. 
Second, in the present study, we used drugs that act mainly on the 
d2-receptor. Although, from the literature, it appears that drug effects 
on eye blink rate are mediated mainly through the d2-receptor, there are 
also indications that d1 plays a role (Elsworth et al., 1991). The specifi city 
of the drugs could have prevented dopaminergic effects mediated 
through other dopamine receptor subtypes.
No drug concentrations were determined during this study. 
Thus, there is no absolute certainty that clinically relevant plasma drug 
concentrations were reached that could be expected to elicit an effect. 
However, it should be noted that, generally, there is no strong correlation 
between functional dopaminergic (therapeutic) effects and drug plasma 
concentrations. On the other hand, we can assume that relevant brain 
concentrations were reached. First, the dosages of both drugs were 
potent (twice the starting dose). Furthermore, sulpiride administration 
evoked a clear prolactin response (a maximum increase of approximately 
10 times baseline), which indicates central penetration and d2-
antagonistic effect.
Although apparent (fi g. 2, lower panel, shows a clear decrease 
after lisuride), the decrease of prolactin after lisuride administration 
did not reach statistical signifi cance. This could be due to the small 
Fig. 4 & 5  – p. 140
Fig. 2 – p. 138
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range of possible effects on physiologically low prolactin levels and the 
limited number of subjects. The subjective effects (decreases on vas 
scales for mood and alertness and nausea/vomiting) also demonstrate 
pharmacologically active lisuride levels.
In conclusion, in spite of dopaminergically active drug levels, this 
study did not show evidence of any effects of lisuride or sulpiride on 
spontaneous eye blink rate in healthy male volunteers. There are no 
indications that spontaneous eye blink rate is a marker for central 
dopaminergic activity of drugs, mediated through the d2-receptors. 
Prolactin provides a good measure of d2-dopaminergic activity, 
particularly for an antagonist.
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figure 1 Average number of blinks. Mean ± sd time-effect profi les of blinks for placebo 
(•), lisuride (°) and sulpiride (:).
figure 2 Average prolactin concentration. Mean ± sd time-effect profi les of prolactin 
concentration for placebo (•), lisuride (°) and sulpiride (:). 
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figure 2 
figure 3 Average percentage smooth pursuit. Mean ± sd time-effect profi les of 
percentage smooth pursuit for placebo (•), lisuride (°) and sulpiride (:).
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figure 4 Average visual analogue scales for alertness. Mean ± sd time-effect profi les 
of visual analogue scales for alertness for placebo (•), lisuride (°) and sulpiride (:)
figure 5 Average visual analogue scales for mood. Mean ± sd time-effect profi les 
of visual analogue scales for mood for placebo (•), lisuride (°) and sulpiride (:).
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Conclusions and discussion
The main objective of this thesis is to provide a conceptual framework 
for the use of central nervous system (cns) biomarkers in early phase 
clinical drug development. A classifi cation into four groups of biomarkers 
was suggested, based on four general questions on which these markers 
should provide information on: 
1.  Proof of cns-penetration and functional cns effects, which can be 
 sub-divided into:
 a. Biomarkers of cns pharmacokinetics
 b.  Biomarkers of adverse effects
2. Proof of pharmacodynamic principle (biomarkers of mechanism of  
 action)
3. Proof of pathophysiological principle (biomarkers of effects on  
 relevant pathophysiological process)
4. Proof of therapeutic principle (biomarkers of therapeutic effects)
Clinical studies with markers for functional cns effects were presented 
in chapters 1-4. The approach of selecting sensitive markers for these 
functional cns effects proved fruitful; not only in evaluating adverse 
effects (chapters 2: cns effects of sumatriptan and rizatriptan, 
3: pk/pd assessment of tolerance to central nervous system effects 
of a 3 mg sustained release tablet of rilmenidine in hypertensive 
patients and 4: cns effects of moxonidine experimental sustained 
release formulation in patients with mild to moderate essential 
hypertension) but also in creating a cns-profi le of a novel drug (chapter 
1: cns effects, pharmacokinetics and safety of the naaladase-
inhibitor gpi 5693). In these studies, the profi le of cns-effects can 
be considered as a ´surrogate´ of prevailing cns drug levels, even 
though the effects themselves do not necessarily hold any relevance 
for the pharmacological or therapeutic effects of the drug. Although 
individually these cns-effects are non-specifi c, they may in combination 
be unique for a particular drug class. An attempt to fi nd a drug class 
specifi c combination of these individually non-specifi c markers was 
described in chapter 5. As far as data was available, it showed a unique 
drug class specifi c relationship between saccadic eye movements, 
visual analogue scales and eeg for diverse agents like benzodiazepines, 
imidazoline-receptor modulators and 5ht1-agonists. Thus, biomarker 
combinations can be used to establish the similarities or differences 
between a novel agent and comparators within or outside its own 
class. However, this approach remains empirical, because there are 
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no clear explanations why a certain biomarker combination should 
show this relationship to a particular drug class. Chapter 6 described 
the fi rst steps in the development of hypoxia as a potential disease 
model for cognitive impairment (proof of therapeutic principle), using 
markers for functional cns-effects. In Chapter 7, another approach 
was explored, by investigating the response of a cns-biomarker with 
an established pharmacological action mechanism, to drugs that act 
on the same mechanism. However, this receptor specifi c marker, eye 
blinking for central d2-dopaminergic drug effect of mesocortical or 
mesolimbic pathways, failed to be validated. This would have been a 
useful adjunct to a pharmacological biomarker like prolactin, which in 
this study was confi rmed to be a useful indicator for tuberoinfundibular 
d2-dopaminergic activity. The interpretation of the results of these 
individual studies was discussed in each chapter. However, a few general 
remarks on the use of biomarkers in early cns drug development can be 
made, based on these observations.
In the life of a cns biomarker, its main ambition seems to be to 
become a surrogate marker for a clinical endpoint, and should thus 
provide information on how a patient “feels, functions or survives”. 
Consequently, its distance to a clinical endpoint determines the merits 
of a biomarker. This view of what a biomarker should be is especially 
prominent in phase iii and iv drug development programs. In early 
cns drug development, we are very short of such biomarkers. The only 
potential class of biomarkers that could be considered to be ‘clinically 
relevant’ is disease models, and such validated models are quite rare, 
and they hardly ever refl ect all aspects of the disease. Nevertheless, 
biomarkers can provide valuable information even if they never become 
surrogate endpoints in this clinical sense. 
To appreciate a biomarker, one should be very explicit as to what kind 
of information it can provide. The aim of the suggested categorization 
of biomarkers can help in this process. Figure 1 shows three of the four 
categories on an x, y and z-axis. Ideally, a biomarker would refl ect the 
drugs pharmacological properties, its effects on pathophysiological 
pathways, and its therapeutic effects. This biomarker would lie in 
the upper right quadrant of the fi gure. However, most biomarkers 
used in early cns drug development will provide information on the 
pharmacology of the drug (moving along the z-axis). Some biomarkers 
will also refl ect disease related (patho)physiological systems (moving 
along the y-axis). Very few biomarkers in healthy volunteers, if any, will 
be related to therapeutic effects (moving along the x-axis). Of course, 
biomarkers could be placed anywhere in the cube. Figure 1 also shows 
the position of potential biomarkers presented in this thesis.
Fig. 1 – p. 149
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If we look at the suggested classifi cation of biomarkers, one could argue 
that the fi rst category of “markers for functional cns effects” isn’t useful 
at all (it is also not represented in the above fi gure). These biomarkers 
merely show that a drug has penetrated the cns and has an effect, 
which could be desired or undesired and could be related to a therapeutic 
effect, but usually isn’t. This group basically constitutes a vast amount 
of tests that would, if we understood the pharmacology of the drug, cns 
physiology and pathophysiology fully, be categorized under markers 
for a pharmacological principle, a (patho)physiological principle or even 
therapeutic principle, or a combination of the above. Then, should we 
abandon this category? Our lack of understanding of the cns and related 
diseases still seems to necessitate the use of this category, and most 
biomarkers used in early cns drug development fall in it. Within the 
limitations mentioned, an effort should be made to make use of these 
biomarkers to the full, and place them somewhere in the fi gure. How can 
we make the most of these “markers for functional cns effects”? Here, 
the subdivision into “biomarkers of cns kinetics” and “biomarkers of 
adverse effects” becomes important. 
Can a biomarker be used to get an impression of cns kinetics? 
Measuring drug concentrations in the cns effect compartment is 
diffi cult. Pet-studies or drug concentrations in cerebrospinal fl uid 
are often the closest we can get to cns-pharmacokinetics. Plasma 
kinetics of a drug are much easier to assess. If a drug has an effect 
on the cns, and this effect is somehow picked up by an effect on a 
biomarker, this is usually a direct consequence of the presence of the 
drug in the brain. Such a biomarker could be informative about the 
cns pharmacokinetics, even if the pharmacodynamics of the drug are 
not fully understood. If plasma concentrations a drug can be related 
to functional cns effects, these effects can thus provide information 
on cns kinetics. Pharmacokinetic/pharmacodynamic (pk/pd) analysis 
provides a means to establish this relationship, and is often used in early 
drug development. For a biomarker to be useful in this manner, it should 
however be sensitive to a drug effect, and show some indication of a 
concentration-effect relationship. If these requirements are met, and 
subsequently a pk/pd relationship is found, it is often a sounder basis 
for establishing future dose regimens for the drug under investigation 
than plasma kinetics alone. However, some caution is needed when 
using a biomarker for cns kinetics. Systemic drug effects can provoke a 
secondary cns effect (eg nausea provoked by local gastric irritation can 
induce a prolactin release), and in this way lead to false conclusions on 
cns kinetics.
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Maybe the most frequent use of biomarkers in early cns drug develop-
ment is as indicators of adverse events. These biomarkers can provide 
valuable information on the general cns properties of a drug. This is 
vital information in the early stages of drug development, which primar-
ily aims to assess the tolerability of a drug. It allows us to identify for 
example dose limiting tolerability issues at a relatively early stage. This 
approach does require that sensitive biomarkers are being used and that 
these show at least a consistent and signifi cant response across differ-
ent studies and drugs in the same therapeutic class. Thus, the effects 
of related positive controls provide a benchmark for the (adverse) event 
profi le of a novel agent from the same class. For these biomarkers to be 
useful, a consistent and signifi cant response at therapeutic doses and a 
dose response relationship is also needed. The clinical relevance of these 
biomarkers for adverse events in daily practice, require further validation 
under different clinical circumstances (e.g. effects of sleep deprivation, 
circadian rhythms) for an effect to be attributed to a drug action. 
More often than not, these basic requirements for fully validated 
effect biomarker are not met. Nevertheless, a test battery composed of 
tests fulfi lling several of these requirements can be helpful in creating 
a cns tolerability profi le of drugs with a novel mechanism of action, 
especially since phase i drug development is constantly confronted with 
new drugs with only partly elucidated mechanisms of action, indicated 
for diseases with frequently only partially known pathophysiology. 
The inclusion of a positive control (i.e. a drug with a known effect on 
the biomarker) in studies with these drugs increases the validity of the 
observed effects.
What can biomarkers tell us about the pharmacodynamic properties 
of a drug, i.e. Its mechanism of action? It seems safe to assume that 
if a drug shows a cns effect (in a manner described in the above 
paragraphs), it will be somehow related to its pharmacodynamic 
properties. It would therefore also be safe to assume that whatever is 
measured, this biomarker will refl ect the pharmacodynamic properties 
of the investigated drug, and thus the biomarker would be proof of a 
“pharmacodynamic principle”. But what pharmacodynamic principle is 
proven? Does it demonstrate the unique pharmacodynamic properties 
of the drug under investigation? For most biomarkers this is not the 
case. As shown in this thesis, a decrease in saccadic peak velocity and 
a decrease of visual analogue scales for alertness can be observed after 
administration of a benzodiazepine (temazepam), a imidazoline receptor 
modulator (rilmenidine, moxonidine) as well as after a 5ht1 agonist 
(sumatriptan, rizatriptan) and indeed several other drugs. Here an 
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important issue arises, that of specifi city. Most ‘functional’ biomarkers 
are not very specifi c. The ‘cns, to a large extent, is still a “black box” with 
motor function or subjective changes as its main outputs. This is true 
especially for most markers in the cognitive domains. And even for non-
motor neurophysiologic measures, such as eeg or fmri, it is uncertain 
if they have any additional relevance to the “motor output” of the cns. 
Here we are confronted, again, with our lack of understanding and the 
complexity of even basic cns-functions, such as attention.
An important question arises: if the same biomarkers are affected 
by drugs with different pharmacological properties, are they affected 
in a similar way? To put it in another way: can we identify a drug’s 
pharmacological action by combining different biomarkers that are 
affected by drugs with different pharmacological properties? If we 
could, this approach to the use of biomarkers has some advantages: 
even if the exact pharmacological pathway of a drug is unknown, and 
the relevance to the pathophysiology is unclear, a “pharmacological 
footprint” of a drug could be construed. In this approach, it would not 
matter if after taking a certain drug, a person would prefer the color 
red over blue and the taste of apples over pears, as long as it would be 
specifi c to a certain mechanism of action of the drug. To achieve this kind 
of “pharmacological footprints” it would be necessary to prospectively 
evaluate drugs with high receptor specifi city with a combination of 
sensitive (non-specifi c) biomarkers, thus creating templates for drugs 
with unknown mechanisms of actions. In chapter 5 of this thesis, such an 
attempt was made to evaluate drugs with known mechanisms of action 
on their combined effect on sensitive but non-specifi c biomarkers.
The chances of a single biomarker to be specifi c to a certain drug 
(or even drug class) are slim. To create a specifi c pharmacological and 
adverse event profi le of a drug, a combination of biomarkers will be 
required. If the above mentioned approach would provide a useful set 
of biomarkers, would this help in assessing the action of the drug on 
relevant pathophysiological pathways at which the drugs are targeted? 
This largely depends on our knowledge of the pathways involved in 
diseases affecting the cns. For the majority of cns diseases, these 
pathways are, at best, partly elucidated. However, some indications of 
an effect on a particular pharmacological system can often be obtained, 
because many such systems have well-established physiological 
relevance or well-known effects in experimental animals. For instance, 
a combination of increased alertness, rem sleep reduction and body 
temperature elevation would stongly point to serotonergic activation, 
even though none of the individual effects is very specifi c. The defi nite 
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answers most likely will come from physiological and clinical research 
in patients, not from biomarker research. Such research is important, 
because individual or combined biomarkers can only show to which 
degree a new drug is similar to well-known drugs. If we do not 
understand the physiological or pharmacological relevance of these 
biomarker, and if no new understanding of these pathways arises, the 
use of well-established functional biomarkers would simply facilitate 
the development of “me too drugs”, as has been the case, for example, 
with the increasing number of ssri’s for the treatment of depression. 
The main distinguishing feature between these drugs seems to be 
their adverse effect profi le, not clinical effi cacy. However useful, 
biomarkers used in early drug development in healthy volunteers are 
primarily targeted at assessing the adverse effects, not to provide a 
pathophysiological proof of principle. But do we need to know the exact 
pathophysiology of a disease to fi nd and use a biomarker related to it?
The use of disease models and challenge tests in drug development 
rely on the fact that we need not know the exact pathophysiology of a 
disease in order to use these models and the biomarkers derived from 
them. For example, the scopolamine model for memory impairment 
has greatly aided in the development of cholinesterase inhibiting anti-
alzheimer drugs. Disease models, like the scopolamine model, often only 
model the part of the pathophysiology leading to identical symptoms, 
affecting a “fi nal common pathway” (a decrease of acetylcholinergic 
neurotransmission). Models like these allow the evaluation of 
symptomatic drugs that affect the same physiological pathway. The 
scopolamine model will not necessarily be useful in the evaluation of a 
tau-tangle inhibitor for alzheimers disease. 
In chapter 6 an attempt was made to develop a disease model for 
cognitive impairment (hypoxia). Cerebral (cortical) hypoxemia and the 
resulting impairment of function seem to be a “fi nal common pathway” 
for several clinical cognitive impairment syndromes (e.g. Alzheimers 
disease, vascular dementia). The aim was to create a practical model 
that, if eventually used in drug development, does not have the draw 
back of pharmacological interaction of the scopolamine model, and can 
perhaps be applied more widely to other cognitive enhancers. In this 
study the effects on the biomarkers were small and bidirectional for 
different levels of hypoxia. Before this model can potentially be used in 
drug development, the physiology of cerebral hypoxia should be further 
investigated.
This attempt to validate a disease model does illustrate vital steps 
in it’s development: to have a conceptual idea of what part of disease 
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physiology is affected, to search for sensitive biomarkers to pick up these 
effects and to see if a dose-effect relationship is present. These steps 
should be taken carefully, prior to pharmacological intervention.
Disease models, and also challenge tests, are important in the 
development of cns drugs even in the absence of complete knowledge 
of disease pathophysiology. This does require that they relate to a part of 
physiology that is affected by the disease and the drug under evaluation 
affects this particular part of physiology. Furthermore, biomarkers 
should be available that provide reliable information on that physiology. 
If these requirements are met, disease models and challenge tests are 
most likely to eventually provide biomarkers for therapeutic effects. 
In conclusion, despite all the limitations, biomarkers can be of 
great value in early cns drug development. But different biomarkers 
have different purposes. A critical evaluation of existing biomarkers, 
and positioning them in relation to drug pharmacology, disease 
pathophysiology and therapeutic effect, is a more fruitful approach 
than to increase their number. This seems particularly relevant for the 
evaluation of drug effects on cognitive function, where a large number 
of tests is being used that lack sensitivity and reproducibility. The 
development of challenge tests and disease models will not only increase 
our understanding of diseases, but may also provide us with biomarkers 
for therapeutic effects in healthy volunteers.
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figure 1 The position of potential biomarkers presented in this thesis in relation to 
pharmacological, pathophysiological an therapeutic parameters. a: eyeblinking (Chp 7.), 
b: combined markers (Chp 5), c: hypoxia-model (Chp 6).
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Samenvatting
Het doel van deze dissertatie is het scheppen van een conceptueel 
raamwerk voor het gebruik van Centraal Zenuwstelsel (czs) biomarkers 
in de vroege fase van klinisch geneesmiddelonderzoek. In de inleiding 
wordt een beeld geschetst van het huidige gebruik van biomarkers en de 
mogelijke tekortkomingen daar in. De noodzaak van een vraag gestuurde 
indeling in biomarkergroepen wordt bepleit. Er wordt een onderverdeling 
in vier groepen gesuggereerd, gebaseerd op vier algemene vragen waar 
een biomarker informatief over zou kunnen zijn:
1. Bewijs van czs-penetratie en functionele czs-effecten, die   
 onderverdeeld kunnen worden in:
 a. biomarkers van czs farmacokinetiek
 b. biomarkers van bijwerkingen
2. Bewijs van het farmacodynamisch principe (biomarkers van het  
 werkingsmechanisme)
3. Bewijs van het pathofysiologisch principe (biomarkers van effecten  
 op relevante pathofysiologische processen
4. Bewijs van het therapeutisch principe (biomarkers van therapeutische 
 effecten)
In hoofdstuk 1 t/m 4 worden vroege fase geneesmiddelstudies 
gepresenteerd waarin gebruik werd gemaakt van biomarkers van 
functionele czs-effecten. Deze benadering van het selecteren van 
de meest sensitieve biomarkers voor deze functionele effecten bleek 
productief. 
Hoofdstuk 1 “The central nervous system effects, pharmacokinetics and 
safety of the naaladase-inhibitor gpi 5693” beschrijft een onderzoek 
waarin het czs profi el van een nieuw geneesmiddel in gezonde 
vrijwilligers werd vastgesteld. Een deel van de gebruikte biomarkers 
(adaptive tracking, Visual Analogue Scales (vas)) lieten effecten zien van 
de hoogste gebruikte dosis van dit geneesmiddel, die aantonen dat het 
middel doordringt in het centrale zenuwstelsel en zouden kunnen wijzen 
op klinisch relevante sedatie. 
In Hoofdstuk 2 “cns effects of sumatriptan and rizatriptan in healthy 
female volunteers” worden sensitieve biomarkers van o.a. sedatie 
gebruikt om de czs effecten van twee triptanen te kwantifi ceren. 
De resultaten laten zien dat zowel sumatriptan en rizatriptan kleine 
153 samenvatting
maar duidelijke effecten op het czs hebben, die met deze biomarkers 
te onderscheiden zijn van de reeds bekende effecten van het 
benzodiazepine temazepam.
Hoofdstuk 3 “Pharmacokinetic/pharmacodynamic assessment of 
tolerance to central nervous system effects of a 3 mg sustained release 
tablet of rilmenidine in hypertensive patients” worden de sedatieve 
effecten onderzocht van rilmenidine, een in het czs werkzaam 
antihypertensivum, bij patiënten met hypertensie. In deze studie wordt 
van deze sedatieve effecten het verloop in de tijd en de relatie met gene
esmiddelconcentraties onderzocht, gedurende langdurige behandeling. 
De subjectief ervaren sedatie, vastgesteld met vas-sen voor alertheid, 
nam in deze studie af na langdurige behandeling, hetgeen met name 
toe te schrijven was aan een toename van alertheid vóór inname van de 
dagdosis van het geneesmiddel. Hoofdstuk 4 beschrijft een vergelijkbaar 
onderzoek naar de czs effecten van het qua werkingsmechanisme 
verwante antihypertensivum moxonidine. Deze studie liet met gebruik 
van identieke biomarkers vergelijkbare resultaten zien.
Een aantal van de biomarkers gebruikt in de onderzoeken beschreven in 
de Hoofdstukken 1 t/m 4 kan een indruk geven (door farmacokinetiek-
farmacodynamiek (pk-pd) modellering) van geneesmiddel concentraties 
in het brein en zo een surrogaat vormen voor niet beschikbare genees-
middelconcentraties op de plaats van werking. Daarbij is het niet strikt 
noodzakelijk dat de biomarker informatief is over de farmacodynamiek 
van het geneesmiddel of het eventuele therapeutische effect, als er 
tenminste geen belangrijke systemische effecten die secundair het 
zenuwstelsel beïnvloeden. Uit de onderzoeken beschreven in deze 
hoofdstukken blijkt tevens dat de meest sensitieve biomarkers elk voor 
zich weinig specifi ek zijn voor een geneesmiddel of geneesmiddel klasse.
Hoofdstuk 5 “Drug class specifi c composite effects on saccadic peak 
velocity, visual analogue scales and electroencephalography” beschrijft 
een poging sensitieve maar non-specifi eke biomarkers te combineren 
tot een nieuwe specifi eke biomarker. Hiertoe werd gebruik gemaakt 
van data uit een aantal binnen het Centre for Human Drug Research 
verrichtte studies. Er blijk een unieke geneesmiddelklasse specifi eke 
relatie te bestaan tussen saccadische oogbewegingen, visual analogue 
scales en eeg voor diverse geneesmiddelklassen zoals benzodiazepines, 
imidazoline-receptor modulatoren and 5ht1-agonisten. Op deze wijze 
zouden biomarkercombinaties gebruikt worden om overeenkomsten 
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of verschillen aan te tonen tussen nieuwe geneesmiddelen en actieve 
controle geneesmiddelen binnen of buiten de geneesmiddelklasse. 
Deze aanpak blijft empirisch en verklaart niet waarom een specifi eke 
combinatie van biomarkers gerelateerd is aan een bepaalde 
geneesmiddelklasse.
Hoofstuk 6 “Evaluation of tests of central nervous system performance 
after hypoxemia for a model for cognitive impairment” beschrijft 
de ontwikkeling van een potentieel ziektemodel voor cognitieve 
functiestoornissen. Potentieel zou dit biomarkers voor therapeutische 
effecten van “cognitive enhancers” kunnen opleveren. Hoewel er effecten 
waren op diverse biomarkers, was de invloed van verschillende niveaus 
van hypoxemie hierop complex. Daardoor is dit model niet zonder meer 
bruikbaar voor geneesmiddelonderzoek.
In Hoofdstuk 7 “No evidence of the usefulness of eye blinking as a 
marker for central dopaminergic activity” wordt een poging beschreven 
een receptor specifi eke biomarker te ontwikkelen. Dit zou dan een 
biomarker voor (een deel van) het werkingsmechanisme zijn. Uit 
de literatuur waren aanwijzingen dat de frequentie van spontaan 
oogknipperen selectief beïnvloed zou worden door de centrale 
dopaminerge activiteit op de d2-receptor. Potentieel zou de frequentie 
van het oogknipperen een biomaker kunnen zijn voor de centrale d2 
activiteit van een geneesmiddel. Deze marker kon echter niet gevalideerd 
worden. In deze studie kon wel worden bevestigd, dat de afgifte van het 
hypofysehormoon prolactine onder invloed staat van d2-dopaminerge 
systemen.
In het Hoofdstuk “Conclusions and Discussion” wordt een kritische 
evaluatie gegeven van het gebruik van biomarkers in vroege fase 
geneesmiddelonderzoek. Er wordt gesteld dat ondanks alle beperkingen 
het gebruik van biomarkers van groot nut kan zijn. Hiervoor is echter 
nodig dat bestaande biomarkers gepositioneerd worden in relatie tot 
de farmacologie van een geneesmiddel, tot de pathofysiologie van een 
ziekte waarvoor een middel geïndiceerd is en het therapeutisch effect 
dat verwacht wordt. Dit lijkt belangrijker dan om het aantal biomarkers 
te vergroten. Het ontwikkelen van challenge tests en ziektemodellen 
zal niet alleen onze kennis vergroten van een ziekte, maar zou tevens 
biomarkers voor de therapeutische effecten van een nieuw geneesmiddel 
kunnen opleveren.
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